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Chapter 1
Introduction
Barend Mees
Partly adapted from:
A Different Outlook on the Role of Bone Marrow Stem Cells in Vascular Growth: Bone 
Marrow Delivers Software, not Hardware
Matthias Heil, Tibor Ziegelhoeffer, Barend Mees and Wolfgang Schaper
Circ. Res. 2004;94;573-574
From the Max-Planck-Institute for Physiological and Clinical Research (M.H., T.Z., W.S.) 
and Kerckhoff-Clinic (T.Z.), Bad Nauheim, Germany; and Departments of Vascular 
Surgery and Cell Biology and Genetics (B.M.), Erasmus Medical Center, Rotterdam, 
the Netherlands.
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Introduction
“You are only as old as your endothelium”, as often stated by Paul M Vanhoutte, when 
opening his famous “Mechanisms of Vasodilation” meetings from 1980 onwards, high-
lights the importance of endothelium and the continuous process of vascular remodeling 
in many physiological and pathophysiological situations as embryogenesis, wound heal-
ing, tumor growth and ischemic disease. In chronic and acute cardiovascular occlusive 
disease, different types of vascular remodeling contribute to tissue repair and vascular 
growth. Firstly, collateral growth represents the expansive growth of preexisting vessels, 
forming collateral bridges between arterial networks. Secondly, neovascularization refers 
to vascular growth from a combination of three different mechanisms: vasculogenesis 
is the formation of blood vessels by endothelial progenitors while angiogenesis refers 
to capillary sprouting or intussusceptive growth and arteriogenesis to the subsequent 
stabilization of these new vascular structures by mural cells1. Distinct, but partially over-
lapping, cellular and molecular pathways drive collateral growth and neovascularization 
(Figure 1)2. Hypoxia is known to stimulate neovascularization in the setting of ischemia, 
whereas fluid shear stress (FSS) might be the most important trigger for initiation of 
collateral growth. Besides these specific initial triggers, all types of vascular remodeling 
share growth factors, chemokines, proteases, and inflammatory cells, which play differ-
ent roles in promoting and refining these processes.
Collateral growth 
Neovascularization 
Occlusion 
Inflammation 
Shear stress 
Inflammation 
Shear stress 
Hypoxia 
Figure 1. During postocclusive vascular remodeling, increased shear stress in preexisting arterioles is 
the most important stimulus for collateral growth, while hypoxia in the more distant vascular bed is the 
major trigger for neovascularization. See text for further description of differences in vascular remodeling 
pathways.
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Therefore, in case of occlusive arterial disease, the different types of vascular remodel-
ing are considered as complementary parts of the process of blood flow and ischemic 
tissue perfusion recovery.
Collateral Growth
Following an arterial occlusion outward remodeling of preexistent interconnecting 
arterioles occurs by proliferation of vascular smooth muscle and endothelial cells. This 
is initiated by deformation of the endothelial cells through increased pulsatile fluid 
shear stress (FSS) caused by the steep pressure gradient between the high preocclusive 
and the very low postocclusive pressure regions that are interconnected by collateral 
vessels.
A study in mice by Scholz and Schaper speculates that
collateral arteries continue to remodel after the increase of shear
stress is no longer present, indicating only an initiating role for
shear stress in arteriogenesis.11 On the other hand, collateral
vessels regress after shear stress ceases. During this process,
called ‘‘pruning’’, most collateral anastomoses degenerate, while
a small number of large collateral arteries continue to grow in
size.12 Enhancing the magnitude of fluid shear stress over the
pre-existent collateral vasculature in an animal model by
implementation of an arteriovenous shunt leads to a restoration
of flow even exceeding the levels of flow of the native
circulatory system.13
A recent study showed that collateral flow was undiminished
in patients 24 h after opening of a chronic total occlusion
(CTO) of a coronary artery,14 whereas another investigation
described a rapid re-recruitment of collateral-dependent perfu-
sion directly after PCI of the original artery.15 In a large study
comprising more than 100 patients with CTO, collateral
function declined by 23% directly after PCI and by another
23% after 5 months. Collateral arteries were not readily
recruitable after acute re-occlusion, but had the potential to
recover in cases of chronic re-occlusion.16
Role of circulating cells
Monocytes were first recognised as important players in
arteriogenesis by Schaper et al in 1976.4 After activation of the
endothelium by shear stress, monocytes are recruited to the site
of collateral artery growth. Details of monocyte recruitment,
adhesion to the endothelial surface molecule ICAM-1 via their
receptor Mac-1 and transmigration to the perivascular tissue
have been reviewed in detail elsewhere.17
Experimental research in recent years has further elucidated
monocyte function and emphasised its importance in arterio-
genesis. Once in the perivascular region, monocytes become
macrophages and create an inflammatory environment. The
glycoprotein tumour necrosis factor a (TNFa) is one of the
inflammatory factors secreted by macrophages.18 TNFa knock-
out mice show delayed arteriogenesis, and the inhibition of
TNFa signalling using the TNFa antagonists infliximab and
etanercept also resulted in attenuated arteriogenesis.19 Anti-
inflammatory treatment with aspirin attenuated arteriogenesis
in a rabbit model.20
The glycoprotein CD44 is of importance for the interaction of
transmigrating monocytes with the extravascular matrix. It is
functionally involved in arteriogenesis in mice and was
Figure 1 Mechanisms of arteriogenesis. (A) Without significant stenosis, there is no significant pressure gradient over pre-existing collateral
anastomoses, which are small and barely carry blood. (B) Development of a significant arterial obstruction leads to a drop in pressure and oxygen
saturation distal in the vascular bed (purple-blue colour), while proximal pressure and oxygen saturation proximal remain normal (red colour). The
pressure gradient over the collateral circulation increases fluid shear stress in these arterioles. (C) Close-up on the cellular level. The endothelium
senses increased fluid shear stress via its cytoskeleton, transmembrane proteins (integrins, ion channels) and the glycocalyx. In an activated state, the
endothelium expresses adhesion molecules (ICAM-1), to which circulating monocytes bind via their Mac-1 receptor. Monocytes transmigrate into
perivascular tissue, differentiate to macrophages and secrete growth factors and cytokines that attract further monocytes and stimulate proliferation of
smooth muscle cells and endothelial cells. (D) Adequately developed collateral arteries restore distal perfusion and provide sufficiently oxygenated
blood to distal tissues. bFGF, basic fibroblast growth factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; ICAM, intercellular adhesion
molecule; MCP, monocyte chemoattractant protein; MMPs, matrix metalloproteinases; TGFb, transforming growth factor b.
Review
192 Heart 2009;95:191–197. doi:10.1136/hrt.2007.136119
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Fi re 2. Mechanisms of collateral growth; increased shear stress in preexisting collateral arteries 
activates the endothelium, leading t  an inflammatory-lik  reactio  with i vading mo ocytes and finally 
endothelial and smooth muscle cell proliferation. (Figure taken from Schirmer et al5 with permission)
The primary physiological response to FSS is an activation of end thelial cells via 
transduction of the mechanical stimulus, and a large number of genes are controlled 
by shear stress responsive elements in their promoters3,4. Increased FSS results i  
increased production of endothelial adhesion molecules and chemokines and its 
receptors (Figure 2). The most extensively studied chemokine contributing to collat-
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eral growth is monocyte chemoattractant protein-1 (MCP-1). MCP-1 and its receptor 
chemokine receptor 2 (CCR2) are significantly upregulated in collateral arteries and in 
absence of MCP-1 or CCR2 collateral growth is severely impaired. A second important 
pathway activated by FSS is fractalkine/CX3C receptor 1, which is involved in adhesion 
and migration of leukocytes. Furthermore, increased FSS may also enhance synthesis 
of proinflammatory cytokines as tumor necrosis factor α (TNFα) and interleukin-6 (IL-6). 
Thus, production of the above cytokines, chemokines and adhesion molecules lead 
to attraction and activation of proinflammatory cells (monocytes, NK cells and T-cells) 
into the adventitial space or attachment of these cells to the endothelium. Inflam-
matory cells then produce proteases and growth factors to digest the extra-cellular 
scaffold and allow motility and provide space for the new cells. The bulk of new tissue 
production is carried by the smooth muscle cells of the media, which transform their 
phenotype from a contractile into a synthetic and proliferative one6,7.
Vasculogenesis
For many years, the prevailing dogma stated that vessels in the embryo developed 
from endothelial progenitors, whereas sprouting of vessels in the adult resulted only 
from division of differentiated endothelial cells. However, evidence from the last de-
cades indicates that endothelial progenitors contribute to vessel growth both in the 
embryo and in specific conditions in the adult, including ischemia, inflammation and 
malignancy. Endothelial cells differentiate in the embryo from angioblasts8 and in the 
adult from endothelial progenitor cells (EPC) that are derived not only from bone mar-
row, but also from other tissues like adipose tissue, liver, spleen and even vessel wall9-12. 
In the condition of postischemic vascular remodeling, progenitor cells are mobilized 
and attracted towards the ischemic tissue via homing signals as a response to hypoxia. 
This recruitment of stem cells to the neovascularization sites strongly resembles an 
inflammatory response. Once in the vicinity of ischemic tissue, progenitor cells interact 
with the endothelial monolayer in a similar way as leucocytes interact with activated 
endothelial cells13. The activated endothelium produces chemoattractant molecules 
as stromal-cell derived factor-1 (SDF-1) and adhesive molecules as selectin and inter-
cellular adhesion molecule-1 (ICAM-1) and binds progenitor cells to their equivalent 
receptors chemokine receptor 4 (CXCR4), placenta growth factor-1 (PlGF-1) and β2 
integrin. Subsequently the endothelial lineage allows progenitor cells to incorporate 
in the endothelium or infiltrate the vessel wall through increased vasopermeability. 
Progenitor cells will then differentiate into an endothelial cell phenotype or produce 
different factors involved in tissue remodeling exerting an important paracrine effect.
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Angiogenesis and Arteriogenesis
The nascent vascular bed expands by sprouting and matures into a system of stable 
vessels. Hypoxia is the main stimulus for expansion of the vascular bed and occurs 
when tissue oxygen demand is beyond the limit of oxygen diffusion. Hypoxia triggers 
endothelial cell sprouting by signaling through hypoxia-inducible transcription fac-
tors (HIFs)14. HIF-1 and HIF-2 upregulate many angiogenic genes, but the induction 
of vascular endothelial growth factor-A (VEGF-A) is the most remarkable. VEGF-A is a 
key regulator of physiological and pathological angiogenesis. Two receptor tyrosine ki-
nases, VEGFR-1 and VEGFR-2, mediate its biological effects15. Furthermore, hypoxia also 
controls the inflammatory reaction. Activation of HIF-1α is essential for myeloid cell 
infiltration and activation and it modulates adhesion capacity of inflammatory cells, 
through a mechanism independent of VEGF. As endothelial cells migrate during vessel 
sprouting the extracellular matrix is proteolytically broken down and its composition 
altered. This proteolytic remodeling of the extracellular matrix is an extremely balanced 
process16. Establishment of a functional vascular network further requires that nascent 
vessels mature into durable vessels. The association of pericytes and smooth muscle 
cells with newly formed vessels regulates endothelial cell proliferation, survival, migra-
tion, differentiation, vascular branching, blood flow and vascular permeability. At least 
two important molecular pathways are involved in regulating this process: the platelet-
derived growth factor B (PDGFB) pathway and the transforming growth factor β (TGFβ) 
pathway17. Finally, flow has an essential role in determining whether neovessels regress 
or persist. By affecting several factors (including growth factors, integrins and matrix 
metalloproteinases) flow stimulates hyperplasia of endothelial and smooth muscle 
cells and induces the reorganization of endothelial junctions and the deposition of 
extracellular matrix, all of which contribute to vessel maturation1.
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Vasculogenesis 
Arteriogenesis 
Angiogenesis Lymphangiogenesis 
Figure 3. Neovascularization is the combination of vasculogenesis, angiogenesis and arteriogenesis. 
(Figure taken from Adams & Alitalo18 with permission)
Discovery of Nitric Oxide
There are few discoveries with the magnitude of the impact that nitric oxide (NO) has 
had on biology during the 25 years since its discovery as an important molecule in the 
cardiovascular system. NO was discovered in 1772 by Joseph Priestly as a clear, color-
less gas with 6 - 10 seconds lifetime in vivo. In 1980, Robert Furchgott discovered that 
endothelial cells produce an endothelium-derived relaxing factor (EDRF) in response 
to stimulation by acetylcholine19. In 1987, Salvador Moncada and Louis Ignarro inde-
pendently proved that EDRF is NO20,21. A decade earlier, Ferid Murad had shown that 
nitrovasodilators (e.g., exogeneous NO, nitroglycerin, sodium nitroprusside) are able 
to relax vascular tissues22. All this work contributed to the recognition of NO being a 
major signaling molecule in the cardiovascular system. In 1992, the cover of the journal 
Science proclaimed NO as the molecule of the year and awarding the Nobel Prize in 
Physiology and Medicine to Furchgott, Ignarro and Murad six years later underlined 
the importance of their work. In 1999, Moncada was the most highly cited U.K. scientist 
of the decade, reflecting his seminal work on NO. Since then, NO has been found to be 
involved in almost every area of biomedicine, including cardiovascular function, neu-
rotransmission, pain, diabetes, wound healing and tissue repair, skin renewal, cancer, 
immune function, infection, respiratory function and eye disease23.
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Nitric Oxide Regulation
NO is a gaseous signaling molecule that is synthesized by the nitric oxide synthase 
(NOS) enzyme in almost all tissues and organs. There are three isoforms of NOS that are 
encoded by different genes. Their names are derived from the tissue from which they 
were initially isolated24. Neuronal NOS (nNOS/NOS1) was isolated from the brain and 
was the first NOS enzyme to be identified25. Inducible NOS (iNOS/NOS2) was isolated 
from macrophages26. The third NOS enzyme, endothelial NOS (eNOS/NOS3) was iso-
lated from bovine aortic endothelial cells27. NO is synthesized by all three NOS isoforms 
by the conversion of L-arginine to L-citrulline. eNOS and nNOS are calcium-dependent 
whereas iNOS is calcium-independent. However, all isoforms require calmodulin bind-
ing to achieve full catalytic activity. The availability of L-arginine and the cofactor for 
the reaction tetrahydrobiopterin (BH4), affect the production of NO. In addition, gua-
nosine triphosphate (GTP) cyclohydrolase 1, which catalyzes GTP to dihydrobiopterin 
triphosphate, appears to be the rate-limiting enzyme. Reduced substrate and cofactor 
availability, conditions that may pertain in disease states, results in NOS uncoupling 
where superoxide anion (O2-) is produced preferentially over NO.
Figure 4. NO is produced in the endothelial cell upon exposure to shear stress or receptor antagonists 
(eg., acetylcholine, bradykinin, VEGF). (Figure taken from Rabelink et al30 with permission)
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iNOS produces more NO than eNOS but it also has a greater tendency to uncouple and 
produce free radical oxygen species (ROS) as superoxide anion. At low concentrations 
ROS acts physiologically, however at higher concentrations superoxide anion alone 
can be damaging and moreover also react with NO to produce peroxynitrite, thereby 
causing further damage.
The NOS enzymes are also regulated by phosphorylation. Phosphorylation of eNOS at 
specific residues (as serine 1777), mainly through the Akt/phosphatidylinositol 3-kinase 
(PI3K)-mediated pathway, causes the enzyme to produce higher levels of NO24. Finally, 
the activity of eNOS is also regulated by its cellular localization and by its interaction 
with a number of different proteins. Localization of eNOS to the Golgi region and the 
plasmalemmal caveolae is required for optimal NO production28. Regulation via pro-
tein–protein interactions both positively and negatively affect NOS activity29.
Nitric Oxide in the Cardiovascular System
In the cardiovascular system, NO has an astonishingly wide range of physiological and 
pathophysiological activities. NO influences vascular homeostasis in many ways be-
yond modulation of vasomotion, such as inhibition of smooth muscle cell proliferation, 
platelet aggregation, platelet and monocyte adhesion to the endothelium, low-density 
lipoprotein (LDL) oxidation, expression of adhesion molecules and endothelin produc-
tion. Defects in these functions usually result from decreased NO bioavailability and 
dysfunction in the NOS enzymes and are responsible for diseases such as atherosclero-
sis, coronary artery disease, diabetes, hypercholesterolemia, hypertension, immune re-
actions (transplant rejections), inflammation, migraine, meningitis, peripheral vascular 
disease, vascular restenosis, septic shock, sickle cell disease and stroke31.
Nitric Oxide-Based Therapies
The involvement of NO in such a wide variety of disease states has made it an attractive 
target for both pharmacological and gene therapies. In 1998 Pfizer introduced Viagra®, 
a drug with a mechanism of action (phosphodiesterase inhibition) based on the NO-
cGMP system, which revolutionized the management of erectile dysfunction. In the 
following years many experimental studies were performed to develop a therapeutic 
increase in NO bioavailability using pharmacological agents, NO-releasing donor 
compounds or NOS gene therapy. However, the complex regulation of NOS in the 
cardiovascular system needs to be carefully considered in the context of gene therapy 
Chapter 1: Introduction
14
with substrate availability, enzyme uncoupling and superoxide generation potentially 
having deleterious effects, in particular in different vascular disease states32.
Nitric Oxide in Vascular Remodeling
Vasodilation
Nitric oxide is clearly the major endothelium-dependent vasodilator produced by 
large blood vessels. Endothelial cells produce NO via eNOS and NO activates the cyclic 
guanosine monophosphate (cGMP) pathway through soluble guanylate cyclase (sGC) 
leading to vascular smooth muscle cell relaxation and vasodilation. In the aorta or 
carotid arteries of mice deficient in eNOS (eNOS KO mice), endothelium-dependent 
vasodilation is eliminated33. However, the vasodilatory roles for NO in arterioles and 
venules appear to be more complex and the importance of NO as a vasodilatory agent 
(deciphered by the sensitivity of the response to blockage of NOS) depends on the 
stimulus (flow versus other agonists such as acetylcholine, VEGF, histamine), the vas-
cular bed studied (coronary, cremaster, gracillus, mesentery), the species (human, rat, 
mouse, hamster) and the number of endothelial-smooth muscle interconnections (i.e. 
myo-endothelial gaps)33. For example, in eNOS KO mice, the local vasodilatory actions 
of acetylcholine or flow induced changes in blood flow are not diminished, due to 
compensation by upregulation of nNOS, endothelium-derived hyperpolarizing factor 
(EDHF) and vasodilatory prostaglandins34,35. However, the local vasodilatory action of 
histamine was absent from arterioles in eNOS KO mice36.
Another theory imparting NO as an important factor in microvascular blood flow con-
trol is the concept that NO bound to hemoglobin in red blood cells can serve as a stable 
NO-adduct for delivery at sites of resistance37. Although this principle can be demon-
strated in model systems, the physiological role of NO via its release from hemoglobin 
in regulating blood flow in the microcirculation remains controversial.
Finally, studies on postocclusion vascular remodeling demonstrated that apart from 
endothelial cells producing NO also bone marrow-derived cells homing towards isch-
emic tissue were able to produce NO and thus induce vasodilation38.
Collateral growth
Collateral growth is characterized as the response of adult arteries with structural 
changes to changes in blood flow, during which the lumen is controlled by an immedi-
ate physiological adjustment in vascular tone induced by the change in flow, and by a 
delayed anatomical change that occurs when the change in flow persists39. During this 
early adaptive response to increased fluid shear stress a strong vasodilation results in 
a transient, temporary increase in flow through the collaterals. The persistent increase 
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in shear stress subsequently triggers endothelial production of a host of molecules 
(growth regulatory, inflammatory and adhesive) leading to the complex inflammatory-
based mechanism of collateral enlargement with endothelial and vascular smooth 
muscle cell proliferation. While ample evidence exists for the function and critical 
role of endothelial NO in vasomotion and angiogenesis, the role of eNOS in collateral 
growth is less clear, and is even known as the NO-paradox6.
On the one hand, increased shear stress upregulates the expression of eNOS augment-
ing endothelial NO production, probably resulting in the rapid vasodilatory response. In 
contrast, NO also acts as a potent inhibitor of the expression of adhesion molecules and 
smooth muscle cell proliferation, which are both indispensable for collateral growth. 
NO has emerged as a crucial endogenous antiinflammatory mediator in a number of 
pathophysiological states including hypercholesterolemia and ischemia-reperfusion 
injury. More specifically, NO can act by downregulating cytokines, resulting in the 
downregulation of endothelial cell adhesion molecules (ECAMs). The mechanism of 
leukocytes recruitment is mediated by these ECAMs such as the selectin family (P- and 
E-selectin), which are important modulators of leukocyte-endothelium interaction via 
leukocytes rolling along the endothelium and adhesion to the endothelium. Once the 
cells begin to roll, they can then firmly attach to the endothelium via integrin interac-
tion with endothelial intercellular adhesion molecules (ICAMs) to promote leukocyte 
adhesion33. Pharmacological studies have shown that NOS inhibitors could increase 
leukocyte adhesion, an effect that can be reversed by large amounts of exogenous 
L-arginine. Similar studies using eNOS KO mice confirmed that upon activation of an 
inflammatory response, eNOS derived NO is critical for the reduction of leukocytes 
adhesion and the extent of tissue injury. Using another inflammatory model, namely 
the myocardial ischemia–reperfusion injury, NO was also shown to provide a protective 
role in the injury cascade leading to inflammation33.
In addition to the role of NO as an inhibitor of leucocyte adhesion, NO in the microcir-
culation can also prevent platelets from adhering to the endothelium and assist with 
the dis-aggregation of activated platelets to the endothelium or underlying basement 
membrane. This concept was unequivocally demonstrated in mice deficient for eNOS, 
in which platelet adhesion was increased and consequently bleeding times were de-
creased40,41.
Finally, while eNOS upregulation in the vessel wall was demonstrated in immunohisto-
chemical studies of collateral arteries, eNOS-deficient mice display decreased vascular 
remodeling in response to femoral artery ligation and suffer from severe peripheral 
ischemic complications. Recent studies have attributed this effect in eNOS KO mice to 
impaired collateral growth, angiogenesis, vasculogenesis, or a combination of these42-44. 
However, in these studies the different competing or complementary mechanisms of 
vascular growth could not be isolated because of the use of a severe ischemia model, 
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which causes substantial damage to the lower limb. Thus, the role of eNOS in the differ-
ent types of vascular remodeling could not be elucidated. Therefore, in absence of an in 
vivo model specific for collateral growth, the role of eNOS in collateral growth remains 
paradoxical.
Vasculogenesis
The first step in vasculogenesis is mobilization of progenitor cells in their microenviron-
ment, sometimes described as stem cell niche. A variety of cytokines (granulate-colony-
stimulating factor (G-CSF), SDF-1, VEGF, PlGF and erythropoietin) induce the mobiliza-
tion of progenitor cells via activation of proteases (cathepsins, MMPs), which interfere 
with receptor ligand-interactions that maintain progenitor cells in their environment45. 
This process is dependent on eNOS-mediated release of NO. In eNOS KO mice MMP-9 
induction via VEGF signaling is significantly decreased, thus mobilization from bone 
marrow progenitor cells is impaired and the neovascularization response to ischemia 
hampered42. Transplantation of wild-type eNOS-expressing bone marrow cells was not 
able to rescue the neovascularization response, indicating that NO provided by the 
local (ischemic) environment also regulates progenitor cell functions.
eNOS 
NO 
Figure 5. eNOS is a mediator of progenitor cell mobilization via VEGF-A/MMP-9 pathway. (Figure modified 
from Rafii & Lyden46 with permission)
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Furthermore, progenitor cells are able to produce growth factors involved in vascular 
remodeling. At arrival at the target ischemic tissue, progenitor cells interact with the 
activated endothelium through SDF-1 and CXCR4 signaling and release NO via an 
eNOS-dependent pathway. Production of NO subsequently induces a marked vasodila-
tion and disruption of vascular endothelial-cadherin/β-catenin complexes, leading to 
increased vascular permeability. Progenitor cells from eNOS-deficient mice were not 
able to induce this vasodilation and vasopermeability demonstrating that the ability of 
progenitor cells to produce NO is critical for their proangiogenic function38.
Angiogenesis and arteriogenesis
The mechanisms that regulate angiogenesis in hypoxia or hypoxic microenvironment 
are modulated by various pro- and antiangiogenic factors. Hypoxia-inducible factors 
(HIFs) have been established as the basic and major inducers of angiogenesis, up-
regulating expression of these angiogenic proteins. A complex interplay with NO exists 
upstream from HIF activation, as NO drives HIF-1α stabilization under normoxia while 
NO favors the degradation of HIF-1α under hypoxia47. Thus, via HIF-1α, NO is able to 
mediate the activation of several angiogenic proteins.
Progenitor Cells 
differentiation adhesion 
invasion 
proliferation 
ATHEROSCLEROSIS paracrine 
 effects 
vasodilation homing NO 
NO 
NO NO 
NO 
Figure 6. Consecutive proangiogenic effects of NO release in neovascularization. (Figure modified from 
Dimmeler et al48 with permission)
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When activated by HIFs, angiogenic growth factors as VEGF, PDGF, angiopoietin-1 (Ang-
1) or sphingosine 1-phosphate (S1-P) signal through their receptors on endothelial 
cells and activate endothelial NO synthase. This process is mediated through increased 
calcium concentration, by activating Akt via the phosphatidylinositol 3-kinase (PI3K)-
mediated pathway and the recruitment of heat-shock protein 90 (Hsp90). Vice versa, 
NO is able to stimulate the expression of VEGF-A and its receptors. Finally, NO release 
induces angiogenesis by stimulating endothelial cell migration, proliferation and 
survival. Although NO is an inhibitor of the TGFβ pathway inhibiting vascular smooth 
muscle cell proliferation in various models (pulmonary hypertension, arterial calcifica-
tion) there is no evidence of hampered vessel stabilization by NO production.
Therapeutic Vascular Remodeling
To prevent or treat ischemic cardiovascular disease, the concept of therapeutic vascu-
lar remodeling, eg. the stimulation of tissue vascularization after ischemia, has been 
developed and recently made the step from bench to bedside. Therapeutic vascular 
remodeling strategies fall into two categories: single gene/protein- or cell-based.
Angiogenic growth factor (e.g., VEGF, FGFs, and hepatocyte growth factor) therapy 
has been tested clinically for more than 5 years. Overall, benefit for peripheral arterial 
occlusive disease (PAOD) patients has been disappointing49,50. While repeated admin-
istration of the angiogenic gene may increase the chances of success as demonstrated 
by a recent study treating PAOD patients with FGF-151, the current thought is that 
use of a combination of growth factors, or “master switches” (e.g., hypoxia-inducible 
factor (HIF)-1α), may be better strategies for successful revascularization due to the 
molecular complexity of collateral growth and neovascularization52. Moreover, recently, 
the concept of combining angiogenesis (determining oxygen delivery) with induction 
of metabolic changes (regulating oxygen consumption) by (ischemic) muscle was 
introduced as a promising new strategy to treat patients with ischemia53,54.
In addition, the disappointing results may be related to a combination of endothelial 
dysfunction and the reduced amount or the lack of responsiveness of endogenous pro-
genitor (vascular) cells in patients with cardiovascular disease, as the success of admin-
istration of growth factors depends on the ability of progenitor cells to be recruited and 
to expand. In this context, the concept of (stem) cell-based revascularization emerged 
in 1997, when Isner and coworkers described circulating cells in adults –called ‘endo-
thelial progenitor cells’ (EPC)– with the capacity to differentiate into endothelial cells 
(EC) and incorporate into new vessels in ischemic tissue12. Since then, the number of 
studies reporting on (stem) cell-related revascularization has exponentially increased 
and recent clinical studies have demonstrated the safety, feasibility and efficacy of 
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intracoronary and intramuscular infusion of adult bone marrow-derived mononuclear 
cells (BMMNC) in patients with PAOD, acute myocardial infarction, and ischemic cardio-
myopathy50,55.
However, despite this excitement regarding the possible clinical use of BMMNC, in ath-
erosclerosis, diabetes and other risk factors for cardiovascular diseases the availability 
of bone marrow cells is reduced. In addition their function is impaired to varying de-
grees hampering proneovascularization effects of autologous cell-based therapies50,55. 
Moreover, the safety of BMMNC treatment has been questioned by studies finding an 
increase in atherosclerotic plaque size after BMMNC treatment56,57. This potentially 
hazardous dual effect of therapeutic neovascularization on atherogenesis is explained 
by the many common pathways of both mechanisms and has been named the “Janus 
Phenomenon”58.
Therefore, although pioneering clinical experience with stem cell-related therapy 
seems promising, many questions remain unanswered and it seems too early for gen-
eral clinical use of this technique.
Aim of the thesis
Decreased bioavailability of nitric oxide is a hallmark in cardiovascular disease, result-
ing in or due to endothelial dysfunction. The aim of the present thesis was to unravel 
the role of NO in vascular remodeling. To this aim, we developed in our laboratory two 
different lines of transgenic mouse models with increased human eNOS expression, 
leading to elevated bioavailability of NO in physiological and pathophysiological 
circumstances. Using these eNOS transgenic (eNOS TG) mice we studied the complex 
regulation of eNOS in collateral growth, cell adhesion and neovascularization and the 
effects of elevated NO production on these processes of vascular remodeling. Fur-
thermore, in order to increase the clinical relevance, we evaluated the effects of eNOS 
overexpression under pathophysiological conditions as diabetes and atherosclerotic 
disease. Finally, we developed a new concept of eNOS transgenic progenitor cell trans-
plantation for therapeutic vascular remodeling in ischemic disease.
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Abstract
In the vascular system, nitric oxide is generated by endothelial NO synthase (eNOS). NO 
has pleiotropic effects, most of which are believed to be atheroprotective. Therefore, 
it has been argued that patients suffering from cardiovascular disease could benefit 
from an increase in eNOS activity. However, increased NO production can cause oxida-
tive damage, cell toxicity and apoptosis, and hence could be atherogenic rather than 
beneficial. To study the in vivo effects of increased eNOS activity, we created transgenic 
mice overexpressing human eNOS. Aortic blood pressure was ~20 mm Hg lower in 
the transgenic mice compared to control mice because of lower systemic vascular 
resistance. The effects of eNOS overexpression on diet-induced atherosclerosis were 
studied in apolipoprotein E-deficient mice. Elevation of eNOS activity decreased blood 
pressure (~20 mm Hg) and plasma levels of cholesterol (~17%), resulting in a reduc-
tion in atherosclerotic lesions by 40%. We conclude that an increase in eNOS activity is 
beneficial and provides protection against atherosclerosis.
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Introduction
Endothelial nitric oxide synthase (eNOS) plays an important role in the regulation of 
vascular tone, vascular biology and haemostasis. For example, NO produced by eNOS 
causes vasodilation. Thus, eNOS knock out mice are hypertensive1, while eNOS trans-
genic mice have hypotension2. In addition, NO reduces the activation and aggregation 
of platelets3,4, attenuates adhesion of leukocytes to the endothelium5-7, reduces the 
permeability of the endothelium and inhibits proliferation and migration of vascular 
smooth muscle cells8. Impaired activity of eNOS is associated with endothelial cell 
dysfunction9. For these reasons eNOS has been proposed to modulate atherosclerotic 
disease10-12. Indeed, impairment or deficiency of eNOS gives rise to accelerated ath-
erosclerosis in animal models10,12-14, indicating that physiological levels of eNOS are 
antiatherogenic. This suggests that patients at increased risk of atherosclerotic vascular 
disease could possibly benefit from an increase of eNOS activity by pharmacological 
means or (local) gene therapy. However, eNOS derived NO also has detrimental ef-
fects15, like the generation of superoxides16, making it difficult to predict whether in-
creased eNOS activity is beneficial or harmful17. To determine whether increased eNOS 
activity may be beneficial, we created transgenic mice that express the human eNOS 
gene. These mice were crossbred to apolipoprotein E-deficient (apoE0) mice in order to 
evaluate the effects of a constitutive increase in eNOS activity on the development of 
atherosclerosis.
Experimental Procedures
Mice
A DNA fragment containing the human eNOS gene was isolated from a home made 
human genomic cosmid library18 using eNOS cDNA (kindly donated by Dr. S. Janssens, 
Leuven, Belgium19) as a probe. In addition, the DNA fragment contained ~6kb of 5’ natu-
ral flanking sequence, including the native eNOS promoter, and ~3kb of 3’ sequence to 
the gene. Vector sequences were removed by restriction endonucleases. A solution of 
1-2 µg/ml of DNA was used for microinjection of fertilized oocytes from FVB donor mice 
and transplanted into the oviducts of pseudopregnant B10xCBA mice. Founder mice 
and offspring were genotyped by PCR on DNA isolated from tail biopsies. Primers used 
were: 5’-GTC CTG CAG ACC GTG CAG C-3’ (sense) and 5’-GGC TGT TGG TGT CTG AGC 
CG-3’ (antisense). Mice were backcrossed to C57Bl6 for at least 5 generations (>96% 
C57Bl6). All eNOS transgenic mice were hemizygous. ApoE0 mice were obtained from 
the The Jackson Laboratory, Bar Harbor, ME. Male mice were used in all experiments. 
All animal experiments were performed in compliance with institutional (Erasmus MC, 
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Rotterdam, The Netherlands) and national (Ministry of Health, Welfare and Sport, The 
Hague, The Netherlands) guidelines.
Western blotting and immunohistochemistry
Aortas were collected and homogenized in 50 mM Tris-HCl, pH7.4 containing 1 mM 
EDTA, 0.25 M sucrose and 20 mM CHAPS. Western blotting was performed as described 
previously20. 25 µg of protein (BCA protein assay kit; Pierce Chemical Company, Rock-
ford, IL) was applied to each lane. Anti-eNOS was obtained from Santa Cruz Biotech-
nology Inc., Santa Cruz, CA. This antibody was also used for immunohistochemistry 
experiments, which were performed according to Bakker et al21.
Hemodynamic measurements
Baseline blood pressure measurements
Mice were weighed, anesthetized with ketamine (100 mg/kg ip) and xylazine (20 mg/
kg ip), intubated and ventilated with a mixture of O2 and N2 (1/2 vol/vol) with a pressure 
controlled ventilator (Servo ventilator 900C, Siemens-Elema, Sweden). The ventilation 
rate was set at 100 strokes/min with a peak inspiration pressure of 18 cmH2O and a 
positive end expiration pressure of 6 cmH2O. After intubation the mice were placed on 
a heating pad to maintain body temperature at 37°C and a polyethylene catheter (PE 
10) was inserted into the right carotid artery and advanced into the aortic arch, for the 
measurement of aortic pressure. In the first part of the study we used 12 eNOS-Tg2 and 
5 eNOS-Tg3 mice for screening of eNOS expression, and compared them to 33 wild-
type mice. Ten minutes after a second intraperitoneal bolus of anesthetics (100 mg/kg 
ketamine and 20 mg/kg xylazine) baseline blood pressure recordings were obtained.
Effect of L-NAME on systemic vascular resistance
Subsequently, we chose the eNOS-Tg2 line to determine whether the lower aortic blood 
pressure was the result of an NO-mediated decrease in systemic vascular resistance. For 
this purpose, in 17 eNOS-Tg2 mice and 17 wild-type mice a polyethylene catheter (PE 
10) was inserted into the right carotid artery and advanced into the aortic arch, for the 
measurement of aortic pressure, while another PE 10 catheter was introduced into the 
right external jugular vein and advanced into the superior caval vein for infusion of 
L-NAME. After thoracotomy through the second right intercostal space, the ascend-
ing aorta was exposed and a transit-time flow probe (ID 1.5 mm; Transonics systems 
Inc. T206) was placed around the aorta for measuring aorta flow. Ten minutes after a 
second intraperitoneal bolus of 100 mg/kg ketamine and 20 mg/kg xylazine, baseline 
recordings were obtained. A continuous 10 minutes intravenous infusion of L-NAME 
(100 mg/kg) was started: 10 minutes after completion of the infusion, measurements 
were repeated.
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Effects of dietary suppletion of L-arginine on baseline hemodynamics
In the eNOS-Tg2 line we studied whether L-arginine deficiency contributed to the mod-
est effects of eNOS overexpression on systemic vascular resistance. For this purpose, in 
six eNOS-Tg2 male mice and seven wild-type male mice, L-arginine was supplemented 
in their drinking water (2.5% w/v). One week later, animals were instrumented as 
described above and hemodynamic measurements were performed under baseline 
conditions.
Data analysis
Hemodynamic data were recorded and digitized using an on-line 4 channel data ac-
quisition program (ATCODAS, Dataq Instruments, Akron, OH), for later analysis with a 
program written in MatLab (Mathworks Inc, Natick, MA). Fifteen consecutive beats were 
selected for determination of heart rate, aortic pressure, and aorta blood flow.
eNOS activity assay
Aortas were collected and homogenized in 50 mM Tris-HCl, pH7.4 containing 1 mM 
EDTA, 0.25 M sucrose and 20 mM CHAPS. eNOS activity assays were performed by 
measuring L-arginine to L-citrulline conversion using a nitric oxide synthase assay kit 
(Calbiochem, La Jolla, CA; cat.no. 482700) according to the manufacturer’s instructions. 
Protein content was measured by the BCA protein assay kit (Pierce Chemical Company, 
Rockford, IL).
Lipid measurements
Blood was collected via orbital puncture after an overnight fasting period. Plasma was 
frozen freshly or subjected to ultracentrifugation in a Beckman 42.2 Ti rotor (42000 
rpm, 3 h, 12°C) at d = 1.063 g/ml. Tubes were sliced and two fractions were collected: 
very low-density lipoprotein (VLDL) + low-density lipoprotein (LDL): d < 1.063 g/ml, 
and high-density lipoprotein (HDL): d > 1.063 g/ml. Cholesterol was measured with 
the F-chol kit (Roche Molecular Biochemicals) after hydrolysis of cholesteryl esters with 
cholesterol esterase from Candida cylindracea (Roche Molecular Biochemicals).
Atherosclerosis
Atherosclerosis experiments were performed in age- and sex-matched mice. Male mice 
of 8 weeks were fed a Western type diet, containing 15% (w/w) cacoa butter and 0.25% 
(w/w) cholesterol (diet W, Hope Farms, Woerden, The Netherlands) for 6 weeks, which 
leads to appreciable atherosclerosis22-24. Animals were anesthesized using isoflurane, 
and in situ fixation was performed via the left ventricle of the heart using phosphate 
buffered formalin (4%, v/v). A Sony digital camera was used to obtain images of sec-
tions of the aortic root. These were analyzed by Scion Image processing and analyzing 
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software (available from www.scioncorp.com). Atherosclerosis was quantified in five 
sections per mouse with 80 µm intervals using the method of Paigen et al25.
Data analysis
Analysis of data was performed using two-way or one-way analysis of variance followed 
by Scheffé’s test, as appropriate. Statistical significance was accepted when P<0.05 
(two-tailed). Data are presented as mean ± S.E.
Results and Discussion
For the generation of eNOS transgenic mice, we used a DNA fragment that comprised 
the complete human eNOS genomic sequence, including all exons and introns as well 
its natural flanking sequences. Therefore, our mice are different from those described 
by Ohashi et al which overexpressed bovine eNOS cDNA, driven by the murine pre-
proendothelin-1 promoter2. Our approach was chosen in order to preserve the natural 
regulation of the gene and to prevent ectopic expression. For example, the endothe-
lium enhancer element that is located 4.9 kilobases upstream from the transcription 
start site of the eNOS gene26 is included in this construct. By using this construct we 
mimic the human situation in terms of regulation and tissue distribution of eNOS as 
much as possible.
Two independent lines with appreciable overexpression of the transgene, as measured 
by RT-PCR (not shown), were selected and arbitrarily designated eNOStg2 and eNOStg3. 
Production of human eNOS protein was demonstrated by Western blotting of aorta ho-
mogenates (Fig. 1A). Subsequently, eNOS activity in aortas from control (wild-type) and 
eNOS-overexpressing mice was measured, using the L-arginine to L-citrulline conver-
sion assay27. In aorta, the level of active eNOS enzyme was 10-fold increased in eNOStg2 
mice and 7.5-fold in eNOStg3 mice, respectively, when compared to wild-type animals 
(Fig 1B). Expression of human eNOS was also investigated by immunohistochemistry. 
There was no human eNOS staining of aortas of wild-type mice, whereas the endothelial 
layer of the aorta was clearly stained in both human eNOS transgenic lines (Fig 1C).
The expression pattern of the the human eNOS transgene was investigated by immu-
nohistochemistry in heart (Fig. 2A), liver (Fig. 2B), kidney (Fig. 2C), adrenal (Fig. 2D) and 
testis (Fig. 2E). Sections from wild-type controls show virtually no immunostaining (not 
shown). The lining of the larger vessels is clearly stained (Fig. 2A, 2D and 2E) . Staining 
of capillaries is visible in the heart, between the cardiomyocytes. Immunoreactivity is 
observed in the sinusoids in the liver, and, in the kidney, in the peritubular capillaries 
as wells as in the capillaries from the glomeruli. In the adrenal, the cortical capillaries as 
well as medullary capillary sinusoids and veins are stained.
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Fig. 1. Expression of eNOS in transgenic mice. (A) Western blot analysis of aortas from control 
(wild-type littermates), eNOStg2 or eNOStg3 mice. 25 µg of homogenate was applied per lane. The 
blot was probed with anti human eNOS antibody. A single protein band of the expected molecular 
size (~130 kDa) was detected. (B) eNOS activity was measured in aortas from control (Wt), eNOStg2 
(Tg2) or eNOStg3 (Tg3) mice by the L-arginine to L-citrulline conversion assay using a nitric oxide 
synthase assay kit (Calbiochem). Activity is expressed as percentage of the activity in controls, which 
was 1.56 ± 0.31 pmol/µg/min. Each value represents the mean ± S.E. of three animals. One of three 
experiments is shown. *P<0.05 vs controls, †P<0.05 vs eNOStg2 mice (ANOVA followed by Scheffé’s test). 
(C) Immunohistochemistry on aortas from control, eNOStg2 or eNOStg3 mice. Aortas were collected 
after in situ fixation. Paraffin sections were incubated with antihuman eNOS antibody and a peroxidase-
conjugated secondary antibody. Original magnification, x630.
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Fig. 2. Expression pattern of human eNOS in transgenic mice. Organs from eNOStg2 mice were 
collected after in situ fixation. Paraffin sections were incubated with antihuman eNOS antibody and 
a peroxidase-conjugated secondary antibody. A: heart, B: liver, C: kidney, D: adrenal, E: testis tissue. 
Arrowheads indicate representative immunoreactive capillaries; arrows indicate larger blood vessels. 
Original magnification, x400.
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In the testis, only blood vessels between the seminiferous tubules are stained. The 
parenchyma cells of none of these organs show appreciable immunoreactivity. Similar 
results were found with sections from eNOStg3 mice (not shown).
Our results show that the genomic sequences included in the DNA fragment we used are 
sufficient for expression in endothelial cells. Although eNOS activity is tightly regulated 
at the posttranslational level28,29, there is also extensive regulation at the transcriptional 
level30,31. The present study shows that our construct results in high level expression of 
human eNOS which is not prevented by a feedback mechanism.
To study the effect of increased eNOS activity on blood pressure and vascular tone, 
we performed hemodynamic studies32. Heart rates were similar for wild-type controls 
and eNOS transgenic lines, whereas both eNOS transgenic lines each exhibited a 20-25 
mmHg lower mean aortic blood pressure compared with littermate controls (Fig. 3A). 
Subsequent hemodynamic studies were performed in eNOStg2, the transgenic mouse 
line with the highest expression. These experiments showed that the lower aortic blood 
pressure was the result of a 30% lower systemic vascular resistance, because mean 
aortic blood flow and heart rate were similar in both groups (Fig. 3B). Subsequent infu-
sion of the NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME) increased systemic 
vascular resistance and abolished the difference between control and eNOStg2 mice. 
We therefore conclude that the lower basal systemic vascular resistance in eNOStg2 
mice is the result of increased NO production (Fig. 3B). This is corroborated by the 
significantly larger increase in blood pressure in response to L-NAME in the transgenic 
mice. Suppletion of L-arginine had no effect on the already lower mean aortic blood 
pressure and heart rate in the transgenic mice (Fig. 3C). We therefore also conclude 
that the blood pressure lowering effect of eNOS overexpression was not limited by a 
shortage of substrate.
The present study shows that the lower blood pressure associated with eNOS over-
expression (as reported before2) is the result of a lower systemic vascular resistance. 
Thus eNOS activity was not only increased in the larger blood vessels but also in the 
microcirculation. Although eNOStg2 and eNOStg3 mice showed a slight variation in 
eNOS activity (Fig. 1B), the degree to which blood pressure was lowered was not dif-
ferent. This suggests that another rate-limiting factor, or one or more compensatory 
mechanisms prevented a further decrease in blood pressure in the eNOStg2 mice.
To study whether the increased expression of eNOS protects the mice against the 
development of diet-induced atherosclerosis, eNOS transgenic mice were cross-bred 
to apoE0 mice, which represent a well-known mouse model for studying atheroscle-
rosis33,34. The animals were fed a Western type diet for 6 weeks. As shown in Fig. 4A, 
overexpression of eNOS also caused a decrease in systemic blood pressure under these 
conditions, although heart rates were similar.
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Fig. 3. Hemodynamic measurements. (A) Mean aortic pressure and heart rate were measured in 
anesthetized control (Wt, wild-type littermates), eNOStg2 (Tg2) or eNOStg3 (Tg3) mice. (B) Mean aortic 
pressure, heart rate, mean aortic blood flow and systemic vascular resistance were analyzed in control 
(Wt, wild-type littermates) or eNOStg2 (Tg) mice before and following infusion of L-NAME. (C) Mean aortic 
pressure and heart rate were measured in anesthetized control (Wt, wild-type littermates), or eNOStg2 
(Tg) mice following one week of drinking water with or without L-arginine supplementation (L-Arg, 2.5% 
w/v). Each value represents the mean ± S.E. of ≥ five animals. *P<0.05 vs controls (Wt), †P<0.05 vs baseline 
(before infusion of L-NAME), ‡P<0.05 vs controls (Wt) after infusion of L-NAME (ANOVA followed by 
Scheffé’s test).
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Table 1. Plasma lipid and lipoprotein analysis
Total cholesterol concentrations in plasma from apoE-deficient control (apoE0), apoE0/eNOStg2 or apoE0/
eNOStg3 mice after feeding a normal chow diet or an atherogenic diet. Cholesterol concentrations were 
determined by enzymatic methods. VLDL + LDL and HDL fractions were isolated by ultracentrifugation. 
TC: total cholesterol (mM); VLDL + LDL: cholesterol in VLDL and LDL (mM); HDL: cholesterol in HDL (mM).
Chow Atherogenic diet
n TC TC VLDL+LDL HDL
apoE0 32 10.9 ± 0.3 28.4 ± 0.9 27.3 ± 0.8 0.4 ± 0.02
apoE0/eNOStg2 22  9.2 ± 0.4** 23.3 ± 1.1** 21.9 ± 1.1*** 0.4 ± 0.02
apoE0/eNOStg3 19  9.0 ± 0.2*** 24.4 ± 1.1* 24.3 ± 1.0* 0.4 ± 0.02
* P<0.05
** P<0.01
*** P<0.001
Plasma cholesterol levels were measured before the start of the atherogenic diet (i.e. 
on normal chow diet) and at the end of the experiment (Table 1). Both eNOS transgenic 
lines showed a decrease in plasma cholesterol of ~15% when compared to apoE0 mice 
when fed a normal chow diet.
As expected, the Western diet resulted in a dramatic increase (~3-fold) in plasma cho-
lesterol levels, while the total cholesterol concentration remained lower in the eNOS 
transgenic animals when compared to apoE0 controls (~ –16%). This difference was 
due to variations in the VLDL and LDL, which contain the bulk of the plasma cholesterol 
under these conditions: HDL-cholesterol concentration in plasma was 0.4 mM and did 
not differ between the groups (Table 1). These findings indicate that elevated eNOS 
activity results in a slightly more favorable (i.e. less atherogenic) lipoprotein profile, be-
cause VLDL and LDL contain the atherogenic portion of plasma cholesterol35, whereas 
HDL is protective against the development of atherosclerosis36,37.
 To study the effect of eNOS overexpression on atherosclerosis, the atherosclerotic le-
sion areas in the aortic roots were measured. Fig. 4B shows representative examples of 
histological sections. Compared with apoE0 mice, we observed a decrease in athero-
sclerosis in both lines of eNOS transgenic mice studied (Fig. 4C).
Several studies have described a relation between plasma cholesterol and eNOS activ-
ity38-40. However, these investigations exclusively focused on the effects of changes in 
plasma cholesterol levels on eNOS activity. Hypercholesterolemia is associated with 
decreased eNOS activity, probably via an interaction of oxidized LDL with caveolae, the 
plasma membrane domains in which eNOS resides41. Cholesterol synthesis inhibitors 
(statins) have been reported to increase eNOS activity in addition to their cholesterol 
lowering effects, but these actions appear to be independent38.
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Fig. 4. Analysis of eNOS transgenic/apoE-deficient mice. (A) Mean aortic pressure and heart rate were 
measured in anesthetized apoE-deficient control (apoE0; n=15), apoE0/eNOStg2 (n=8) or apoE0/eNOStg3 
(n=8) mice. (B) Representative photomicrographs of H&E stained paraffin sections with lesion areas in the 
aortic valves (arrowheads). Original magnification, x25. (C) Lesion area in the aortic root of apoE-deficient 
control (apoE0; n=32), apoE0/eNOStg2 (n=22) or apoE0/eNOStg3 (n=19) mice. Areas were measured in 
five sections with 80-µm intervals and expressed as µm2 per section per animal.
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In the present study we observed that the level of eNOS-expression affects the level 
of plasma cholesterol: plasma levels of cholesterol were about 15% lower in eNOStg/
apoE0 mice as compared with apoE0 controls.
A similar difference in plasma cholesterol levels was found after feeding the mice a 
Western type diet for 6 weeks, indicating that eNOS overexpression alleviates diet-
induced hypercholesterolemia. This effect is not caused by ectopic expression in or-
gans involved in lipid metabolism, e.g. the liver, as the expression pattern is restricted 
to endothelial cells in all organs that were examined (Fig. 2). Recently it was shown 
that hypercholesterolemia in mice results in CD36-mediated cholesterol depletion of 
caveolae, followed by translocation of eNOS from caveolae and subsequent inactiva-
tion of the enzyme42. Thus, eNOS activity is directly related to the cholesterol content 
of caveolae. Possibly, the moderate decrease in plasma cholesterol that we observed 
in our eNOS transgenic mice is caused by a recruitment of plasma cholesterol by the 
endothelial cells in order to handle the increased level of eNOS protein. This small de-
crease in plasma cholesterol likely contributed, at least in part, to the observed lower 
susceptibility to diet-induced atherosclerosis.
Although it has been proposed that elevation of eNOS activity would attenuate ath-
erosclerosis11, serious doubts have also been expressed as to whether an increase in 
eNOS activity in vivo would have beneficial effects, because high levels of NO (e.g. as 
produced by inducible NO synthase) have been implicated in cell toxicity and apopto-
sis15,43. During the preparation of our manuscript, Ozaki et al44 reported the unexpected 
observation that relatively modest overexpression of eNOS resulted in increased athero-
sclerosis. Based on our findings, we conclude that this conclusion cannot be general-
ized, taking into account the following considerations. First, because enzyme activity is 
± 1.5 fold increased, the level of eNOS overexpression in the mice used by Ozaki et al is 
relatively low, when compared with the much higher NO production levels by activated 
iNOS (inducible NO synthase). A 1.5 fold increase is also rather low in terms of possible 
drug or gene therapy applications. Second, the observed increase in atherosclerosis is 
explained by measurements indicating that the overexpressed eNOS enzyme is dys-
functional in the mouse model used by Ozaki et al This finding is not unexpected, given 
the moderate level of overexpression in their mice, as it has been previously reported 
that endogenous eNOS is indeed dysfunctional in terms of NO production in apoE0 
mice fed a Western type diet45. The results from the study by Ozaki et al are probably (at 
least in part) explained by the construct used by the authors, which consists of cDNA 
(often leading to low expression levels) and a heterologous promoter. In contrast, our 
results demonstrate that overexpression of human eNOS in endothelial cells indeed 
results in decreased atherosclerosis, most likely via lowering blood pressure and plasma 
cholesterol. Our study therefore suggests that elevation of eNOS activity could be ben-
eficial for patients at risk of developing atherosclerotic disease.
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Abstract
The activity of endothelial nitric oxide synthase (eNOS) is subject to complex transcrip-
tional and posttranslational regulation including the association with several proteins 
and variations in subcellular distribution. In the present study we describe a transgenic 
mouse model expressing eNOS fused to green fluorescent protein (GFP), which allows 
the study of localization and regulation of eNOS expression. We tested the functionality 
of eNOS in the eNOS–GFP mice. Expression of eNOS was restricted to the endothelial 
lining of blood vessels in various tissues tested, without appreciable expression in non-
endothelial cells. Activity of the enzyme was confirmed by essaying the conversion of 
L-arginine to L-citrulline. NO production in isolated vessels was increased in transgenic 
mice when compared to non-transgenic control animals 4.88± 0.59 and 2.48± 0.47 µM 
NO, respectively, P<0.005). Both the mean aortic pressure and the pulmonary artery 
pressure were reduced in eNOS–GFP mice (both ~30%, P<0.05). Plasma cholesterol lev-
els were also slightly reduced (~20%, P<0.05). In conclusion, eNOS–GFP mice express 
functional eNOS and provide a unique model to study regulation of eNOS activity or 
eNOS mediated vascular events, including response to ischemia, response to differ-
ences in shear stress, angiogenesis and vasculogenesis, and to study the subcellular 
distribution in relation with functional responses to these events.
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Introduction
In endothelial cells, nitric oxide (NO) is generated by the enzyme endothelial nitric 
oxide synthase (eNOS) via the conversion of L-arginine to L-citrulline. NO produced by 
eNOS affects a number of biological processes in the vessel wall. It is important for the 
regulation of blood pressure and plays an important role in the aggregation of blood 
platelets, adhesion of leukocytes to the vessel wall and migration of vascular smooth 
muscle cells1. A decrease in NO availability is one of the hallmarks of endothelial dys-
function, which can occur in a number of cardiovascular disorders, including hyperten-
sion, heart failure, diabetes and atherosclerosis2. It has been shown in animal models 
that a decrease in eNOS activity results in accelerated atherosclerosis3,4. Conversely, 
stimulation of eNOS activity by statin treatment has been implicated in the protective 
actions of these drugs5-7.
For these reasons, the regulation of eNOS activity is considered to be of major physi-
ological and pathophysiological importance. Although eNOS was originally termed 
endothelial constitutive NOS (ecNOS)8-10, several laboratories have found that its 
protein expression and enzymatic activity is under tight regulation10-13. In addition to 
regulation at the transcriptional level, protein activity is controlled in several ways. 
Regulatory processes include N-myristoylation and cysteine palmitoylation, serine/
threonine phosphorylation, and protein-protein interactions. These events affect the 
intracellular localization of eNOS, which might influence its enzymatic activity. Nor-
mally, eNOS is localized in two subcellular compartments: the Golgi complex and the 
plasma membrane14. Although it has been suggested that translocation between these 
two compartments is important in the regulation of the enzymatic activity, it has been 
demonstrated that eNOS in both pools can be phosphorylated and activated14. In vitro 
studies of cells transfected with eNOS cDNA fused to DNA encoding green fluorescent 
protein (GFP) have provided valuable information of eNOS localization and regulation. 
However, to date such studies have not been performed in vivo. Consequently, we de-
veloped a transgenic mouse model in which an eNOS–GFP fusion protein is expressed. 
The results indicate that the eNOS fusion protein is functionally intact. These eNOS–GF-
Ptg mice can be used to study vascular reactions in which eNOS is involved, including 
angiogenesis or response to variations in shear stress.
Materials and Methods
Generation of eNOS–GFP transgenic mice
A genomic DNA fragment was isolated from a homemade human cosmid library. It 
included 6 kb of 5’ sequence, the complete eNOS gene, and 3 kb of 3’ sequence. At 
Chapter 3: The eNOS-GFP Transgenic Mouse
44
the STOP codon of the eNOS gene, a linker was introduced that allowed the in frame 
insertion of a BamHI-NotI DNA fragment encoding eGFP which was derived from the 
pEGFP-N1 plasmid (BD-Sciences Clontech, Palo Alto CA). Fertilized oocytes from FVB 
mice were microinjected with a solution of 1-2 µg/ml in 8 mM Tris-HCl, 0.1 mM EDTA 
and transplanted into the oviducts of pseudopregnant B10xCBA mice. Founder mice 
and offspring were genotyped by PCR on DNA isolated from tail biopsies. Primers used 
were: 5’-GTCCTGCAGACCGTGCAGC-3’ (sense) and 5’-GGCTGTTGGTGTCTGAGCCG-3’ 
(antisense). Mice were backcrossed to C57Bl6 for at least 5 generations (>96% C57Bl6). 
Transgenic mice used in the present study were hemizygous. All animal experiments 
were performed in compliance with institutional and national guidelines.
Immunohistochemistry, fluorescence microscopy, confocal microscopy
Immunohistochemistry experiments were performed according to Bakker et al15 on 7 
µm paraffin sections. The antibodies used were raised against the carboxy terminus 
of eNOS (Santa Cruz Biotechnology Inc., Santa Cruz, CA, cat.nr. sc-654). For confocal 
microscopy, mice were sacrificed using an overdose of isoflurane (1-chloro-2,2,2-
trifluoroethyl-difluoromethyl-ether). Subsequently, in situ perfusion fixation was per-
formed by flushing 20 ml PBS through a cardiac puncture followed by 20 ml 4% (v/v) 
paraformaldehyde in PBS. The common carotid arteries were then harvested, fixed in 
4% paraformaldehyde in PBS at 4°C, and mounted in Vectashield® (Vector Laboratories, 
Inc, Burlingame, CA) between glass slides. Samples were examined under a Zeiss LSM 
inverted laser scanning confocal fluorescence microscope. Images of GFP fluorescence 
were acquired after excitation with a 488-nm argon laser and after filtering the fluo-
rescence with a 500-550 nm bandpass barrier filter. The thickness of the optical slice 
images is 0.6 μm.
Western blotting
Western blotting experiments were performed as described previously16. The antibod-
ies used were directed against human eNOS or human eNOS phosphorylated at Ser-
1177, both obtained from Santa Cruz Biotechnology Inc., Santa Cruz, CA (cat.nr. sc-654 
and sc-12972, respectively).
eNOS enzyme activity and nitric oxide measurements
eNOS activity was measured in the L-arginine to L-citrulline conversion assay using a 
nitric oxide synthase assay kit (Calbiochem, La Jolla, CA; cat.no. 482700) as described 
previously16. For NO measurements, mice were anaesthetised with 0.2 ml i.p. sodium 
pentobarbital (Apharmo BV, Arnhem, The Netherlands) and intracardially perfused 
with 10 ml Krebs Henseleit buffer solution (118 mM NaCl, 4.7 mM KCl, 3.0 mM CaCl2, 1.2 
mM KH2PO4, 1.2 mM MgSO4, 25 mM NaHCO3, 0.5 mM EDTA, 10 mM D-glucose and 0.1 
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mM L-arginine, equilibrated with 95% air and 5% CO2 at room temperature resulting in 
a pH of 7.4). The aorta was dissected and in situ cannulated with two metal cannulas, 
proximal at the level of aortic arch and distal at the level of the diaphragm. The can-
nulas were connected to a homemade device keeping the vessel at its original length. 
Next, the vessel was transported to the set-up, where the cannulas were fixed to two 
holders. The two holders were placed in a chamber filled with Krebs buffer. The can-
nula at the proximal end of the vessel was connected to Tygon® tubing coming out 
of a reservoir with Krebs buffer. Between the reservoir and the cannula a flow pump 
(Watson Marlow, UK) and an infusion pump (Perfusor VI, B.Braun, Germany) were po-
sitioned. The settings of the pump were adjusted to perfuse the aorta with a constant 
flow of 10 ml/min, measured by an EMF flow sensor. This value was based on measure-
ments of the cardiac output of our mice with a clinical Doppler device (Prosound 4000, 
Aloka, Japan) or by a transit-time flow probe (see below). Next, the aorta vessel was 
equilibrated by perfusing it for 30 minutes. During that period the experimental set 
up was switched to its calibration state and the NO-sensor was calibrated by infusing 
known NO concentrations through a tube mounted in parallel to the vessel (0.1 to 30 
µM). Then, L-arginine (0.1 M) in Krebs buffer was added to the perfusate via the infu-
sion pump. The NO-sensitive electrode was positioned at the distal end of the aorta, 
in order to measure the NO-production by the vessel. The electrode was connected 
to an NO measurement system (Iso-NO mark II, World Precision Instruments, USA). All 
data, including temperature, pressure drop, flow and NO measurements were stored in 
a PC equipped with a AD converter and analysis software (Acodas, Dataq Instruments, 
Natick, MA).
Hemodynamics and heart weights
Hemodynamic measurements were performed as described16. Shortly, blood pressure 
measurements were performed in mice anesthetized with ketamine (100 mg/kg ip) and 
xylazine (20 mg/kg ip), intubated and ventilated with a mixture of O2 and N2 (1/2 vol/
vol). A flame stretched PE 50 polyethylene catheter was inserted into the right carotid 
artery and advanced into the aortic arch for measurement of aortic pressure and con-
nected to a pressure transducer (Braun). For infusion of L-NAME, a second catheter was 
introduced into the right external jugular vein and advanced into the superior caval 
vein. After thoracotomy through the second right intercostal space, the ascending 
aorta was exposed and a transit-time flow probe (ID 1.5 mm; Transonics systems T206) 
was placed around the aorta for measuring aorta flow. Ten minutes after a second in-
traperitoneal bolus of 100 mg/kg ketamine and 20 mg/kg xylazine, baseline recordings 
were obtained. Then, a continuous 10 minutes intravenous infusion of L-NAME (100 
mg/kg) was started and measurements were continued until 10 minutes after comple-
tion of the infusion. For the measurements of pulmonary artery pressure, the second 
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left intercostal space was opened and a 30G needle connected to a PE 10 polyethylene 
catheter was directly inserted into the pulmonary artery. Hemodynamic data were 
recorded and digitized using an on-line 4 channel data acquisition program (ATCODAS, 
Dataq Instruments, Akron, OH). Ten consecutive beats were selected for determina-
tion of heart rate, aortic and pulmonary artery pressures, and aortic blood flow. For 
determination of ventricular weights the heart was removed and the ventricles were 
separated from the atria, the aorta and the pulmonary artery. The right ventricle was 
carefully separated from the left ventricle (incl. septum) and the right and left ventricle 
were weighed on a microbalance (Sartorius AG Göttingen). For the measurements of 
dry weights, tissue fluids were removed by lyophilization.
Cholesterol and lipoprotein analysis
Blood was collected by orbital puncture after an overnight fast. Plasma from 6-10 mice 
was pooled and subjected to gel filtration analysis on two HR10/30 FPLC columns in 
tandem (Superdex 200 and Superose 6, both prepgrade, Pharmacia Biotech., Uppsala, 
Sweden)17. Cholesterol concentrations were measured with the free cholesterol C kit 
(WAKO, Neuss, Germany) after hydrolysis of cholesterol esters with cholesterol esterase 
from Candida cylindracea.
Data analysis
Analysis of data was performed using two-way or one-way analysis of variance followed 
by Scheffé’s test, as appropriate. Statistical significance was accepted when P<0.05 
(two-tailed). Data are presented as mean ± SEM.
Results
eNOS–GFP transgenic mice
We aimed to create mice transgenic for human eNOS, in which the expression 
resembled that of the endogenous gene as much as possible, both with respect to 
the expression pattern as well as the regulation. Therefore, we used a DNA fragment 
to generate transgenic mice that comprised the complete human eNOS genomic 
sequence, including the natural promoter. This fragment was isolated from a human 
cosmid library. In addition to the eNOS gene, the DNA fragment contained ~6 kb of 5’ 
sequence, including the endothelial enhancer sequence identified by Laumonnier et 
al18, and ~3 kb of 3’ sequence. At the STOP codon of the eNOS gene, a DNA fragment 
encoding enhanced GFP was inserted in frame with the eNOS gene, in order to obtain a 
DNA construct encoding an eNOS–GFP fusion protein. This fragment (Fig. 1a) was used 
for the generation of eNOS–GFP transgenic (eNOS–GFPtg) mice.
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Figure 1. Transgenic mice expressing eNOS–GFP. a. The DNA construct used for the generation of 
eNOS–GFPtg mice consisted of the complete eNOS gene in which an eGFP encoding cassette was cloned 
in frame at the position of the eNOS STOP codon. The natural flanking sequences of the eNOS gene 
were left intact. b. Sections of aorta from control mice or eNOS–GFP transgenic mice, inspected with 
immunohistochemistry using an antibody directed against human eNOS (left panels) or by fluorescent 
microscopy (right panels). Original magnifications: 630x. c. Green fluorescence in endothelial cells from an 
intact carotid artery inspected with confocal microscopy. Double arrowheads point at fluorescence at the 
position of the plasma membrane, the white arrow at fluorescence at the position of the Golgi complex. 
The non-filled arrow points at the cell nucleus. Scale bar: 10 µm. d. Immunoblotting of aorta (upper panels) 
or lung (lower panels) homogenates with antibodies directed against human eNOS (left panels), which 
show cross-reactivity with endogenous mouse eNOS, or antibodies directed against phosphorylated 
Ser-1177 from human eNOS (right panels). e. eNOS activity measured in aorta or lung homogenates by the 
L-arginine to L-citrulline conversion assay. n=9. *P<0.001. f. NO production in isolated aortas measured 
with an NO-sensitive electrode. n=11 (C), n=8 (Tg). *P<0.005. b, d-f: C: control mice, Tg: eNOS–GFP 
transgenic mice.
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Fig. 1b shows sections from mouse aorta, taken from eNOS–GFPtg mice or wild-type 
littermates (controls). Immunohistochemistry studies on these sections using an anti-
body directed against human eNOS revealed a strong staining of the endothelial layer 
of the aorta in the eNOS–GFPtg mice, while there was no staining in the media of the 
aorta (Fig. 1b, lower left panel). Sections from non-transgenic controls showed virtually 
no staining (Fig. 1b, upper left panel). Inspection with fluorescence microscopy showed 
a strong fluorescent signal in the endothelial layer of the aorta from eNOS–GFPtg mice 
(Fig. 1b, lower right panel), which is much higher than the autofluorescence from the 
elastic lamellae that is present in both eNOS–GFPtg mice and in wild-type controls (Fig. 
1b, upper right panel). The subcellular localization was studied by confocal microscopy 
in the carotid artery (Fig. 1c). The expression pattern exactly matches the sites where 
eNOS is known to be primarily located: in the Golgi complex and at the plasma mem-
brane. We performed Western blotting experiments with aorta and lung tissue from 
eNOS–GFPtg mice and non-transgenic controls (Fig. 1d). Using an antibody directed 
against human eNOS, both the endogenous murine eNOS is detected, caused by cross-
reactivity of the antibody, as well as the eNOS–GFP fusion protein, which has a slightly 
higher molecular mass caused by the GFP moiety (approximately 130 kDa and 155 
kDa, respectively; Fig. 1d, left panels). In addition, we used an antibody that recognizes 
eNOS that is phosphorylated on serine 1177 (P-eNOS), which is the activated form of 
the enzyme. P-eNOS–GFP is present in both aorta and lung tissue from eNOS–GFPtg 
mice (Fig. 1d, right panels). In order to determine whether the expressed eNOS–GFP 
fusion protein is catalytically active, enzymatic activity was measured in aorta and lung 
tissue from eNOS–GFPtg mice and non-transgenic controls. As shown in Fig. 1e, the 
transgenic mice show an increase in eNOS activity of approximately 35-fold in aorta and 
27-fold in lung tissue. In addition, NO production was measured in isolated vessels ex 
vivo, using an NO sensor. Aortas from eNOS–GFP transgenic mice showed an increased 
NO production compared with aortas from control mice (Fig 1f ). The data could be 
described by a first order kinetic reaction, which was confirmed by a Lineweaver-Burke 
transformation (data not shown).
Localization of eNOS–GFP
In order to investigate the cell specificity of the expression of the transgene, sections 
from organs of eNOS–GFPtg mice were inspected by immunohistochemistry using an 
antibody directed against human eNOS (Fig. 2). eNOS immunoreactivity was detected 
in small blood vessels in the heart (Fig. 2a), in the sinusoids in the liver (Fig. 2b), in the 
peritubular capillaries and in the endothelial cells in the glomeruli in the kidney (Fig. 
2c) and in the capillary sinusoids in the adrenal (Fig. 2d).
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Figure 2. Localization of eNOS–GFP in various organs from eNOS–GFPtg mice visualized by 
immunohistochemistry using an antibody directed against human eNOS. a. heart, b. liver, c. kidney, 
d. adrenal. Original magnifications: 400x.
eNOS protein was not found in the parenchymal cells of these organs. Sections from 
non-transgenic controls showed no immunoreactivity (not shown). This expression pat-
tern was confirmed by fluorescence microscopy. Fig. 3 shows micrographs from heart 
(Fig. 3a,b), liver (Fig. 3c,d), kidney (Fig. 3e,f ) and adrenal gland (Fig. 3g,h). The lining of 
the larger vessels was clearly fluorescent (Fig. 3c). A dense capillary network was fluo-
rescent in the heart, surrounding the cardiomyocytes, and in the adrenal. The sinusoids 
in the liver, as well as the peritubular capillaries in the kidney showed a positive signal, 
just like the capillaries of the glomeruli in the kidney. The parenchymal cells of none of 
these organs showed appreciable expression. In sections from non-transgenic controls, 
no fluorescent signal was detected (not shown).
Chapter 3: The eNOS-GFP Transgenic Mouse
50
Figure 3. Localization of eNOS–GFP in various organs from eNOS–GFPtg mice visualized by 
fluorescence microscopy. a.,b.: heart, c.,d. liver, e.,f. kidney, g.,h. adrenal. Original magnifications: 100x 
(a.,c.,e.,g.), 400x (b.,d.,f.,h.).
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Hemodynamic properties of eNOS–GFPtg mice
We performed hemodynamic measurements in eNOS–GFPtg mice compared to non-
transgenic control mice. This was done in order to establish the functional activity 
of the eNOS–GFP fusion protein, as eNOS derived NO is an important modulator of 
vascular tone. As shown in figure 4a, the mean aortic pressure (MAP) was decreased in 
eNOS–GFP expressing mice compared to wild-type littermates by approximately 29%. 
Treatment with the NO synthase inhibitor NG nitro-L-arginine methyl ester (L-NAME) 
resulted in an increase of the MAP and abolished the difference between transgenic 
mice and wild-type littermates. The increase in the MAP (DMAP) caused by L-NAME 
treatment was greater in transgenic mice than in non-transgenic controls. There were 
no differences found in heart rate (Fig. 4b) or mean aortic blood flow (Fig. 4c) between 
transgenic or control mice, with or without treatment with L-NAME. Consequently, the 
difference in MAP can be attributed to a difference in systemic vascular resistance (Fig. 
4d). In addition to a lower pressure in the systemic bed, we also observed a lower mean 
pulmonary artery pressure in eNOS–GFPtg mice of 30% (Fig. 4e). We also analyzed the 
heart weights of the transgenic mice in comparison with controls. No differences were 
found (Fig. 4f ).
Plasma cholesterol levels in eNOS–GFPtg mice
Finally, we measured levels of plasma cholesterol in eNOS–GFPtg mice with different 
genetic backgrounds as models for variations in plasma cholesterol levels. We com-
pared wild-type background, heterozygous low-density lipoprotein receptor-deficient 
background, which results in a condition of slight hypercholesterolemia, and apolipo-
protein E-deficient background, which results in a condition of more severe hypercho-
lesterolemia. We found a slight decrease in cholesterol levels in all backgrounds when 
comparing eNOS–GFP transgenic animals with animals without this transgene (Fig. 5a). 
Next, we analyzed the lipoprotein profile in two of these backgrounds. In wild-type 
background, plasma cholesterol is predominantly found in high-density lipoproteins 
(HDL)19. Thus, the cholesterol lowering observed in eNOS–GFP transgenic animals is 
found in HDL (Fig. 5b). In apolipoprotein E-deficient background however, plasma cho-
lesterol is present in the atherogenic lipoproteins, very low-density lipoproteins (VLDL) 
and low-density lipoproteins (LDL)16. In this background, expression of eNOS–GFP 
results in a decrease in both VLDL+LDL and HDL (Fig. 5c).
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Figure 4. Hemodynamics and ventricular weights were measured in control mice (C) or eNOS–GFPtg 
mice (Tg) before and after addition of L-NAME. a. Mean aortic pressure; b. heart rate; c. mean aortic 
blood flow; d. systemic vascular resistance; e. pulmonary artery pressure; f. ventricular wet weights; g. 
ventricular dry weights. a-d: n=10 (C), n=9 (Tg), e: n=8 (C), n=6 (Tg), f-g: n=20 (C), n=12 (Tg). *: P<0.05 vs 
controls; †: P<0.05 vs controls before addition of L-NAME; ‡: P<0.05 D in C vs D in Tg (before and after 
addition of L-NAME).
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Figure 5. Cholesterol measurements. a. Plasma cholesterol concentrations of wild-type, LDLR 
heterozygous knock out (LDLR+/-) and apolipoprotein E homozygous knock out (ApoE-/-) mice with (Tg) 
or without (C) the eNOS–GFP transgene. *: P<0.01 vs controls; . **: P<0.001 vs controls. b.,c. Fractionation 
of lipoproteins by gel filtration of plasma from mice with wild-type background (b) or apolipoprotein E 
knock out background (c). Fraction 1-5 contain VLDL, 6-11 contain LDL and 12-20 contain HDL.
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Discussion
We generated transgenic mice that express human eNOS in fusion with GFP. In order to 
preserve transcriptional regulation, we used a genomic construct which contains the 
intronic sequences as well as the natural flanking sequences, including the previously 
identified endothelial enhancer located 4.9 kilobases upstream of the transcription 
initiation site18. The expression pattern was visualized either indirectly, via immuno-
histochemistry using antibodies directed against eNOS, or directly via fluorescence 
microscopy. Both techniques showed virtually the same distribution of the eNOS–GFP 
transgene in a variety of organs: endothelial cells of smaller and larger vessels in vari-
ous organs are positive, while the parenchymal cells are not. These results indicate that 
the DNA construct used for microinjections resulted in expression of the transgene 
predominantly, if not exclusively, in endothelial cells.
The functionality of the eNOS–GFP fusion protein was demonstrated in two different 
ways. Using the L-arginine to L-citrulline conversion assay, it was shown that eNOS 
enzyme activity is ~30 fold higher in eNOS–GFP transgenic animals compared with 
non-transgenic controls. In ex vivo measurements with an NO sensor, NO production by 
endothelial cells in isolated blood vessels was shown to be 1.8 fold higher when vessels 
from eNOS–GFP transgenic mice were used.
The apparent discrepancy between these measurements can be explained by the differ-
ence between the methods that were used. In the L-arginine to L-citrulline conversion 
assay, a homogenate of aortic tissue was used. Cofactors and reagents are added to 
the assay in order to optimize the conditions for the enzymatic reaction. Therefore, the 
actual measurement represents the maximal eNOS activity, thereby reflecting the total 
amount of enzyme present. In contrast, the ex vivo measurements with the NO sensor 
were performed in intact blood vessels. As a consequence, the cellular regulation of 
the activity of the enzyme is still intact. In this system, the actual NO production is 
measured. This is much lower than the maximal enzymatic activity, probably because 
posttranslational control of eNOS activity is intact.
In addition, blood pressure measurements showed that the mean aortic pressure was 
lower in eNOS–GFP transgenic animals compared with non-transgenic controls. This is 
in agreement with findings in other transgenic models of eNOS overexpression16,20. In 
the latter models, pulmonary pressures have not been measured. However, these are 
expected to be decreased as well, as the pulmonary vasodilator response following NO 
inhalation in patients is well known21,22. Indeed, we found lower pulmonary pressure in 
eNOS–GFP transgenic animals compared with non-transgenic controls.
GFP expression has been used in various transgenic mouse models and in numerous 
in vitro studies using cultured cells. It is generally assumed that the GFP protein itself 
does not interfere with any biological function of other proteins studied. However, 
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specific expression in cardiomyocytes has been reported to result in hypertrophy23. 
Although the transgene in our mouse model is expressed in endothelial cells and not in 
cardiomyocytes, we measured the ventricular weights of transgenic and control mice. 
No differences were found, demonstrating that hypertrophy probably does not occur 
in eNOS–GFPtg mice.
Previously, we generated and studied transgenic mice overexpressing eNOS without 
GFP16. In addition to a lower blood pressure, these animals displayed a decrease in 
plasma levels of cholesterol. Thus, we measured plasma cholesterol in eNOS–GFP 
transgenic mice and found a decrease of ~20% compared with non-transgenic mice 
(Fig. 5a). Plasma cholesterol in mice is for the larger part in HDL, which is generally 
believed to be atheroprotective19. Therefore, atherosclerosis in mouse models is usu-
ally studied in a genetic background with increased cholesterol in atherogenic very 
low-density lipoproteins (VLDL) and low-density lipoproteins (LDL). We crossbred 
eNOS–GFPtg mice with two of these models. In the first place, we crossbred them to 
low-density lipoprotein receptor-deficient mice, resulting in a background of heterozy-
gous deficiency. This genetic background causes mild hypercholesterolemia24. In addi-
tion, we crossbred the mice in a apolipoprotein E-deficient background, which causes 
more severe hypercholesterolemia16. In both of these backgrounds, we found that 
expression of eNOS–GFP results in lower levels of plasma cholesterol (Fig. 5a). While in 
wild-type background a reduction in HDL-cholesterol was found (Fig. 5b), the effect in 
apolipoprotein E-deficient mice was primarily in VLDL+LDL cholesterol (Fig. 5c). This is 
in agreement with our previous work, in which it was tentatively concluded that this 
effect contributed to the antiatherogenic properties of elevated eNOS expression16.
The mouse model described in the present study can be used to study the unusually 
complex regulation of eNOS11,13. Regulation takes place at the transcriptional level25-27, 
and is responsive to variations in shear stress28,29. In addition, extensive regulation of 
eNOS activity at the posttranslational level exists. These pathways are probably also 
active in the eNOS–GFPtg mice, as these are most likely responsible for the remarkable 
discrepancy between the level of protein overexpression and the physiological level 
of NO production (compare Fig. 1d,e with Fig. 1f ). The posttranslational regulatory 
mechanisms include protein–protein interactions, some of which affect the subcel-
lular localization of the protein. eNOS is primarily located in the Golgi complex and in 
the caveolae in the plasma membrane, which were shown to be two pools of active 
enzyme14, although others have suggested that active eNOS is largely restricted to 
caveolae30-32. A number of proteins have been shown to interact with eNOS and affect 
its activity. Caveolin, the structural protein of the caveolae, forms an inhibitory complex 
with eNOS32, for which further evidence was provided by studies in caveolin-deficient 
mice33. Upon activation by calcium, calmodulin can activate eNOS by displacing it from 
caveolin34,35. Another protein that binds to eNOS and subsequently activates it is heat 
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shock protein 9036. The latter protein appears to play a role in the caveolin–calmodulin 
regulatory complex37. Recently identified proteins that interact with eNOS have been 
termed NOSIP and NOSTRIN38,39. The functions of these proteins have not been estab-
lished yet. Still another way of posttranslational regulation of eNOS activity is protein 
modification, like palmitoylation and myristoylation40,41, or phosphorylation, especially 
of the serine at position 1177 (human eNOS)42,43.
The eNOS–GFPtg mice described in the present study are particularly suited to study 
various aspects of the complex regulation of eNOS activity. Subcellular localization 
under various conditions or dynamic changes in this pattern upon various stimuli 
can be studied, as well as interactions with other proteins or with the cytoskeleton44. 
Valuable information has been achieved by studying expression of eNOS–GFP cDNA 
in transfected cells45,46. Our model also allows ex vivo and in vivo studies, including real 
time imaging by intravital microscopy. These types of studies will be useful to further 
assess the impact of eNOS activity in processes like reactivity to variations in shear 
stress or angiogenesis under conditions of ischemia or in tumor growth.
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Abstract
Arteriogenesis is the major mechanism of vascular growth, which is able to compen-
sate for blood flow deficiency after arterial occlusion. Endothelial nitric oxide synthase 
(eNOS) activity is essential for neovascularization, however its specific role in arterio-
genesis remains unclear. We studied the role of eNOS in arteriogenesis using three 
mouse strains with different eNOS expression.
Distal femoral artery ligation was performed in eNOS-overexpressing mice (eNOStg), 
eNOS-deficient (eNOS-/-) mice and wild-type (WT) controls. Tissue perfusion and col-
lateral-dependent blood flow were significantly increased in eNOStg mice compared 
to WT only immediately following ligation. In eNOS-/- mice, although tissue perfusion 
remained significantly decreased, collateral-dependent blood flow was only decreased 
until day 7, suggesting normal, perhaps delayed collateral growth. Histology confirmed 
no differences in collateral arteries of eNOStg, eNOS-/- and WT mice at one and three 
weeks. Administration of an NO donor induced vasodilation in collateral arteries of 
eNOS-/- mice, but not in WT, identifying the inability to vasodilate collateral arteries as 
main cause of impaired blood flow recovery in eNOS-/- mice.
This study demonstrates that eNOS activity is crucial for NO-mediated vasodilation of 
peripheral collateral vessels following arterial occlusion but not for collateral artery 
growth.
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Introduction
The stimulation of vascular growth has become an important therapeutic goal for 
prevention and treatment of tissue ischemia in cardiovascular disease and is referred 
to as therapeutic neovascularization. Three distinct processes of vascular growth can 
contribute to the recovery of blood flow and preservation of tissue: arteriogenesis, 
i.e. collateral artery growth, angiogenesis, i.e. sprouting of capillaries from preexisting 
blood vessels, and vasculogenesis, i.e. formation of blood vessels from endothelial pro-
genitors1. From a therapeutic point of view, it is essential to isolate the distinct mecha-
nisms of vascular growth, because these occur in different types of tissue and vessels 
and are regulated by separate stimuli. For example, in the experimental ischemic hind 
limb model, arteriogenesis is initiated and stimulated in collateral vessels in the up-
per part of the hind limb by an increase in fluid shear stress2. In contrast, in the lower 
part of the limb, both angiogenesis and vasculogenesis are mainly driven by tissue 
ischemia3,4. Clinical trials based on stimulation of therapeutic VEGF- and FGF-mediated 
angiogenesis have not shown convincing results5,6. Therefore, in this study we focus 
on arteriogenesis, as this is the most upstream mechanism and the most efficient one 
to provide bulk flow to the ischemic area after occlusion or stenosis of a major artery7.
A potential mechanism for inducing therapeutic neovascularization is to increase the 
production of endothelial NO. eNOS activity has been shown essential for neovascu-
larization. eNOS-/- mice display a decreased neovascularization in response to severe 
ischemia. Recent studies have attributed this to impaired arteriogenesis, angiogenesis, 
vasculogenesis, or a combination of these8-10. However, in these studies the different 
competing or complementary mechanisms of vascular growth could not be isolated, 
because the use of a severe murine ischemia in vivo model, which causes substantial 
damage to the lower limb. Thus, the role of eNOS in each specific mechanism could 
not be elucidated. In addition, the role of eNOS in arteriogenesis has been paradoxical. 
Increased shear stress is known to upregulate the expression of eNOS augmenting en-
dothelial NO production11-13. In contrast, NO has also been shown to inhibit expression of 
adhesion molecules and smooth muscle cell proliferation, which are both indispensable 
for arteriogenesis11,14,15. Besides, given the importance of eNOS in regulating vascular to-
nus and blood flow, other mechanisms could be involved. In this study, we investigated 
the role of eNOS in arteriogenesis in both eNOS-/- and eNOStg mice using a hind limb 
model, which caused only minimal ischemia in the lower limb, to specifically analyze 
arteriogenesis. Using this murine arteriogenesis-specific model several research groups 
have recently described different molecular and cellular mechanisms of arteriogen-
esis16-18. Two lines of eNOStg mice have been previously generated in our laboratory and 
overexpress the human eNOS gene19,20. We have recently reported that in the eNOStg 
mice eNOS expression is functional and restricted to the endothelial lining in all blood 
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vessels. In eNOStg mice eNOS protein and eNOS activity (20-fold greater) levels in the 
vasculature as well as NO-production (1.8-fold increased) are significantly enhanced, 
causing a lower blood pressure, lower plasma cholesterol levels and less atherosclerosis.
In the present study, we first compared eNOStg and WT mice and only found beneficial 
effects of eNOS overexpression on blood flow recovery immediately following ligation 
and no further favorable effects on collateral artery growth. Subsequently, we analyzed 
arteriogenesis in eNOS-/- and WT control mice and confirmed previously published 
data showing impaired blood flow recovery and increased ischemic tissue damage in 
eNOS-/- mice. However, we found no differences in collateral growth between eNOS-
/- and WT mice. Interestingly, we discovered that in eNOS-/- mice blood flow recovery 
and clinical outcome after distal femoral ligation were impaired by the inability to 
sufficiently vasodilate collateral peripheral vessels, and not because of impaired arte-
riogenesis.
Materials and Methods
Animal experiments
Transgenic mice overexpressing eNOS-GFP (eNOStg) were generated as previously 
described20. Briefly, an eNOS-GFP fusion gene was made by inserting a DNA fragment 
encoding the enhanced green fluorescent protein (GFP) in frame at the stop codon 
of the complete human eNOS gene and used to perform microinjections of fertilized 
mouse oocytes. Hemizygous eNOStg mice were used that expressed the human eNOS 
gene fused to GFP under the regulation of the autologous human eNOS promoter, 
and that were backcrossed to C57BL/6J background for >10 generations. For further 
details, see supplemental methods, available online at htttp://atvb.ahajournals.org. 
eNOS-deficient (eNOS-/-) and littermate wild-type C57Bl/6 mice (WT) were originally 
purchased from Jackson Laboratories (Bar Harbor, Maine). All mice used were age- (10 
to 12 weeks) and sex-matched. The experimental protocol was approved by the Animal 
Experiments Committee under the national Experiments on Animals Act and adhered 
to the rules laid down in this national law that serves the implementation of “Guidelines 
on the protection of experimental animals “ by the Council of Europe (1986), Directive 
86/609/EC.
Mouse model of femoral ligation
The surgical procedure was performed as previously described7. Briefly, mice were 
anesthetized with a mixture of ketamin (20 mg/kg) and xylazin (110 mg/kg). After mini-
mal incision in the right mid-thigh, the right superficial femoral artery was dissected 
and ligated just distally to the origin of the deep femoral artery.
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Limb function and muscle atrophy
For a clinical evaluation of the function of the ischemic hind limb the active movement 
of the right foot was scored (1=no use; 2=standing; 3=normal use without spreading 
toes; 4=normal use), as previously described21. For evaluating the extent of atrophy the 
weights of the excised left and right m. gastrocnemius were determined.
Tissue perfusion
Relative hemoglobin oxygen saturation measurements were performed using an Ab-
TisSpec spectrometer (LEA, Medizintecknik) placing the probe alternately on the left 
and right foot. Laser Doppler perfusion imaging (LDI; Moor Instruments Ltd.) was used 
for recording serial relative blood flow measurements. The whole region of the foot was 
analyzed on either side. All measurements were performed in a preheated chamber 
(37°C) after five minutes of warming and under the influence of a mixture of ketamin 
(15 mg/kg) and xylazin (82 mg/kg). Measurements are expressed as right-to-left ratios.
Collateral-dependent blood flow
Blood flow in the three main arteries of both m. gastrocnemius was analyzed by 
Magnetic Resonance Imaging (MRI), as previously described22,23. For further details, see 
supplemental methods. A subset of mice from WT and eNOS-/- groups was studied 
after intraperitoneal injection of 5mg/kg of SNAP (S-nitroso-N-acetyl-penicillamine; 
Sigma).
Histology
For evaluating capillary density, cryosections (7 μm) were cut from the m. gastrocnemius 
and stained with an antibody against lectin (BS-1, Sigma). Capillaries and muscle fibers 
were counted and data expressed as capillary-to-muscle fiber ratio. We used two differ-
ent techniques for collateral artery morphometry. In one set of mice, for ultrastructure, 
collateral vessels in the m. adductor were isolated, dissected and embedded as previ-
ously described7. Ultra-thin sections (1 μm) were cut and stained with toluidine blue. 
Collateral arteries (ligated side) and preexisting arterioles (non-ligated side) were then 
measured with NIH software, and subsequently diameters, wall areas and wall thick-
nesses were calculated. In another set of mice, the complete m. adductor was dissected 
and embedded. Cryosections (7 μm) were cut and immunostained with an antibody 
against α-SM-actin (Sigma). In both ligated and non-ligated muscles arterioles were 
identified and measured as above. For further details, see online data supplement.
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Statistics
Statistical analysis of all data was performed using one-way ANOVA followed by a mul-
tiple comparison test. Data are reported as means ± standard error of the mean (SEM). 
Statistical significance was accepted when P<0.05 (two-tailed).
Results
eNOS-overexpressing mice
Tissue perfusion
Hemoglobin oxygen saturation measurements revealed that oxygen saturation, a 
marker for tissue perfusion, was only significantly increased in eNOStg mice immedi-
ately after ligation, compared with WT (R/L postligation: 0.56±0.06 versus 0.24±0.05 in 
eNOStg and WT respectively, P<0.001, Figure 1A). Equally, LDI measurements of the feet 
only showed a significant increase in relative blood flow in eNOStg mice immediately 
after ligation, compared with WT (R/L postligation: 0.33±0.04 versus 0.13±0.02, P<0.01, 
Figure 1B)
Collateral-dependent blood flow
The inflow of blood in the calf arteries is directly dependent on collateral flow in the 
upper part of the leg and was measured by MRI. In eNOStg mice collateral-dependent 
blood flow was significantly increased only immediately following ligation, matching 
tissue perfusion findings in the foot (R/L postligation: 0.12±0.01 versus 0.05±0.01 in 
eNOStg and WT, respectively; P<0.001, Figure 1C). The above measurements, showing 
differences in blood flow recovery between eNOStg and WT mice only immediately af-
ter the femoral ligation, suggested an increased acute maximal vasodialation in eNOStg 
mice but no beneficial effects of eNOS overexpression on arteriogenesis.
eNOS-deficient mice
Limb function and muscle atrophy
Limb function, assessed by a foot movement score, recovered completely to normal 
within two weeks in WT mice, whereas limb function of eNOS-/- mice did not even 
reach normal levels during complete follow-up (Figure 2A). Similarly, toe necrosis and 
auto-amputation were commonly seen in the eNOS-/- group, in contrary to the mice 
in the other groups (data not shown). Also, significant more m. gastrocnemius atrophy 
was seen in the eNOS-/- mice compared with WT mice (R/L muscle weight: 0.94±0.02 
versus 0.78±0.04 in WT and eNOS-/-, respectively; P<0.01, Figure 2B).
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Figure 1. A. Time course of oxygen saturation in the feet (n≥10). B. Time course of tissue perfusion in the 
feet measured by Laser Doppler Imaging (n≥10). C. Time course of collateral-dependent blood flow in 
the calf muscle measured by MRI (n≥10). All measurements are expressed as ligated/non-ligated ratios, 
***P<0.001 vs WT.
Tissue perfusion
Oxygen saturation remained significantly impaired in eNOS-/- mice during complete 
follow-up (Figure 2C). As expected, relative blood flow in the feet, assessed by LDI, 
remained equally impaired until three weeks after ligation (Figure 2D)
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Figure 2. A. Limb function evaluated by active foot movement score (n≥6). B. M. gastrocnemius atrophy 
(n=8) C. Time course of oxygen saturation in the feet (n≥6). D. Time course of tissue perfusion in the feet 
mea ured by Laser Doppler Imaging (n≥6). All measurements are expressed as ligated/non-ligated ratios, 
**P<0.01 and ***P<0.001 vs WT
Collateral-dependent blood flow
In contrast with tissue perfusion fin ings, a decrease in collateral-dependent blood 
flow was found only up to seven days after surgery in eNOS-/- mice, when compared 
with WT, suggesting normal or possibly somewhat delayed collateral artery growth in 
eNOS-/- mice (R/L blood flow at day 7: 1.02±0.07 versus 0.69±0.08 in WT and eNOS-/-, 
respectively; P<0.01; at day 14: 0.81±0.04 versus 0.83±0.08 in WT and eNOS-/-; Figure 
3A). In eNOS-/- mice the blood flow even continued to increase and was significantly 
higher than in WT mice at three weeks. To circumvent the effects of vasoconstriction 
in eNOS-/- mice, we systemically administered at day 7 the NO-donor SNAP to both 
WT and eNOS-/- mice and measured collateral-dependent blood flow. In WT mice, 
SNAP induced vasodilation and thus an increase of blood flow in the unligated leg, 
whereas in the ligated leg no increase in blood flow could be induced, as vasodilation 
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was already at its maximal (or submaximal) level (Figure 3B). In eNOS-/- mice, however, 
SNAP induced vasodilation and increase of blood flow to the same extent in both legs. 
This suggested that normal functional collateral arteries had grown in the eNOS-/- mice, 
but that these were unable to vasodilate sufficiently because impaired NO production.
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Figure 3. A. Time course of collateral-dependent blood flow in the calf muscle measured by MRI (n≥10). 
Measurements are expressed as ligated/non-ligated ratio, *P<0.05, **P<0.01 and ***P<0.001 vs WT. B. 
Collateral-dependent blood flow before and after administration of NO-donor SNAP seven days after 
femoral artery ligation (n≥13) Measurements are expressed as arbitrary units, #P<0.05 and ##P<0.01 vs 
before SNAP, ***P<0.001 vs WT.
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Collateral morphometry
Finally, to obtain anatomic data of collateral arteries we studied collateral artery growth 
in the adductor muscle of the three groups of mice using two different histological 
analyses.
Cryosections
In complete cross-sections of the adductor muscle conducting arterioles were identi-
fied and analyzed (Figure 4A). Diameters of preexisting arterioles in the non-ligated 
adductor muscle did not differ between eNOStg, WT and eNOS-/- mice (in μm: 37±2 
versus 33±3 versus 34±2 in eNOStg, WT and eNOS-/-, respectively; Figure 4B). Collateral 
diameters significantly and continuously increased after ligation, as compared with 
preexisting arterioles, and no differences between collateral diameters from eNOStg, 
WT and eNOS-/- mice were found at one and three weeks (in μm: 62±11 versus 76±11 
versus 67±15 in eNOStg, WT and eNOS-/-, respectively). Wall areas of preexisting arteri-
oles of eNOStg mice were significantly smaller than in WT mice (in μm2: 557±51 versus 
958±107 in eNOStg and WT, respectively; P<0.01, Figure 4C). In all three groups wall 
areas significantly and continuously enlarged after ligation. At one and three weeks af-
ter ligation no differences were found between the wall areas of collateral arteries from 
eNOStg, WT and eNOS-/- mice (in μm2: 1098±195 versus 1610±240 versus 1598±321 
in eNOStg, WT and eNOS-/-, respectively, at three weeks after ligation). Analysis of 
the wall thickness of collateral arteries revealed the same significant and continuous 
enlarging after ligation in all three groups of mice (Figure 4D). The wall thickness of 
collateral arteries in eNOStg mice was smaller than in WT mice, both before and after 
ligation. However, no differences in wall thickness were observed between eNOS-/- and 
WT mice, neither before nor after ligation (in μm: 8.4±0.5 versus 7.8±0.5 in WT and 
eNOS-/-, respectively, before ligation and 11.8±1.3 versus 10.7±0.8, in WT and eNOS-/-, 
at three weeks after ligation).
Ultra-thin sections
In ultra-thin sections, cut from the predilection area for collateral artery growth in the 
adductor muscle, preexisting arterioles or collateral arteries were identified and ana-
lyzed (Figure 5A). We did not find any significant differences in diameters and wall area 
between preexisting arterioles in eNOStg, WT and eNOS-/- mice (Figure 5B,C). Three 
weeks after ligation diameters and wall areas from collateral arteries were significantly 
enlarged in all three groups of mice, as compared to preexisting arterioles. However, 
as in cryosections, between groups no differences were found in collateral artery size. 
These findings confirmed the above blood flow data and indicate that collateral artery 
growth was normal in conditions of either deficient or increased eNOS activity.
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Figure 4. A. Representative photographs of cryosections with a collateral artery (A) in the adductor 
muscle of eNOStg, wild-type and eNOS-/- mice at different time points. Note the accompanying vein (V). 
Red=artery wall stained with anti-α-SMC actin, blue=nuclei stained with Dapi (magnification x400). B., 
C., and D. Morphometric measurements of diameter, wall area and wall thickness of collateral arteries 
and preexisting arterioles (n≥5). #P<0.05, ##P<0.01 and ###P<0.001 vs preexistent, *P<0.05, **P<0.01 and 
***P<0.001 vs WT.
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Figure 5. A. Representative photographs of ultra-thin sections with a collateral artery (A) in the adductor 
muscle of eNOStg, wild-type and eNOS-/- mice, 21 days after femoral artery ligation (magnification x630). 
Note the accompanying vein (V) and/or nerve (N). In all three collaterals at least one smooth-muscle cell 
nucleus (*) can be identified. B. and C. Morphometric measurements of diameter wall area of collateral 
arteries and preexisting arterioles (n≥5). #P<0.05, ##P<0.01 and ###P<0.001 vs preexistent. D. Capillary 
density measurements in the calf muscle (n≥5). Measurements are expressed as capillary/fiber ratio, 
#P<0.05 and ###P<0.001 vs preexistent, *P<0.05 and **P<0.01 vs WT.
Capillary density
Capillary density measurements in the calf muscle confirmed the arteriogenesis-
specificity of our hind limb model. In unligated calf muscles of eNOStg and eNOS-/- 
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mice capillary density was decreased compared with WT mice (in capillary/fiber ratio: 
1.01±0.06 versus 1.23±0.05 versus 1.00± 0.04, for eNOStg, WT and eNOS-/-, respectively; 
P<0.01; Figure 5D). After ligation the capillary/fiber ratio in calf muscles in both eNOStg 
and WT mice did not change, suggesting the absence of an ischemic stimulus for 
angiogenesis or vasculogenesis in these mice. In eNOS-/- mice, however, a significant 
1.8-fold increase in capillaries was seen in the ligated leg, implying the presence of 
angiogenesis and tissue ischemia.
Discussion
In the present study we evaluated the role of eNOS in a hind limb model, specific for 
arteriogenesis. Firstly, to evaluate the possible benefits of elevated eNOS activity on 
collateral growth we compared transgenic mice overexpressing human eNOS with 
WT control mice. We only found a beneficial effect of overexpression of eNOS in the 
acute phase of blood flow recovery after femoral occlusion. At all later time points 
during follow up blood flow recovery was equal in eNOStg and WT mice. Histological 
analysis revealed no differences in collateral artery growth between the two groups 
of mice. In a previously published study performed with a different transgenic mouse 
overexpressing (bovine) eNOS beneficial effects of eNOS overexpression on blood flow 
recovery after arterial occlusion were found during complete follow-up24. In another 
study adenoviral eNOS-gene transfer in the ischemic hind limb of rats resulted in im-
proved blood flow recovery and increase in capillary density25. However, in both studies 
a much more severe hind limb ischemia model was used, causing large ischemia and 
tissue damage in the lower limb and inducing both arteriogenesis in the upper limb, 
and angiogenesis and vasculogenesis in the lower limb. Therefore, beneficial effects of 
eNOS overexpression could not be extrapolated to one single type of vascular growth. 
Our findings suggest that the beneficial effects of eNOS overexpression on blood flow 
recovery in a severe hind limb ischemia model are not the result of increased arterio-
genesis, but rather increased angiogenesis or vasculogenesis. Besides, the beneficial 
effect of eNOS overexpression in our study immediately after femoral occlusion sug-
gests an important role for NO-mediated vasodilation in the initial phase of blood flow 
recovery, when vascular growth cannot have reached a substantial level yet.
Previous studies suggesting a positive role for eNOS in arteriogenesis have used differ-
ent models, either the severe murine hind limb ischemia model8 or an exercise based-
model in rats26. However, in these studies arteriogenesis and angiogenesis were both 
present and not analyzed separately. The distal femoral artery ligation model used in 
our study is an in vivo model specific for collateral artery growth. In earlier studies of our 
group minimal hypoxia and ischemia where found in the lower leg7,27. Capillary density 
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data from our study also suggest the absence of an ischemic stimulus in the lower leg, 
because of no increase of capillary growth was seen after femoral occlusion in control 
animals. Therefore, our present study is the only study on eNOS and collateral artery 
growth using an in vivo model specific for this type of vascular growth based on acute 
increase of shear stress after arterial occlusion.
As we did not find beneficial effects of eNOS overexpression on arteriogenesis, we were 
interested to evaluate the effect of absence of eNOS activity on arteriogenesis and thus 
compared eNOS-/- and WT mice using the same hind limb model and measurements. 
In earlier studies using eNOS-/- mice and the severe hind limb ischemia model it was al-
ready demonstrated that eNOS-/- mice had a very poor blood flow recovery, suggested 
to be caused by impaired angiogenesis or vasculogenesis9,10. Equally, in our study distal 
femoral artery ligation caused a significantly reduced blood flow recovery as well as 
tissue damage in eNOS-/- mice, despite our observations of an increase in angiogenesis 
and normal arteriogenesis in eNOS-/- mice compared with WT. We demonstrated that 
the impaired blood flow recovery was not caused by impaired arteriogenesis, but by 
insufficient vasodilation in the early recovery phase, before collateral arteries were 
completely formed.
Using MRI, a relatively new technique which measures absolute (and largely deep mus-
cular) blood flow and is less influenced by changes in skin blood flow as LDI, we found 
in eNOS-/- mice a decreased collateral-dependent blood flow only in the first week 
after ligation. In eNOS-/- mice, collateral-dependent blood flow continued to increase 
during three weeks of follow up, while in WT mice blood flow remained the same or 
was slightly decreased after two weeks. We suspect that after two weeks vasodilation 
is reduced in WT mice as growing collaterals adequately provide bulk flow to the distal 
leg, resulting in equal (or slightly decreased) net collateral blood flow after three weeks. 
In the eNOS-/- mice however, in the absence of vasodilation collateral blood flow 
continues to increase as collaterals continue to enlarge. Consequently, administration 
of the NO-donor SNAP confirmed the insufficient vasodilation of collateral arteries in 
eNOS-/- mice due to the absence of eNOS activity.
To obtain conclusive anatomic data of collateral arteries we extensively studied col-
lateral artery growth in the adductor muscle after maximal vasodilation using two 
different histological analyses. Cryosections were immunohistochemically stained and 
used to study collateral artery growth in the general overview of the whole adductor 
muscle. For ultra-thin sections only the predilection area for collateral artery growth 
was isolated. This isolation procedure and the thinness of these sections permitted 
us to analyze a smaller number of vessels in more detail. Both histological analyses 
revealed normal collateral artery growth in eNOS-/- mice after one and three weeks, 
suggesting a crucial role for vascular tonus in the early phase after femoral ligation. 
Finally, the tissue damage in the lower limbs of eNOS-/- mice appeared irreversible, 
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because at three weeks of follow up muscle weights were decreased, tissue perfusion 
of the feet remained impaired, and collateral-dependent blood flow was still increas-
ing. This irreversibility stresses the essential role of NO-mediated vasodilation.
Our findings confirm that eNOS activity is essential for an effective restoration of blood 
flow after femoral artery occlusion, however not by stimulation of arteriogenesis but 
by inducing NO-dependent vasodilation of the collateral-dependent peripheral ves-
sels. Because arteriogenesis itself is not an immediate process and thus cannot protect 
tissue from ischemic injury in the acute phase, the combination of both adequate 
vasodilation (of peripheral collateral vessels) in the acute phase and vascular (ie, col-
lateral artery) growth for continuation is necessary for successful blood flow recovery 
and tissue salvage.
Clinical trials aiming for therapeutic neovascularization by stimulating vascular growth 
using different growth factors have shown disappointing results5,6. These disappoint-
ing results might be due to the preexistent endothelial dysfunction in patients with 
atherosclerosis or diabetes. Endothelial dysfunction causes decreased vasoreactivity as 
a result of a reduced bioavailability of NO. Therefore, there might be (partial) analogies 
between these patients and eNOS-/- mice, in which arteriogenesis is not impaired but 
the inability to sufficiently vasodilate resulted in severe ischemic damage. However, 
similar to the approach to stimulate vascular growth only, stimulation of vasodilation 
only might not be sufficient to adequately restore blood flow distally from the occlusion 
in a clinical situation of chronic ischemia in the lower limb. A combination of stimula-
tion of vascular growth and vasodilation could be essential for successful therapeutic 
neovascularization, specifically in conditions where endothelial dysfunction is present 
(ie, hypercholesterolemia and diabetes). We are currently investigating this hypothesis 
using both diabetic and hypercholesterolemic mice.
In summary, eNOS overexpression did not have beneficial effects for collateral artery 
growth. eNOS deficiency caused severe impaired blood flow recovery after arterial 
occlusion caused by insufficient vasodilation of collateral-dependent vessels, whereas 
collateral artery growth was intact. Therefore, eNOS activity is essential for an effective 
restoration of blood flow after femoral artery occlusion, however not by stimulation of 
arteriogenesis but by inducing NO-dependent vasodilation of the collateral-dependent 
peripheral vessels.
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Abstract
Hypertension is a known risk factor for the development of atherosclerosis. To as-
sess how mechanical factors contribute to this process, mouse carotid arteries were 
maintained in organ culture at normal (80 mmHg) or high (150 mmHg) intraluminal 
pressure during 1, 6, 12 or 24h. Thereafter, fluorescent human monocytic cells (U937) 
were injected intraluminally and allowed to adhere for 30 minutes before washout. 
U937 adhesion was increased in vessels kept at 150 mmHg 12 hours (23.5±5.7 versus 
9.9±2.2 cells/mm at 80 mmHg; p<0.05) or 24 hours (26.7±5.7 versus 8.8±1.5 cells/mm; 
p<0.05). At 24 hours, high pressure was associated with increased mRNA expression 
of monocyte chemoattractant protein-1, interleukin-6, keratinocyte-derived chemo-
kine, and vascular cell adhesion molecule-1 (6.9±2.1, 4.4±0.1, 9.8±2.8 and 2.4±0.1-
fold respectively; p<0.05), as assessed by quantitative RT-PCR and corroborated by 
immunohistochemistry, which also revealed an increase in intracellular adhesion 
molecule-1 expression. Nuclear factor κB inhibition using SN50 peptide abolished the 
overexpression of chemokines and adhesion molecules and reduced U937 adhesion 
in vessels at 150 mmHg. Moreover, treatment of vessels and cells with specific neutral-
izing antibodies established that monocyte chemoattractant protein-1, interleukin-6 
and keratinocyte-derived chemokine released from vessels at 150 mmHg primed the 
monocytes, increasing their adhesion to vascular cell adhesion molecule-1 but not 
intracellular adhesion molecule-1 via α4β1 integrins. The additive effect of chemokines 
on the adhesion of U937 cells to vascular cell adhesion molecule-1 was confirmed 
by in vitro assay. Finally, pressure-dependent U937 adhesion was blunted in arteries 
from mice overexpressing endothelial NO synthase. Hence, high intraluminal pressure 
induces cytokine and adhesion molecule expression via Nuclear factor κB, leading to 
monocytic cell adhesion. These results indicate that hypertension may directly contrib-
ute to the development of atherosclerosis through Nuclear factor κB induction.
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Introduction
Atherosclerosis is an inflammatory disease characterized by an accumulation of 
leukocytes, lipids and fibrous tissue in the intima of arteries. In the early phases of 
atherosclerotic plaque development, activated endothelial cells express elevated 
amounts of adhesion molecules such as selectins (P-selectin and E-selectin) and intra-
cellular (ICAM-1), vascular (VCAM-1) and platelet endothelial cell adhesion molecules 
(PECAM-1) at their surface. Cytokines and chemokines are also secreted in excess by 
activated vascular cells. These conditions favor the recruitment and the accumulation 
of monocytes and lymphocytes in the intima of vessels1.
It is well known that the zones of the vascular tree where blood flow is disturbed or 
oscillatory are predisposed to the formation of atherosclerotic lesions, whereas vessels 
exposed to laminar shear stress remain relatively plaque-free2, mostly credited to local 
release of nitric oxide (NO)3. However, blood pressure also influences plaque formation, 
arterial hypertension being an independent risk factor for atherosclerosis4. In hyper-
tensive patients, high concentrations of circulating ICAM-1, VCAM-1 and E-selectin5, as 
well as monocyte chemoattractive protein (MCP-1)6 have been reported. Experimental 
animal models have also linked hypertension with cytokine and adhesion molecule 
expression, as well as the propensity for atherosclerotic plaque development. The 
expression of MCP-1 is more important in the aorta of hypertensive SHR rats than that 
of control Wistar rats7. Moreover, chronic hypertension due to endothelial NO synthase 
(eNOS) deficiency8 or induced by clamping renal arteries9 or by aortic constriction10 
exacerbates atherosclerosis in ApoE-/- mice. However, the direct role of arterial pressure 
in the development of atherosclerotic plaques has not yet been clearly demonstrated.
A recent study carried out in our laboratory showed that stretch of the arterial wall 
caused by an increase in the intraluminal pressure induces the activation and nuclear 
translocation of the transcriptional factor nuclear factor κB (NF-κB)11. This factor 
intervenes in the transcription of a large number of inflammatory genes coding for 
cytokines, chemokines and adhesion molecules12. Consequently, we hypothesized that 
high arterial pressure could contribute to the development of atherosclerotic lesions 
directly by inducing monocyte adhesion via NF-κB. Using an in vitro organ culture 
model of whole vessel, we assessed monocyte adhesion to the vascular endothelium of 
arteries kept at normal or high pressure. We also evaluated which adhesion molecules 
and chemokines might be implicated in this process, and verified their induction by 
NF-κB.
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Material and methods
Organ culture
Mouse left and right carotid arteries were isolated, cannulated at both extremities, 
and immersed in an organ culture bath filled with Dulbecco’s modified Eagle’s medium 
(DMEM, GIBCO BRL) supplemented with 5% fetal calf serum as described previously11. 
Each arterial segment was connected to a closed perfusion circuit consisting of a 
3-port reservoir, a peristaltic pump (Alitea), and a pressure chamber allowing for the 
application of a controlled intraluminal hydrostatic pressure. Organ culture of carotid 
segments was carried out under sterile conditions in an incubator containing 5% CO2 
at 37°C. The flow was set at 1.38 mL/min, allowing for renewal of the medium within 
the intraluminal space while creating minimal shear forces (0.5 dyne/cm2). Likewise, 
to avoid the potentially confounding effect of cyclic stretch vessels were exposed 
to steady, continuous stretch, although we have previously shown that NF-κB is not 
induced in pulsatile vessels13. Arterial segments were kept at an intraluminal pressure 
of 80 mmHg for 1 hour stabilization after surgery. Thereafter, vessels were exposed to 
a pressure of 80 mmHg or 150 mmHg for 1, 6, 12 or 24 hours. High pressure imposed 
a stretch corresponding to a 20±3% increase in diameter. More details appear in the 
online data supplement, at http://circres.ahajournals.org.
Most experiments were undertaken using vessels from C57BL/6 mice. However, arter-
ies from mice overexpressing (eNOS-tg) and underexpressing (eNOS-/-) eNOS described 
previously14, or their wild-type littermates were also used where indicated. In one set of 
experiments, vessels maintained for 24 hours at 80 mmHg were treated with lipopoly-
saccharide (LPS) (10 μg/mL). Some arteries kept at 80 or 150 mmHg for 24 hours were 
incubated with the NF-κB inhibitor peptide SN50 (AAVALLPAVLLALLAP-VQRKRQKLMP, 
50 μg/mL; Upstate Biotechnology), with the pharmacological inhibitor of NF-κB am-
monium pyrrolidine dithiocarbamate (PDTC, 10 µM; Sigma), or with the eNOS inhibitor 
N-nitro-L-arginine methyl ester (L-NAME, 10 µM, Sigma) added to the culture medium 
at the onset of the equilibration period.
Fluorescent cell preparation
Cells of the human monocytic cell line U937 were cultivated in RPMI medium 1640 
(GIBCO BRL) containing penicillin (100 UI/L) and supplemented with 5% fetal calf 
serum (Boehringer-Mannheim). U937 cells were labeled with 0.5 μM fluorescent dye 
(CellTracker Orange CMTMR; Molecular Probes). Briefly, the cells were incubated with 
the fluorescent dye for 30 minutes and then resuspended in culture medium.
In order to circumvent a potential direct effect of pressure on U937 adhesion, the 
intraluminal pressure of all vessels was reset to 80 mmHg 30 minutes before intralu-
minal cell injection. The fluorescent U937 cells were injected in the lumen of cultured 
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vessels by the distal end and allowed to interact 30 minutes (5x106 cells/mL). After a 
10-minutes washout at low-flow shear stress (0.5 dyne/cm2), vessels were fixed in 4% 
paraformaldehyde for 15 minutes. Adherent cells were counted under a fluorescence 
microscope. In some experiments, blocking antibodies targeting VCAM-1 (25μg/mL; 
AF643), ICAM-1 (5μg/mL; AF796), MCP-1 (100μg/mL; AB479), IL-6 (1μg/mL; AF406) or 
KC (10μg/mL; AF453) (R&D Systems) were added to the intraluminal compartment 30 
minutes before U937 injection. Alternatively, U937 cells were incubated with a blocking 
anti-α4 (5μg/mL, BBA37 R&D Systems) or anti-β1 integrin antibody (5μg/mL, 553715 BD 
PharMingen), or with a non-blocking anti-α4 antibody (5μg/mL, 9C10 Research Diag-
nostics), before being injected in vessels.
Immunohistochemical analysis and quantitative RT-PCR
Details regarding immunohistochemical analysis and quantitative RT-PCR appear in the 
online supplement, at http://circres.ahajournals.org. Primary goat polyclonal antibod-
ies used for immunohistochemistry and targeting VCAM-1, ICAM-1, E-selectin, MCP-1, 
IL-6, and KC, were obtained from Santa Cruz Biotechnology. All primers were designed 
using Primer Express 2 Software and are reported in Table 1.
Table 1. Forward (F) and reverse (R) primers used for the quantitative analysis of adhesion molecule 
and chemokine expression.
mouse VCAM-1-F AAC CAG AAA AGT TCT GCT TGA CAA GT
mouse VCAM-1-R ATT AAG TTA CAA CAG TCA GTC CAA GCA A
mouse E selectin-F CAA GGC CAG CCC TCT ACC A
mouse E selectin-R AAA GCA ATA AAA CGC TGT TTC TGT T
mouse ICAM-1-F CCC CCC GAC ACA GGA AAG
mouse ICAM-1-R TCC CCA GAC TCT CAC AGC ATC T
mouse MCP-1-F GCA GCA GGT GTC CCA AAGAA
mouse MCP-1-R ATT TAC GGG TCA ACT TCA CAT TCA A
mouse IL6-F ATT ACA CAT GTT CTC TGG GAA ATC GT
mouse IL6-R TAT ATC CAG TTT GGT AGC ATC CAT CA
mouse KC-F CCA CCC GCT CGC TTC TCT GTG
mouse KC-R CCG TTA CTT GGG GAC ACC TTT TAG CA
Cell adhesion assay
Cell culture plates were coated with recombinant mouse VCAM-1/Fc chimera (2μg/
mL R&D Systems) at 4°C overnight. After washout, saturation with a 2% bovine serum 
albumin was performed for 1 hour. Fluorescent U937 cells (103/well) were made to 
adhere untreated or in presence of recombinant mouse IL-6 (0.06 ng/mL), MCP-1 
(10 ng/mL) and/or KC (5 ng/mL R&D Systems) for 1 to 30 minutes. In another set of 
experiments, fluorescent U937 were made to adhere for 30 minutes in the presence 
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of a blocking anti-α4 (5μg/mL, R&D Systems) or anti-β1 integrin antibody (5 μg/mL, 
PharMingen). After washout, adherent U937 cells were counted under a fluorescence 
microscope.
Statistics
Data are presented as mean±SEM. Data were analyzed by ANOVA, and when results 
were found to be significant comparisons were performed by Bonferroni test or Stu-
dent’s paired t-test (to compare arteries from the same animal). Statistical significance 
was accepted for P<0.05.
Results
Pressure induces monocytic cell adhesion via NF-κB
The effects of high intraluminal pressure on monocytic cell adhesion were first assessed 
in carotid arteries maintained in culture for 1, 6, 12 or 24 hours at 80 or 150 mmHg 
(figure 1A). The number of adherent U937 cells did not vary significantly between ves-
sels maintained at 80 or 150 mmHg for 1 (2.15±1.32-fold increase in cell adhesion at 
150 mmHg) or 6 hours (2.19±0.66-fold). However, high intraluminal pressure led to a 
significant increase in U937 adhesion when maintained for either 12 hours (5.90±2.34-
fold P<0.05) or 24 hours (6.01±2.15-fold; P<0.05). High intraluminal pressure likewise 
enhanced primary mouse mononuclear cell adherence at 24 hours (online figure 1). 
Thus, maintenance of vessels at high intraluminal pressure for at least 12 hours favors 
monocytic cell adhesion.
We have previously shown that high pressure induces NF-κB in cultured arteries11,15. To 
evaluate the role of NF-κB in pressure-dependent U937 binding to the vascular wall, 
some carotid arteries were treated for 24 hours with SN50, an inhibitor that binds the 
nuclear localization sequence on NF-κB and prevents its translocation to the nucleus. 
We confirmed that phosphorylation of the p65 subunit of NF-κB and its nuclear translo-
cation was significantly more important in vessels kept at 150 mmHg for 24 hours than 
in arteries at 80 mmHg, and that SN50 prevented these effects. Baseline monocytic 
cell adhesion was not significantly affected by the NF-κB inhibitor treatment in vessels 
kept at 80 mmHg. However, in vessels at high pressure SN50 treatment prevented the 
increase U937 adhesion (4.4±1.5 cells/mm at 80 mmHg versus 8.2±3.2 cells/mm at 150 
mmHg) (figure 1A). Similar results were obtained with the NF-κB inhibitor PDTC (data 
not shown). Therefore, we concluded that high pressure induces monocytic cell adhe-
sion via activation of the NF-κB pathway.
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Figure 1. High intraluminal pressure leads to an increase in monocytic cell adhesion via NF-κB. A: Vessels 
were incubated at 80 or 150 mmHg for 1, 6, 12 or 24 hours. Fluorescent U937 cells were then injected in 
the intraluminal space for 30 minutes, and adherent cells were counted after washout. Monocytic cell 
adhesion was enhanced in vessels exposed to high pressure for 12 and 24 hours. However, in vessels 
cultured with a peptide inhibitor of NF-κB, SN50 (50 µg/mL), high pressure failed to induce monocyte 
adhesion. B: Monocytic cell adhesion in arteries incubated for 24 hours at high pressure is equivalent to 
that attributable to LPS (10 µg/mL). Data are mean±SEM of n=6 to 10 experiments. *P<0.05 vs 80 mmHg 
at the same time point, untreated. §P<0.05 vs 150 mmHg untreated at 24h.
Pressure-dependent monocytic cell adhesion is equivalent to LPS stimulation
To compare the effects of the stretch stimulus to a more traditional inflammatory 
mediator, vessels were cultured for 24 hours at 80 mmHg and treated or not with LPS, 
a known activator of endothelial cells16,17. We found that the number of adherent U937 
cells in arteries incubated with LPS (18.7±3.5 cells/mm) was almost three-fold more 
important than that in arteries cultured without LPS (5.9±1.6 cells/mm, P<0.05, figure 
1B), equivalent to that induced by high pressure.
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Pressure-dependent expression of adhesion molecules and chemokines
We then studied the expression of adhesion molecules and chemokines potentially 
involved in regulating monocytic cell adhesion to the vascular wall. Quantitative RT-
PCR of genes encoding VCAM-1, ICAM-1, E-selectin, MCP-1, IL-6 and KC was undertaken 
in vessels maintained for 24 hours at normal or high intraluminal pressure (figure 2). 
On the one hand, the expression of ICAM-1 and E-selectin was not different in vessels 
maintained at 80 or 150 mmHg. On the other hand, the expression of VCAM-1, MCP-1, 
KC and IL-6 was respectively 2.0±0.1, 8.1±2.0, 9.8±2.8 and 5.8±0.1 fold greater at 150 
mmHg than at 80 mmHg (P<0.05).
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Figure 2. Quantitative RT-PCR carried out on vessels incubated during 24 hours reveals that the 
expression of VCAM-1, MCP-1, IL-6, and KC is upregulated in vessels incubated at 150 mmHg. The dotted 
line represents the expression of adhesion molecules and chemokines at 80 mmHg (100%). Data are 
mean±SEM of n=4 experiments evaluated in duplicate. *P<0.05, **P<0.01, ***P<0.001 vs 80 mmHg.
To verify whether pressure-dependent changes in mRNA expression corresponded to 
modified protein content, immunohistological staining for cytokines and adhesion 
molecules was evaluated. High pressure did not alter the expression of E-selectin in 
vessels (figure 3A), whereas staining for ICAM-1 and VCAM-1 was significantly en-
hanced in vessels incubated for 24 hours at 150 mmHg compared with arteries kept 
at 80 mmHg (figure 3A). Quantification of relative vessel wall surface staining revealed 
greater expression of ICAM-1 in the endothelium (6.9±0.9% versus 1.8±0.5%, P<0.01) 
and more VCAM-1 in the endothelium and the media (25.8±3.5% versus 9.8±1.6%, 
P<0.001) of arteries at 150 mmHg compared with 80 mmHg (figure 3B). The expression 
of MCP-1, IL-6, and KC was also increased in the endothelium and the media of vessels 
maintained for 24 hours at 150 mmHg versus 80 mmHg (17.4±1.1% versus 10.8±0.9%, 
P<0.001; 18.3±1.9% versus 6.8±1.5%, P<0.05; and 15.9±1.6% versus 8.4±3.3%, P<0.05 
respectively, figure 3A and B).
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Figure 3. A: IHC studies demonstrate that high intraluminal pressure leads to an increase in the 
expression of VCAM-1, MCP-1 and IL-6 and KC throughout the vascular wall at 24 hours, whereas 
ICAM-1 expression is enhanced only in the endothelium and E-selectin levels remain unchanged. The 
NF-κB inhibitor SN50 prevents pressure-dependent overexpression of these proteins. Representative 
of 4 separate experiments. Surface staining for these molecules at 24 hours is quantified in B. Data are 
mean±SEM of n=4. *P<0.05, **P<0.01, ***P<0.001 vs 80 mmHg, §P<0.05, §§P<0.01, §§§P<0.001 vs 150 
mmHg untreated at 24 hours.
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In all cases, incubation of vessels with the inhibitor of NF-κB reduced the intensity of 
immunostains such that protein expression of the cytokines and adhesion molecules no 
longer differed between 80 and 150 mmHg (figure 3A and B). These immunohistologic 
studies indicated that high intraluminal pressure induces an increase in the vascular 
expression of adhesion molecules and chemokines via the NF-κB pathway.
Adhesion molecules and chemokines contribute to pressure-dependent monocytic 
cell adhesion
To determine the relative importance of adhesion molecules and cytokines in pressure-
dependent U937 adhesion, vessels maintained for 24 hours at 80 or 150 mmHg were 
treated with blocking antibodies directed against these proteins for 1 hour before the 
intraluminal monocytic cell injection. The anti-ICAM-1 antibody did not affect U937 ad-
hesion at all in vessels cultured at 80 mmHg (10.9±2.5 cells/mm) or 150 mmHg (24±3.8 
cells/mm), such that the difference between the two remained significant (P<0.01, 
figure 4). In comparison, there was complete inhibition of pressure-dependent U937 
adhesion in vessels treated with antibodies directed against VCAM-1 or MCP-1 (7.0±0.4 
cells/mm and 6.8±1.3 cells/mm at 150 mmHg, respectively; P<0.001 versus 150 mmHg 
untreated). Blocking IL-6 and KC strongly reduced the number of adherent monocytic 
cells associated with high pressure (P<0.001), although a small increment in U937 ad-
hesion was still distinguishable in arteries kept at 150 mmHg compared with 80 mmHg 
(P<0.05).
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Figure 4. Quantification of monocytic cell adhesion in cultured vessels maintained at 80 or 150 mmHg 
for 24 hours, then treated for 1 hour with blocking antibodies targeting ICAM-1, VCAM-1, MCP-1, IL-6 or 
KC before intraluminal monocytic cell injection. Blocking ICAM-1 fails to prevent the increase in U937 cell 
adhesion associated with high pressure, but all other treatments prevent stretch-induced adhesion, either 
completely (VCAM-1, MCP-1) or partially (IL-6, KC). Data are mean±SEM of n=4 to 6 experiments. *P<0.05, 
**P<0.01, ***P<0.001 vs 80 mmHg, §§§P<0.001 vs 150 mmHg untreated.
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The direct effect of chemokines on monocytic cell adhesiveness was verified an in vitro 
cell adhesion assay, which was performed using fluorescent U937 cells made to adhere 
to VCAM-1-coated plates. U937 adhesion was bolstered by cytokine treatment (MCP-1, 
IL-6 and KC), reaching 223.0±9.8 cells/well at 30 minutes compared with 102.5±18.5 
cells/well for untreated monocytes (figure 5A). Cell adhesion on plastic was negligible. 
The independent effect of MCP-1, IL-6 and KC on monocytic cell adhesion was evalu-
ated at 30 minutes (figure 5B). All three cytokines induced a significant increase in U937 
adhesion to VCAM-1 compared with control (119.8±16.7 cells/well), rising to 169.8±17.4 
(MCP-1), 162.8±15.0 (IL-6) and 167.0±15.7 cells/well (KC; P<0.05), and they exerted an 
additive effect on U937 adhesion to VCAM-1 (244.7±26.0 cells/well; P<0.01).
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Figure 5. Quantification of U937 cell adhesion in vitro. A: Untreated or chemokine-stimulated monocytic 
cells were left to adhere for 1 to 30 minutes on VCAM-1-coated or uncoated plates. Results show that 
combined treatment with MCP-1, IL-6 and KC enhanced U937 cell adhesion on VCAM-1 compared with 
controls, whereas no cells adhered on uncoated plates. B: Treatment of monocytic cells with MCP-1, 
IL-6 or KC enhances their adhesion to VCAM-1-coated plates at 30 minutes, and treatment with all three 
chemokines at once reveals an additive effect. Data are mean±SEM of n=3 to 6 experiments. *P<0.05, 
**P<0.01 vs untreated control, §P<0.05 vs MCP-1+IL-6+KC cotreatment.
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Role of α4 and β1 integrins in pressure-dependent monocytic cell adhesion
To establish that monocytic α4β1, known to interact with endothelial VCAM-1, was 
implicated in pressure-dependent monocyte adhesion, U937 cells were treated with 
blocking antibodies directed against α4 or β1 integrin for 1 hour before intraluminal 
injection in vessels. The blockade of either α4 or β1 strongly decreased U937 adhesion 
in vessels maintained at 150 mmHg for 24 hours compared with untreated monocytic 
cells (4.9±0.6 and 7.2±1.7 respectively, versus 16.9±0.5; P<0.001; figure 6A). Similarly, 
pretreatment of U937 cells with the blocking anti-α4 or anti-β1 integrin antibodies sig-
nificantly blunted their adhesion on VCAM-1-coated plates 30 minutes after combined 
MCP-1, IL-6, and KC stimulation (164.5±21.9 versus 93.2±4.9 with anti-α4 and 104.1±6.7 
with anti-β1; P<0.01; figure 6B). In comparison, non-blocking anti-α4 antibodies did 
not significantly interfere with monocytic cell binding to the vessel wall or to VCAM-1-
coated plates (data not shown). These results strongly suggest that MCP-1, IL-6 and KC 
released from vessels at 150 mmHg primes monocytic cells, increasing their adhesion 
to VCAM-1 via α4β1 integrins.
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Figure 6. Key role of α4 and β1 integrins in monocytic cell adhesion. A: Increased U937 adhesion in vessels 
maintained for 24h at 150 mmHg was blunted by incubating the cells with blocking anti-α4 or anti-β1 
antibodies 1 hour before their intraluminal injection. Data are mean±SEM of n=6 experiments. ***P<0.001 
vs 80 mmHg, §§§P<0.001 vs 150 mmHg untreated. B: Similarly, the blocking anti-α4 or anti-β1 antibodies 
reduced the adhesion of chemokine-stimulated monocytic cells on VCAM-1-coated plates at 30 minutes. 
Data are mean±SEM of n=4. ***P<0.001 vs untreated control, §§P<0.01 vs MCP-1+IL-6+KC treated 
monocytes without antibody incubation.
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Figure 7. Overexpression of eNOS counters enhanced monocytic cell adhesion associated with high 
intraluminal pressure. Carotid arteries from eNOS-overexpressing (eNOS-tg), eNOS knockout and wild-
type littermates were maintained for 24 hours at 80 of 150 mmHg, with or without L-NAME treatment, 
before U937 cell injection. Monocytic cell adhesion was similarly increased in wild-type and eNOS-/- 
carotids exposed to high intraluminal pressure. This response was blunted in arteries of eNOS-tg mice, 
but restored by treatment with L-NAME. Data are mean±SEM of n=6 to 8 experiments. *P<0.05, **P<0.01, 
***P<0.001 vs 80 mmHg.
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Enhanced NO production prevents pressure-induced monocyte adhesion
The protective effect of shear stress is mostly attributable to the local synthesis and 
release of NO via activation of eNOS. To verify whether the protective effects of NO may 
counterbalance the proatherosclerotic effects of high pressure, we verified stretch-
induced U937 adhesion in vessels obtained from mice overexpressing (eNOS-tg) or 
underexpressing (eNOS-/-) endothelial NO synthase, or from wild-type littermates. As 
demonstrated in figure 7, lack of NO synthase in eNOS-/- vessels did not affect high-
pressure-induced monocyte adhesion, but overexpression of eNOS was accompanied 
by a marked reduction of U937 binding in vessels maintained at 150 mmHg, such that 
cell adhesion levels no longer varied between arteries exposed to normal or high pres-
sure. Treatment of vessels with L-NAME restored the stretch-dependent increment in 
monocyte adhesion in eNOS-tg vessels but did not affect U937 binding in vessels from 
eNOS-/- mice or wild-type littermates.
Discussion
The present study reveals that exposing arteries to high intraluminal pressure induces 
the expression of adhesion molecules and cytokines by endothelial and smooth muscle 
cells, leading to increased monocyte adhesion to the vascular wall. Moreover, we show 
that NF-κB plays a central role in this mechanosensitive process. To the best of our 
knowledge, this is the first demonstration of a direct proatherogenic effect of pressure 
alone, independent of hormonal conditions associated with hypertension.
Many studies in human subjects and animal models have described an association 
between hypertension and increased atherosclerotic plaque formation6-10,18. However, 
it was recently demonstrated in a rat model of aortic coarctation that enhanced expres-
sion of adhesion molecules occurred only in aortic segments exposed to a high pres-
sure19. Similarly, in a rabbit model of experimental atherosclerosis with aortic stenosis, 
monocyte adhesion and expression of VCAM-1 were more important in the proximal 
aorta where pressure is elevated than in the normotensive distal aorta20. These reports 
showed that high pressure is necessary to stimulate monocyte adhesion. Nevertheless, 
increased levels of angiotensin II, which characterize these models, may very well have 
acted synergistically with the applied stretch to produce proatherosclerotic effects. 
Indeed, angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor 
blockers prevent adhesion molecule overexpression as well as monocyte infiltration 
in hypertensive transgenic rats21,22 and are associated with reduced plaque size in 
hypertensive ApoE-/-, eNOS-/- mice8. However, our study clearly demonstrates that the 
hypertensive mechanical environment is sufficient to elicit chemokine and adhesion 
molecule expression leading to monocyte adhesion to the vascular wall, in the absence 
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of confounding hormonal factors. Moreover, even adding angiotensin II to the culture 
medium did not enhance U937 adhesion to the vessel wall, either at normal or high 
pressure, indicating that stretch is a more potent stimulus of monocytic cell adhesion 
than angiotensin II in whole arteries, at least in the ex vivo setting.
Arteries are exposed to a complex mechanical environment, including both cyclic 
strain and shear stress. Some studies have shown that exposing smooth muscle cells 
to cyclic stretch stimulates the expression of IL-6 and IL-8 via the activation of c-Jun N-
terminal kinase and NF-κB pathways23,24, whereas cyclic stretching of endothelial cells 
was associated with increased expression of ICAM-125 and E-selectin, along with greater 
monocyte adhesion26. Reproducing the tonic component of vessel stretch, continuous 
stretch also stimulated the expression of IL-6 via NF-κB in cultured endothelial cells27. 
Nevertheless, the phenotype of vascular cells is deeply altered in vitro, such that the 
responses to mechanical stimuli differ significantly from in vivo conditions where cells 
are exposed to a complex, tensile and 3D matricial environment. Indeed, unlike what is 
reported in vascular cells in vitro, cyclic stretch did not activate NF-κB in whole vessels13. 
Moreover, exposing arteries to a normotensive degree of stretch (80 mmHg), sufficient 
to maintain smooth muscle cell phenotype28, did not activate NF-κB or induce mono-
cyte adhesion in the present study. High intraluminal pressure alone, reminiscent of the 
hypertensive state, stimulated NF-κB-dependent expression of chemokines and adhe-
sion molecules, allowing for monocytic cell adhesion. On the other hand, overexpres-
sion of eNOS, associated with enhanced NO release14, blunted these proatherosclerotic 
effects of high pressure in vessels from eNOS-tg mice. Hence, hypertensive mechanical 
conditions facilitate atherosclerotic plaque formation in vascular regions where blood 
flow is low or oscillatory, whereas the protective effect of NO release prevails in vessels 
exposed to laminar shear stress.
It has been shown that monocytes preincubated with MCP-1 and IL-8 adhere on 
endothelial cells29. Likewise KC, the murine homologue of IL-830, but not MCP-1, trig-
gered monocyte arrest on early atherosclerotic endothelium in a reconstituted flow 
chamber system, and blockade of α4β1 integrins or VCAM-1, but not ICAM-1, inhibited 
this process31. Moreover, VCAM-1 and its ligand α4β1 are critical for monocyte rolling 
and adhesion in early atherosclerotic lesions32, and formation of lesions is markedly 
reduced in atherosclerosis-prone mice after peptide perfusion to block α4β1, compared 
with unperfused mice33. In the present study, we found that high pressure increases 
the endothelial expression of ICAM-1 and induces a strong overexpression of VCAM-1, 
MCP-1, IL-6 and KC in all vascular cells, through induction of NF-κB. In agreement with 
the previous studies cited above, we demonstrated that monocyte adhesion occurs via 
the interaction of α4β1 integrins with VCAM-1 rather than ICAM-1. However, blockade 
of MCP-1, IL-6 or KC led to a strong decrease in monocyte adhesion to the vascular 
wall, and our in vitro studies confirmed that all three cytokines are necessary to prime 
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monocyte adhesion. This contrasts with a previous report establishing that KC plays a 
predominant role in mediating monocyte adhesion in vessels from ApoE-/- mice fed a 
Western-type diet31; disparities between that study and our present findings indicate 
that the nature of the proatherosclerotic stimulus may influence which chemokines 
participate in monocyte recruitment. Regardless, beyond the initial endothelial cell 
adhesion step, the enhanced VCAM-1 and chemokine expression observed in smooth 
muscle cells of arteries at high intraluminal pressure could facilitate inflammatory cell 
infiltration in the vascular wall. Finally, the fact that all of the outcomes of high pres-
sure described here could be reversed by blocking NF-κB highlights the key role of 
this transcription factor in the deleterious, proatherosclerotic effects associated with 
hypertensive conditions.
In summary, our results demonstrate that high intraluminal pressure alone, in the 
absence of external hormonal factors, is sufficient to induce chemokine and adhe-
sion molecule expression and so trigger monocyte adhesion to vascular wall. More 
importantly, our work indicates that high blood pressure may directly contribute to 
the development of atherosclerosis though induction of NF-κB, suggesting that this 
pathway may provide an interesting therapeutic target to counter adverse effects of 
hypertension.
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Abstract
Bone marrow–derived mononuclear cells (BMMNC) enhance postischemic neo-
vascularization, and their therapeutic use is currently under clinical investigation. 
However, cardiovascular risk factors, including diabetes and hypercholesterolemia 
lead to the abrogation of BMMNC proangiogenic potential. Nitric Oxide (NO) has 
shown to be critical for the proangiogenic function of BMMNC and increased 
endothelial NO Synthase (eNOS) activity promotes vessel growth in ischemic condi-
tions. We therefore hypothesized that eNOS overexpression could restore both 
the impaired neovascularization response and decreased proangiogenic function 
of BMMNC in clinically relevant models of diabetes and hypercholesterolemia. 
Transgenic eNOS overexpression in diabetic, atherosclerotic and wild-type mice 
induced a 1.5 to 2.3-fold increase in postischemic neovascularization compared to 
control. eNOS overexpression in diabetic or atherosclerotic BMMNC restored their 
reduced proangiogenic potential in ischemic hind limb. This effect was associated with 
an increase in BMMNC ability to differentiate into cells with endothelial phenotype in 
vitro and vivo and an increase in BMMNC paracrine function including VEGF-A release 
and NO-dependent vasodilation. Moreover, while WT BMMNC treatment resulted in 
significant progression of atherosclerotic plaque in ischemic mice, eNOS transgenic 
atherosclerotic BMMNC treatment even had antiatherogenic effects.
Cell-based eNOS gene therapy has both proangiogenic and antiatherogenic effects 
and should be further investigated for the development of efficient therapeutic neo-
vascularization designed to treat ischemic cardiovascular disease.
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Introduction
To prevent or treat ischemic diseases, therapeutic neovascularization, the stimulation 
of tissue vascularization after ischemia, has recently progressed from bench to bedside. 
Strategies include transplantation of angiogenic bone marrow-derived mononuclear 
cells (BMMNC) or gene transfer for systemic or local up-regulation of proangiogenic 
proteins. Clinical studies have demonstrated the safety, feasibility and efficacy of 
intracoronary and intramuscular infusion of adult BMMNC in patients with peripheral 
arterial disease, acute myocardial infarction, and ischemic cardiomyopathy1,2.
However, despite the excitement surrounding the possible clinical use of BMMNC, in 
atherosclerosis, diabetes and other risk factors for cardiovascular diseases the avail-
ability of bone marrow and progenitor cells is reduced and their function impaired to 
varying degrees1,2. Moreover, the safety of BMMNC treatment has been questioned by 
studies that found an increase in atherosclerotic plaque size after BMMNC treatment3. 
This potentially hazardous dual effect of therapeutic neovascularization on atherogen-
esis is explained by the many common pathways of both mechanisms and has been 
named the “Janus Phenomenon”4.
Impaired bioavailability of Nitric Oxide (NO) is a hallmark in patients with cardiovascular 
disease. Moreover, the enzyme endothelial NO synthase (eNOS) has also been shown 
to be essential for neovascularization. It has a key regulatory function in endothelial 
cell growth5, vascular remodeling6, angiogenesis7 and vasodilation8 and plays a crucial 
role in the functional activity of BMMNC9,10. Thus, impaired bioavailability of NO may 
significantly contribute to the impaired neovascularization response to ischemia in 
atherosclerosis or diabetes. Therefore, using homebred transgenic mice overexpress-
ing human eNOS11, the purposes of the present study were to evaluate whether eNOS 
gene therapy would be able to improve the postischemic neovascularization response 
in diabetes and atherosclerosis and to restore the impaired proangiogenic potential of 
BMMNC without causing simultaneous detrimental proatherogenic effects, overcom-
ing the “Janus Phenomenon”.
Materials and methods
Mice
The experimental protocol was approved by the Animal Experiments Committee un-
der the national Experiments on Animals Act and adhered to the rules laid down in 
this national law that serves the implementation of “ Guidelines on the protection of 
experimental animals “ by the Council of Europe (1986), (Directive 86/609/EC). C57BL/6 
and apolipoprotein E-deficient (ApoE KO) transgenic mice overexpressing the human 
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eNOS gene under regulation of the human eNOS promoter were obtained, as previ-
ously described11. Mice were backcrossed to C57Bl6 for at least ten generations (>96% 
C57Bl6). To induce diabetes, 8-week-old mice were injected intraperitoneally with 40 
mg/kg of streptozotocin (STZ; Sigma) in 0.05 mol/L Sodium Citrate, pH 4.5, daily for five 
days12. Mice were treated with or without NO synthase inhibitor N(G)-nitro-L-arginine 
methyl ester (L-NAME, 10 mg/kg/day in the drinking water, Sigma).
Hind limb ischemia model and quantification of neovascularization
Mice underwent surgery to induce unilateral hind limb ischemia, as previously de-
scribed13. A total of 1x106 freshly isolated bone marrow-derived mononuclear cells 
(BMMNC) were intravenously injected 24 hours after femoral artery ligation. Two weeks 
after ligation, postischemic neovascularization was evaluated by Laser Doppler Imag-
ing and microangiography, as previously described13.
Atherosclerosis
Plasma cholesterol levels were measured and atherosclerotic plaque lesion size and 
composition in the aortic root was evaluated by immunohistochemistry, as previously 
described3.
NO and ROS production
NO production in BMMNC was assessed by measuring intracellular nitrosation of NO-
sensitive fluorochrome 4,5-Diaminofluorescein diacetate (DAF-2/DA; Alexis Biochemi-
cals). Briefly, BMMNC were incubated with 10 μM DAF-2/DA for 180 minutes (37°C). 
Exposure to light was avoided as far as possible throughout experimentation. At 180 
minutes supernatants were removed and cells were washed in fresh DAF-2/DA-free 
buffer followed by immediate FACS analysis. A Becton Dickinson FACSCalibur analyzer 
was used to quantify fluorescence (excitation wavelength: 488 nm and emission wave-
length: 530 nm) at the single-cell level, and data were analyzed using Cellquest version 
3.3 (Becton Dickinson) software. Cellular reactive oxygen species (ROS) levels, reflecting 
a balance between oxidant production and removal by endogenous antioxidants, were 
also quantified using L-012 as described recently12. BMMNC were lysed in 50mmol/L Tris 
buffer (pH 7.5) containing protease inhibitors (Boerhinger) and centrifuged at 10 000 
x g for 15 minutes at 4°C. Supernatants were then incubated with 100 mmol/L L-012 
(Wako). Luminescence was counted (Perkin Elmer Topcount NXT) during 20 seconds 
after a 10 minutes interval allowing for the plates to become adapted to the dark.
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Growth factor assay
After isolation of adherent cells in cell cultures, culture medium was collected and 
analyzed for vascular endothelial growth factor A (VEGF-A) by enzyme-linked immuno-
sorbent assay (R&D Systems).
Measurement of arterial diameter in isolated femoral arteries
After 24 hours of ischemia, ischemic femoral arteries from control animals were 
isolated and cannulated at both extremities in a video monitored perfusion system 
(arteriograph, LSI). A total of 0.5x106 BMMNC from WT, eNOStg control and diabetic or 
hypercholesterolemic mice were then perfused, as earlier described9.
Isolation, and incorporation of bone marrow mononuclear cells
Bone marrow cells were obtained by flushing tibiae and femora of donor mice. Low-density 
BMMNC were then isolated by density gradient centrifugation with Ficoll. BMMNC were 
plated at a density of 1x106 cells per cm2 on 24-well plates (Nunc) coated with 10 µg/ml fi-
bronectin (Sigma) and cultured up to 7 days in M199 medium supplemented with 20% FBS 
(Invitrogen), 0.05 mg/ml Bovine Pituitary Extract (Invitrogen), antibiotics, and 10 units/ml 
heparin (Leo Pharma BV). Nonadherent cells were then removed and adherent cells were 
analyzed by immunochemical assay with DiI-labeled acetylated low-density lipoprotein 
(DiI-LDL; Molecular Probes), fluorescein isothiocyanate-labeled Bandeiraea Simplicifolia 
lectin (BS-1 lectin; Sigma), goat anti-eNOS (Santa-cruz) and subsequently rabbit antigoat 
Alexa fluor 594. Endothelial cell phenotype was revealed by double positive staining 
for both Dil-LDL and BS-1 lectin and both eNOS and BS-1 lectin. These double-positive 
cells were negative for the monocytic marker CD45 (data not shown). Cell numbers were 
counted and expressed in cells per field. Three fields from each culture were counted.
To demonstrate incorporation of BMMNC-derived endothelial cells into ischemic 
muscles, green Alexafluor 546-labeled BMMNC (1x106 cells/100µl PBS) were intrave-
nously administered 24 hours after induction of hind limb ischemia. The gastrocnemius 
muscles were harvested four days after injection of BMMNC. Incorporated BMMNC 
were detected by immunostaining with a biotinylated isolectin B4 (Sigma) followed by 
incubation with rhodamin red streptavidin (Jackson). The number of infiltrating cells 
was also evaluated using green Alexafluor 546-labeled BMMNC isolated from WT or 
eNOStg mice. Two days after BMMNC injection, the ischemic gastrocnemius muscles 
were harvested, weighed, minced and digested in 450 U/ml collagenase I, 125 U/ml 
collagenase XI, 60 U/ml DNAseI and 60 U/ml hyaluronidase (Sigma Aldrich) for 1 hour 
at 37°C. Cell suspensions were layered on histopaque 1083 (Sigma Aldrich) for gradient 
density centrifugation. In the mononuclear cells fraction, the number of cells being 
green Alexafluor 546/DAPI+ was then evaluated on a LSRII Flow Cytometer (Becton 
Dickinson) with the FACSDiva software (Becton Dickinson).
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Statistical analysis
Statistical analysis was performed using Student’s t-test or one-way analysis of variance, 
followed by post-hoc analysis, as appropriate. Data are reported as mean ± standard 
error of the mean (SEM). Statistical significance was accepted when P<0.05.
Results
eNOS overexpression is proangiogenic
Postischemic hind limb neovascularization was impaired in diabetic mice and ApoE 
KO mice compared with WT, demonstrated by a 1.3-fold decreased foot perfusion 
and vessel density (P<0.05, Figure 1A). eNOS overexpression in the endothelium of 
diabetic mice and ApoE KO mice resulted in an increase in foot perfusion and vessel 
density (P<0.001), reaching above WT levels. Endothelial eNOS overexpression in WT 
mice resulted in the strongest neovascularization response (1.5 to 1.7-fold increase 
compared with WT controls; P<0.001). Of interest, treatment with the NOS inhibitor 
N(G)-nitro-L-arginine methyl esther (L-NAME) abrogated postischemic vessel growth 
in mice overexpressing eNOS, underscoring the role of NO in the observed protective 
effects.
The role of eNOS overexpression on cell-based therapeutic neovascularization was 
evaluated by intravenous transplantation of different BMMNC after induction of isch-
emia in WT, diabetic and ApoE KO recipient mice. In WT recipient mice, transplantation 
of WT BMMNC and eNOStg BMMNC resulted in a comparable 1.3 to 1.9-fold increase in 
foot perfusion and vessel density compared with saline (P<0.01, Figure 1B). In diabetic 
mice, diabetic BMMNC transplantation did not improve neovascularization response. 
Conversely, administration of WT BMMNC increased vessel growth in diabetic ischemic 
area but to a lesser extent than that of eNOStg BMMNC. Interestingly, eNOStg diabetic 
BMMNC transplantation resulted in a significant 1.3 to 1.5-fold increase in postischemic 
neovascularization and reached WT BMMNC levels compared with saline and diabetic 
BMMNC (P<0.01). Similarly, eNOS overexpression restored the therapeutic potential of 
ApoE KO BMMNC.
Differentiation of eNOS-overexpressing BMMNC
Western blot analysis of BMMNC confirmed an increased presence of eNOS protein in 
eNOS transgenic BMMNC (P<0.05, Figure 2A). Concordantly, NO production by eNOS 
transgenic BMMNC was significantly elevated compared with control BMMNC (P<0.05, 
Figure 2B). We also showed that BMMNC-derived ROS were up-regulated in diabetic 
and ApoEKO BMMNC, as previously described12. However, eNOS overexpression did not 
affect ROS levels (Figure 2B).
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Figure 1. A) eNOS overexpression increases postischemic neovascularization. Quantification of foot 
perfusion (upper) measurements by Laser Doppler Imaging and vessel density measurements by 
microangiography (lower). Values are mean ± SEM, n=10 and *P<0.05, vs WT control mice, ††P<0.01, 
†††P<0.001 vs WT mice, ≠≠≠P<0.001 vs eNOS transgenic mice. B) Bone marrow eNOS overexpression 
restores the proangiogenic effect on postischemic neovascularization. Quantitative evaluation (upper) of 
foot perfusion by Laser Doppler Imaging and vessel density measurements by micro-angiography (lower). 
Values are ± SEM, n=10 and *P<0.05,***P<0.001 vs PBS-treated mice, ≠P<0.05, ≠≠P<0.01 vs mice receiving 
WT BMMNC, ††P<0.01 vs diabetic mice receiving diabetic BMMNC, &&P<0.01, &&P<0.001 vs ApoEKO mice 
receiving ApoEKO BMMNC.
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Figure 2. eNOS overexpression increases differentiation of BMMNC. Representative quantatitive Western 
blot (A) and NO and ROS production (B) in BMMNC isolated from WT or eNOS transgenic control, diabetic 
and ApoE KO mice. C) Quantification of percentage of BMMNC that double positively stained for BS-1 
Lectin and DiI-LDL (upper) or BS-1 lectin and eNOS (lower), regarded as cells with endothelial phenotype. 
D) Representative images of BMMNC cultures. Arrows indicate double positive cells with endothelial 
phenotype respectively for Dil-LDL (red) and BS-1 lectin (green) or eNOS (red) and BS-1 lectin. Nuclei were 
stained with DAPI (blue). E) Quantitative evaluation of the number of infiltrating BMMNC in the ischemic 
area. BMMNC were isolated from WT or eNOS transgenic control, diabetic and ApoE KO mice. Two days 
after BMMNC injection in WT mice with hind limb ischemia, the gastrocnemius muscles were digested 
and the number of cells being green Alexafluor 546 hi/DAPI+ was then evaluated in the mononuclear cells 
fraction. Quantitative analysis (F) and representative photomicrographs (G) of incorporated BMMNC-
derived endothelial cells in histological sections from ischemic skeletal muscles. BMMNC were stained 
using Alexa fluor 546 cell tracker (green). Mouse vasculature was identified by isolectin B4 staining (red). 
Nuclei were stained with DAPI (blue). Arrows indicate incorporated BMMNC-derived endothelial cells. 
Values are mean ± SEM, n=4. *P<0.05, **P<0.01 vs WT BMMNC, ≠P<0.05 vs WT Diab BMMNC, †P<0.05 and 
††P<0.01 vs ApoE KO BMMNC.
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Immunohistochemical analysis of BMMNC cultured in endothelial-specific medium 
demonstrated a significant increase in BMMNC differentiation into cells with endo-
thelial phenotype of eNOS transgenic BMMNC compared with BMMNC, revealed by a 
greater percentage of BS-1 lectin/Dil-LDL and BS-1 lectin/eNOS double positive cells 
(P<0.01, Figure 2C-D). Similarly, eNOS overexpression increased the number of incor-
porated BMMNC-derived endothelial cells into capillaries of ischemic muscle (Figure 2 
F-G). Conversely, administration of WT or eNOStg BMMNC did not affect the number of 
infiltrating BMMNC in ischemic area (Figure 2E).
Paracrine effects of eNOS-overexpressing BMMNC
BMMNC are also capable of stimulating neovascularization by secretion of proangio-
genic factors. Culture medium was collected from BMMNC differentiation cell cultures. 
Using ELISA assay, quantitative measurements of VEGF-A demonstrated an increase in 
VEGF-A secretion in culture medium from eNOS transgenic BMMNC compared to WT 
BMMNC (Figure 3A). Finally, because proangiogenic effects of BMMNC also rely on the 
cells’ ability to modulate vascular function, we assessed BMMNC effects on vascular 
diameter in isolated perfused mouse femoral arteries (238±5 µm, internal diameter). 
Intraluminal administration of BMMNC induced a rapid vasodilation (internal diameter 
increased by 27±2 μm for 5x105 cells/ml). eNOS transgenic BMMNC increased vasodila-
tion by 1.7-fold over WT BMMNC (p<0.01). Interestingly, WT diabetic BMMNC and ApoE 
KO BMMNC only slightly affected vessel diameter whereas eNOS overexpression fully 
restored the vasodilatory potential of diabetic and ApoE KO BMMNC (Figure 3B).
eNOS overexpression is antiatherogenic
Atherosclerotic lesions were analyzed in ApoE KO mice after induction of hind limb 
ischemia and subsequent BMMNC treatment. Plasma cholesterol levels were similar in 
all groups. Treatment with ApoE KO BMMNC did not affect plaque size or composition 
in contrast with treatment with WT BMMNC (60% increase in lesion size, without dif-
ferences in composition, P<0.001, Table 1). Remarkably, treatment with eNOStg ApoE 
KO BMMNC had an inhibitory effect on plaque progression (44% decrease in lesion 
size, P<0.05). Furthermore, plaque composition changed due to eNOS transgenic ApoE 
KO BMMNC treatment into a more stable phenotype (40% decrease in macrophages, 
P<0.05).
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Figure 3. eNOS overexpression increases the paracrine potential of BMMNC. A) Quantification by ELISA 
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Table 1. Bone marrow eNOS overexpression has inhibitory effects on atherosclerotic lesion size 
progression in the aortic sinus of ApoE KO mice. Values are mean ± SEM, n=10. *P<0.05 vs PBS and 
†P<0.05 vs ApoE KO BMMNC.
PBS WT BMMNC
ApoE KO BMMNC eNOS transgenic
ApoE KO
BMMNC
Total cholesterol 
(mM)
13.2±1.6 12.8±1.2 11.9±2.4 11.4±3.5
Lesion size (μm2) 108838±14257 178257±16687* 110654±13458 75125±9458*†
% of MOMA2
positive staining
28.3±2.4 34.2±3.1 30.4±2.7 20.1±1.9*†
% of α-actin
positive staining
9.4±0.3 10.6±1.1 11.1±2.1 10.2±1.5
% of Sirius red
positive staining
23.1±2.6 20.2±1.9 24.3±2.7 25.4±2.5
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Discussion
In the present study, we showed that endothelial eNOS overexpression improved the 
postischemic neovascularization response in healthy, diabetic and atherosclerotic 
mice. Subsequently, eNOS overexpression in bone marrow repaired the decreased pro-
angiogenic functional activity of diabetic and atherosclerotic BMMNC. Finally, the 
results of the present study demonstrated a unique combined proangiogenic and 
antiatherogenic effect of cell-based eNOS gene therapy in atherosclerotic mice.
The critical role of eNOS in postischemic neovascularization has been well established. 
In eNOS-deficient mice neovascularization is decreased resulting in severe limb loss14 
and in parallel, up-regulation of eNOS activity by eNOS gene delivery15 or bovine eNOS 
overexpression16 enhances postischemic blood flow recovery and limb function. In our 
study we confirmed these findings in healthy mice and extended them to a more clini-
cally relevant model, the diabetic and atherosclerotic mouse. eNOS overexpression in 
diabetic and atherosclerotic mice induced a strong postischemic neovascularization 
response comparable with WT mice. Mechanisms of the positive neovascularization 
effects of eNOS up-regulation included increase in vasodilation8, increase in vessel 
density as shown by microangiographic measurements and increase in vasculogenesis 
as a result of restoration of pathological bone marrow proangiogenic function. Indeed, 
the enhanced postischemic neovascularization response after treatment of ischemic 
mice with eNOS transgenic diabetic or eNOS transgenic ApoE KO BMMNC revealed that 
up-regulation of eNOS repaired the reduced proangiogenic function of pathological 
BMMNC. This was further explained by an increased differentiation into cells with endo-
thelial phenotype, and an increase in their paracrine potential including VEGF-A release 
and NO-dependent vessel dilation9. It is noteworthy that, although no changes in the 
amount of total eNOS protein were observed, NO release was decreased in diabetic 
BMMNC compared with nondiabetic control BMMNC. Our findings are consistent with 
prior reports showing that hyperglycemia and diabetes are associated with impaired 
eNOS functions, at least in part, through inhibition of eNOS phosphorylation17,18.
The term “Janus phenomenon” has been invented for the dual effect of protein (FGF, 
MCP-1)-, gene (VEGF, TNF)- or cell (BMMNC, EPC)-based therapeutic angiogenesis on 
progression and destabilization of atherogenesis4. NO appears a possible exception 
to the “Janus Phenomenon” having established proneovascularization and antiathero-
genic effects. However, these effects have never been investigated at the same time 
in the same model. Our study is the first study using eNOS cell-based gene therapy 
for the stimulation of postischemic neovascularization and simultaneously focusing 
on prevention of supplemental proatherogenic effects. Interestingly, WT BMMNC 
treatment led to increased plaque size in ischemic atherosclerotic mice, whereas ApoE 
KO BMMNC treatment had no effect on lesion size, as previously described3. However 
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at the same time, we could indeed demonstrate an antiatherogenic effect of eNOStg 
atherosclerotic BMMNC, thus blunting the “Janus Phenomenon”. In our studies, only oc-
casional donor BMMNC were identified in the atherosclerotic lesions, making a physical 
or local contribution of transplanted BMMNC to plaque growth less likely. A possible 
other explanation could be the production of chemokines by transplanted BMMNC, 
however we could not detect any differences in MCP-1 and VEGF blood levels in the 
different BMMNC-treated mice (data not shown). It is likely that the potent antiinflam-
matory effect of eNOS overexpression is the main responsible factor in the antiathero-
genic effect of eNOS transgenic ApoE KO BMMNC treatment, as described previously11. 
Definitely, further studies will be necessary to investigate in more detail, not only our 
interesting observation of the combined proangiogenic and antiatherogenic potential 
of eNOS cell-based therapy, but also the complete concept of BMMNC treatment-
induced atherogenesis. Nevertheless, these results imply that eNOS up-regulation is a 
promising target for local or stem cell-based therapeutic neovascularization in patients 
with ischemic (cardio)vascular disease.
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Introduction
Cardiovascular disease is currently still responsible for the largest part of morbidity and 
mortality in the Western world. Endothelial dysfunction due to or resulting in impaired 
bioavailability of Nitric Oxide (NO) is a hallmark in patients with cardiovascular disease, 
leading to atherosclerosis, occlusive disease and subsequent postischemic complica-
tions. Vascular remodeling is the native adaptive response to arterial occlusion, con-
sisting of collateral growth, arteriogenesis, angiogenesis and vasculogenesis1. NO is 
thought to be essential in vascular remodeling, as decreased endothelial NO synthase 
(eNOS) activity inhibits vessel growth in ischemic conditions2 and NO has shown to 
be critical for the proangiogenic function of bone marrow–derived mononuclear cells 
(BMMNC)3,4. In addition, cardiovascular risk factors including diabetes and hypercho-
lesterolemia lead to a decreased quantity and proangiogenic potential of BMMNC, 
resulting in impaired vascular remodeling5-7.
The aim of the present thesis was to further unravel the role of NO in vascular remodel-
ing and to evaluate positive effects on vascular remodeling by elevated eNOS activity 
in physiological and cardiovascular pathophysiological conditions.
eNOS transgenic mice
In chapter 2 and 3 we describe the generation and characterization of two different 
eNOS transgenic (eNOS TG) mouse models8,9. For the generation of eNOS TG mice, we 
used a DNA fragment that comprised the complete human eNOS genomic sequence, 
including all exons and introns as well as its natural flanking sequences. By using this 
construct with the autologous eNOS promotor we were able to simulate the human 
situation in terms of regulation and tissue distribution of eNOS as much as possible. In 
chapter 2 we describe for the first time in literature a human eNOS TG mouse model. In 
chapter 3 we describe a second transgenic mouse overexpressing human eNOS fused 
with a green fluorescent protein (GFP), allowing the study of localization and regula-
tion of eNOS. Localization studies revealed in both mouse models that expression of 
the eNOS transgene was restricted to the endothelial lining of blood vessels in various 
tissues tested, without appreciable expression in non-endothelial cells. In eNOS-GFP TG 
mice GFP was expressed along the same pattern as eNOS expression in all endothelial 
cells, confirming the presence of the eNOS-GFP fusion protein. Using GFP expression 
and confocal microscopy we could demonstrate the localization of human eNOS-GFP 
in the plasma cell membrane and Golgi complex of the cell, where eNOS is normally 
localized10. eNOS activity was 10-fold elevated in the eNOS TG mice. Subsequently, 
NO production in isolated vessels was significantly increased in transgenic mice when 
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compared with non-transgenic control animals. Aortic blood pressure was 20 mm Hg 
lower in the transgenic mice compared with control mice because of lower systemic 
vascular resistance. The effects of eNOS overexpression on diet-induced atherosclerosis 
were studied in a crossbred with apolipoprotein E-deficient (ApoE KO) mice. Elevation 
of eNOS activity in these eNOS TG*ApoE KO mice decreased blood pressure (-20 mm Hg) 
and plasma levels of cholesterol (-17%), resulting in a reduction in atherosclerotic lesions 
by 40%. These results seem in contradiction with earlier reports from another (bovine) 
eNOS transgenic mouse model, in which modest overexpression of eNOS resulted in 
increased atherosclerosis11. A probable explanation for these contradictory results lies 
in the fact that the promotor used for the DNA construct in the bovine eNOS mouse 
model was derived from the endothelin-1 gene12, which is differentially and often even 
inversely regulated when compared with the activity of the eNOS promotor13. Thus, 
endothelin-1 and eNOS have opposite effects on vascular tone and the development of 
atherosclerosis13. Moreover, the marked decrease in atherosclerosis in our mouse model 
is in concordance with earlier studies showing increased atherosclerotic lesion size in 
eNOS KO mice and therefore our results confirm the atheroprotective role of eNOS14.
In conclusion, we generated two eNOS transgenic mouse models with physiological 
regulation of the overexpressing human eNOS gene and a characteristic phenotype 
because of increased NO bioavailability, making these models a very useful tool for 
further research to unravel the role of eNOS in various physiological and pathophysi-
ological conditions.
eNOS in collateral growth
In chapter 4 we studied the role of eNOS in collateral growth using three mouse strains 
with different levels of eNOS expression15. Distal femoral artery ligation was performed 
in transgenic eNOS-overexpressing mice (eNOS TG), eNOS-deficient (eNOS KO) mice, 
and wild-type (WT) controls. In the distal femoral artery ligation model there is no 
limb ischemia in WT mice. Therefore, it is regarded as a model specific for collateral 
artery growth16. Firstly, to evaluate the possible benefits of elevated eNOS activity on 
collateral growth, we compared eNOS TG with WT mice. We could demonstrate a 
beneficial effect of overexpression of eNOS, but only in the acute phase of blood flow 
recovery immediately after femoral occlusion. During three weeks of follow-up, blood 
flow recovery was equal in eNOS TG and WT mice. In agreement with these findings, 
histological analysis showed that there were no differences in collateral artery growth. 
Therefore, we concluded that the increase of NO bioavailability enhanced the early 
vasodilatory response induced by increased fluid shear stress (FSS), but did not further 
enhance the outward vascular remodeling of collateral arteries.
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In the second part of this study we evaluated the effect of absence of eNOS activity on 
collateral growth and thus compared eNOS KO and WT mice using the same hind limb 
model and measurements. Distal femoral artery ligation caused significantly reduced 
blood flow recovery as well as tissue damage in eNOS KO mice, despite our observa-
tions of an increase in angiogenesis and normal collateral growth compared to WT. 
Histological analysis revealed growing collateral artery size to the same extent in eNOS 
KO and WT mice. In vivo the administration of an NO donor induced vasodilation in col-
lateral arteries of eNOS KO mice, but not in WT, as they were already fully vasodilated. 
Therefore, we concluded that in eNOS KO mice impaired blood flow recovery leading 
to severe tissue damage, was the result of insufficient vasodilation in the early recovery 
phase, before collateral artery remodeling was complete.
In a follow-up study performed in the same laboratory, the role of NO in collateral growth 
was further unraveled. Distal femoral artery ligation in both eNOS KO and iNOS KO mice 
confirmed our results on normal collateral growth in eNOS KO mice but demonstrated 
a partially inhibited collateral growth in iNOS KO mice. Pharmacological unspecific NOS 
inhibition with L-NAME (NG-mono-methyl-L-arginine ester) markedly blocked collateral 
growth. Furthermore, the combination of eNOS KO mice, treated with the specific iNOS 
inhibitor L-NIL (L-N6-(1-iminoethyl)-L-lysine) completely abolished collateral growth. 
Both eNOS and iNOS appeared upregulated in FSS-stimulated collateral vessels. Finally, 
the NO donor diethylenetriamine (DETA) NONOate strongly stimulated collateral artery 
growth, activated perivascular monocytes, and increased proliferation markers17.
More recently, it was suggested that NO also has an important role in maintaining na-
tive collateral density during natural growth to adulthood and in collateral remodeling 
in obstructive disease, the latter through regulation of cell proliferation. In particular, 
based on results from array profiling and network analysis, eNOS/NO may coordinately 
regulate expression of a network of genes controlling cell cycle checkpoints necessary 
for cell proliferation during collateral remodeling18.
In summary, irrespective of source, NO is an essential link in the pathways leading to 
arteriogenesis, via a reciprocal counterbalance between NOS isoforms. NO released 
by shear stress-activated endothelium stimulates adhering monocytes to produce 
another NO cascade (and growth factors), resulting in proliferation of endothelial cells 
and subsequently smooth muscle cells of the media (Figure 1). NO may originate also 
from the monocytes/macrophages in the perivascular space where they are activated 
in an autocrine way and stimulated to produce mitogens. However, the paradox of NO 
influence and interplay on activation, regulation and mostly proliferation on both (en-
dothelial and smooth muscle) sides of the elastic lamina still remains not completely 
resolved.
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ulation immediately following arterial occlusions [26].
Targeted deletion of the three isoforms of ANKRD1
showed no delay in blood flow recovery after femoral
artery occlusion [58].
A brief excursion into the clinical situation
The clinical field of arteriogenesis is well covered by
excellent reviews [82, 131, 135]. Today clinicians use
techniques and insights gleaned from experimental
work and collateral hemodynamics can now be
studied in the beating hearts of fully conscious pa-
tients. The roles played by monocytes are fully rec-
ognized and are explored in studies making use either
of the paracrine action of monocytes in adult stem cell
applications, by chemokines that prolong the function
of monocytes like GM-CSF or G-CSF [132] or by
studying the gene expression of monocytes [23] with
the question in mind why only relatively few patients
are able to develop collaterals in spite of the fact that
all human hearts possess the precursors of grown
collateral arteries. Although these studies have
produced interesting results it must be kept in mind
that the development of collaterals needs time, which
is not granted in a situation of acute thrombotic
arterial occlusion. Those patients with a well-devel-
oped collateral circulation may have profited from a
gradually developing stenosis via slow growth of
mural thrombi and not necessarily from a fortuitous
pattern of gene expression of monocytes.
In summary we have unraveled pathways essential
for arteriogenesis that converge to remodel a preex-
istent arteriole into an artery. These pathways origi-
nate at the shear stressed endothelium which attracts
bone marrow derived cells that produce GFs in
response to NO and VEGF and lead to powerful
remodeling mainly of the smooth muscle layer of the
media resulting in a manifold increase of the arteri-
olar diameter able to deliver bulk flow to jeopardized
tissue. The multitude of morphological, protein-
biochemical and molecular changes seen in SMCs of
developing collaterals are of considerable interest but
they are only the consequences of the fundamental
event that occurred with mitogenic stimulation which
is still in need of unraveling.
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Fig. 1 Network analysis of differentially expressed proteins (red symbols)
involved in arteriogenesis. We performed a literature scan (Pathway Studio) in
order to retrieve an extract of regulatory and interaction pathways. Different
ligands and receptors act in concert leading to an activation of a variety of
transcription factors and signalling pathways via the central players calcium
and NO. Bold arrows indicate a fluid shear stress activated new pathway, which
resulted from the molecular investigation of the shunt model. (FSS fluid shear
stress, MCP-1 monocyte chemo-attractant protein, Dll1 delta-like1, JAG1
jagged1, VEGF vascular endothelial growth factor, FN1 fibronectin, Trpv4
transient receptor potential cation channel, subfamily V, member 4, NOS1
neuronal nitric oxide synthase, NOS2A inducible nitric oxide synthase, NOS3
endothelial nitric oxide synthase, ITGA5: aVb3 Integrin, EFNB2 Ephrin B2, NO
nitric oxide, KLF2 Krueppel-like factor2, SRF serum response factor, EGR1 early
growth response1, RHOA ras homolog gene family, member A, CFL1 cofilin1,
Abra actin binding Rho activator, Dream DRE antagonist modulator, TMSB4X
thymosinb4, Dstn destrin)
W. Schaper 15
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Figure 1. Role of NO in the endothelial cell during collateral growth.
Different ligands and receptors act in concert leading to an activation of a variety of transcription factors 
and signaling pathways via the central players calcium and NO, resulting in endothelial cell proliferation. 
(Figure taken from Schaper19 with permission)
eNOS in cellular adhesion
Cellular adhesion is an indispensable mechanism in vascular remodeling, both in growth 
of collateral arteries as in angiogenesis during neovascularization. Furthermore, it is an 
important step in the development of atherosclerotic plaques. In chapter 5 we studied 
the pressure-induced mechanism of cellular a hesion20. Arteries are continuously 
exposed to a complex mechanical environment, including both shear stress and cyclic 
strain by intraluminal pressure, causing stretch of the arterial wall. Stretch of the arte-
rial wall induces an endothelial activation leading to cellular adhesion. There has been 
extensive research on shear stress as a potent activat r of ndothelial cells, inducing 
adhesion of monocytes and inflammatory cells, resulting in an inflammatory response. 
These effects of increased shear stress are mostly attributable to the local synthesis 
and rel ase of NO21. Hence, NO can act by downregula ing cytokines, resulting in the 
downregulation of endothelial cell adhesion molecules (ECAMs), which are important 
modulators of leukocyte-endothelium interaction via leukocyte rolling along the endo-
thelium and adhesion to the endothelium. Once the cells begin to roll, they can then 
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firmly attach to the endothelium via integrin interaction with endothelial intercellular 
adhesion molecules (ICAMs) to promote leukocyte adhesion.
An earlier study performed in our laboratory showed that stretch of the arterial wall 
caused by an increase in the intraluminal pressure also induces an adhesion-inflam-
matory pathway via the activation and nuclear translocation of the transcriptional 
factor nuclear factor-kappa B (NF-κB).22 This factor regulates the transcription of a 
large number of inflammatory genes coding for cytokines, chemokines, and adhesion 
molecules23.
To unravel the role of NO in pressure-induced cellular adhesion, we verified stretch-
induced human monocyte line U937 adhesion in vessels obtained from eNOS TG mice, 
eNOS KO mice, or WT littermates. The lack of NO synthase in eNOS KO vessels did not 
affect high pressure-induced monocyte adhesion, but overexpression of eNOS was ac-
companied by a marked reduction of U937 monocyte binding in vessels maintained at 
high pressure, such that cell adhesion levels no longer varied between arteries exposed 
to normal or high pressure. Treatment of vessels with L-NAME restored the stretch-
dependent increment in monocyte adhesion in eNOS TG vessels.
In conclusion, we suggest that hypertensive mechanical conditions facilitate cellular 
adhesion in vascular regions where blood flow is low or oscillatory via the transcrip-
tion factor NF-κB, leading to the development of atherosclerotic lesions. However, in 
hypertensive vessels exposed to laminar shear stress, shear-induced NO release inhibits 
cellular adhesion and atherosclerotic plaque formation is hampered.
eNOS in neovascularization
The critical role of eNOS in postischemic neovascularization has been well established. 
In eNOS-deficient mice neovascularization is decreased resulting in severe limb loss 
and in parallel, up-regulation of eNOS activity by eNOS gene delivery or bovine eNOS 
overexpression enhances postischemic blood flow recovery and limb function2,24,25. 
In the study described in chapter 6 we confirmed these findings in healthy mice and 
extended them to a clinically more relevant model, the diabetic and atherosclerotic 
mouse26. eNOS overexpression in diabetic and atherosclerotic mice induced a strong 
postischemic neovascularization response when compared with WT mice. Mecha-
nisms of the positive effects on neovascularization of eNOS up-regulation in ischemic 
tissue included increase in vasodilation15, increase in vessel density and increase in 
vasculogenesis as a result of restoration of pathological endothelial and bone marrow 
(proangiogenic) function.
Secondly, the enhanced postischemic neovascularization response after treatment of 
ischemic mice with eNOS TG diabetic or eNOS TG atherosclerotic bone marrow-derived 
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mononuclear cells (BMMNC) revealed that up-regulation of eNOS repaired the reduced 
proangiogenic function of pathological BMMNC. This was explained by an increased 
differentiation into cells with endothelial phenotype, and an increase in their paracrine 
potential including VEGF release and NO-dependent vessel dilation4. The term “Janus 
phenomenon” has been suggested for the dual effect of protein (FGF, MCP-1)-, gene 
(VEGF, TNF)- or cell (BMMNC, EPC)-based therapeutic neovascularization on progres-
sion and destabilization of atherogenesis27. NO appears a possible exception to the 
“Janus Phenomenon” having established proneovascularization and antiatherogenic 
effects. However, these effects have never been investigated at the same time in the 
same model. Our study is the first study using eNOS cell-based gene therapy for the 
stimulation of postischemic neovascularization and simultaneously focusing on pre-
vention of supplemental proatherogenic effects. We showed that WT BMMNC treatment 
led to increased plaque size in ischemic atherosclerotic mice, while atherosclerotic 
BMMNC treatment had no effect on lesion size, as previously described28. Moreover, 
we could demonstrate an antiatherogenic effect of eNOS TG atherosclerotic BMMNC, 
thus blunting the “Janus Phenomenon”. In our studies, only occasional donor BMMNC 
were identified in the atherosclerotic lesions, making a physical or local contribution 
of transplanted BMMNC to plaque growth less likely. Another possible explanation 
could be paracrine effects of transplanted BMMNC through production of chemokines. 
It is likely that the potent antiinflammatory effect of eNOS overexpression is the main 
responsible factor in the antiatherogenic effect of eNOS TG atherosclerotic BMMNC 
treatment, as described previously8.
In conclusion, we demonstrated that local and progenitor cell-based eNOS gene 
therapy has both proangiogenic and antiatherogenic effects and should be further 
investigated for the development of efficient therapeutic neovascularization designed 
to treat ischemic cardiovascular disease.
NO is a master switch in vascular remodeling
The combination of recent insights from literature and the present thesis lead to the 
concept of NO as one of the master switches in vascular remodeling (Figure 2). However, 
several key questions about the role of NO in neovascularization remain unanswered. 
Elucidating the role of NO in vessel specification and maturation would be of significant 
interest for tissue engineering and drug delivery29. The intracellular concentration of 
cGMP, a second messenger of vasodilation induced by NO, is tightly regulated by phos-
phodiesterases, already used clinically. Hence, it is particularly important to identify the 
roles in neovascularization of the cGMP-dependent and independent effects of NO30.
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Recently, an additional mechanism in tissue neovascularization, the expansion of 
isolated vessels by biomechanical forces, named looping angiogenesis, was discovered 
(Figure 3)31. This seems the most important mechanism of vascularization during wound 
healing, but has never been studied in the context of postischemic neovascularization. 
Future work will need to establish to which extent looping angiogenesis participates 
in vascular remodeling and whether there is crosstalk between the pathways for the 
translocation of vessels by biomechanical forces and the classical (NO-regulated) 
mechanisms of neovascularization.
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Figure 2. Both mechanisms of vascular remodeling, e.g. collateral growth and neovascularization, 
are modulated by NO through a complex regulation at different molecular levels. Modified from 
“Introduction” chapter. For more details see text.
Finally, lymphatic vessel function is as important as blood vessel function for the main-
tenance of tissue homeostasis, and disruption of the lymphatic system is encountered 
in many pathologies. Compared with our knowledge of blood vessels, our knowledge 
of NO function in lymphatic vessels still remains in its infancy33.
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Figure 3. Looping angiogenesis, a fourth mechanism of angiogenesis for tissue vascularization, is 
mediated by biomechanical forces through myofibroblastic contraction pulling on existing vessel loops. 
(Modified from Benest & Augustin32 with permission)
NO-based therapeutic vascular remodeling
With the current advances, especially the suggestion of the concept of NO as a master 
switch, the modulation of eNOS should be considered as a potent new strategy to 
stimulate vascular remodeling in diseases with inadequate vessel formation. Regula-
tion of NO and NO-mediated effects can occur through multiple mechanisms, includ-
ing targeting of eNOS, availability of factors that regulate NOS activity or through 
modulation of protein-protein interactions of NOS with its partners. For this purpose 
several pharmacological, gene- and stem cell therapies are under present preclinical 
and clinical investigations.
Modulation of eNOS activity
There are a number of factors which affect the production of NO and the ability of NO 
to reach or diffuse to its cellular targets. An important aspect of NOS function is the 
availability of substrates (L-arginine) and cofactors and the presence of NO scavenging 
by free radicals34.
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Under physiological conditions, the intracellular L-arginine concentration is in excess 
of the Km for eNOS, owing to L-arginine uptake via cationic amino acid transporters35. 
Under pathological conditions, NO-dependent endothelial dysfunction has been 
linked with reduced L-arginine transport, i.e., eNOS might become substrate limited36. 
This may be due to competition with NOS for L-arginine as substrate by other enzymes 
coexpressed in the same cell type, including arginase, an enzyme converting L-arginine 
to urea and L-ornithine, and arginine decarboxylase, a mitochondrial enzyme that pro-
duces carbon dioxide and agmatine37. The administration of L-arginine has been explored 
in conditions such as hypercholesterolemia, diabetes, and coronary artery disease. For 
example, L-arginine supplementation partially reversed the impairment of endothelium-
dependent vasodilation in response to acetylcholine in hypercholesterolemic animals38. 
Whereas in acute studies an increase in NO bioavailability was shown, chronic L-arginine 
administration in patients did not have any beneficial effects39-41. An explanation could 
be that beneficial effects of chronic L-arginine administration are offset by simultaneous 
increments in S-adenosyl-L-homocysteine as a side product reducing NO bioavailability 
at the same time42.
Tetrahydrobiopterin (BH4) is an essential cofactor for NOS and has profound effects on 
NOS function, including stabilizing its dimeric structure and facilitating and enhanc-
ing binding of L-arginine43,44. Reduced bioavailability of BH4 is associated with models 
of diabetes, atherosclerosis and hypertension45-47. Oral administration of BH4 shows 
promise for the treatment of oxidative stress-induced disorders, such as the metabolic 
syndrome in rats, and it slows the progression of atherosclerosis in mice and improves 
endothelial dysfunction in patients with coronary artery disease48-50. In 2008, a first 
study on chronic BH4 supplementation demonstrated an improvement on endothelial 
dysfunction in hypercholesterolemic patients51. Thus, BH4 represents a therapeutic 
relevant tool to modulate NOS function in different diseases that are characterized by 
reduced NOS activity or NO synthesis.
NO levels can also be raised by NO-releasing donor compounds. Delivery of NO-donors 
to vessel walls has resulted in decreased vessel damage in response to injury but opti-
mization of the delivery compound is still required52,53. Furthermore, rather than trying 
to grossly substitute the effect of physiologically produced NO with exogenous sources, 
in many instances, the real added value would be a strategy that restores endogenous 
NO production from eNOS in situ.
Side effects of eNOS elevation
Upon deficiency of substrate or reduced cofactors, NOS no longer produces NO but 
instead transfers electrons to oxygen, thereby producing free oxygen radicals, such as 
superoxide (O2-), if BH4 is lacking, or H2O2, if L-arginine is lacking
54,55. These free oxy-
gen radicals, in turn, can lead to further oxidation of BH4 (as well as other cofactors), 
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thereby catalyzing the whole process. If levels of superoxide increase significantly, NO 
outcompetes superoxide dismutase (SOD), the physiological inactivator of superox-
ide56. This reaction has the triple effect of scavenging NO, reducing its bioavailability 
and producing a potent oxidant, peroxynitrite (ONOO-). This condition is referred to 
as the so-called “uncoupled” state of eNOS. The uncoupled state of eNOS, as well as 
increased superoxide formation, has been associated with many vascular diseases and 
risk factors for atherosclerosis and consequently has been regarded as an abnormality 
of eNOS function34. Therefore, eNOS elevation, especially in pathological conditions, 
resulting in a rapid shortage of substrate or cofactors, may play a dual role, causing 
detrimental opposite effects, namely further endothelial dysfunction and progression 
of atherosclerotic disease.
Secondly, a disadvantage of any proangiogenic therapy is that it might also promote 
angiogenesis in a tumor. If NOS upregulatory therapy was applied in a patient who had 
undiagnosed metastatic cancer it would assist in further spread of the disease. Thus 
patients being enrolled into NOS proangiogenic trials would need a search for occult 
malignancy57.
eNOS gene targeting
The focus of gene therapy has been to deliver the NOS gene directly to the site of injury 
resulting in a local increase of NO generation. The latter approach avoids the problem 
of systemic NO toxicity. NOS gene therapy delivery strategies include the use of either 
plasmid DNA, liposomes or adenoviruses as vectors with the large majority of in vivo 
studies using adenoviral vectors. From the current research reviewed, eNOS appears to 
be the most attractive NOS isoform for gene therapy. Administration of eNOS resulted 
in the best therapeutic outcome following vascular injury. Moreover, in a rat hind limb 
ischemia model both an adenoviral and a non-viral eNOS-gene delivery therapy in-
duced increase in postischemic neovascularization mediated via VEGF24,58. In research 
using a mouse model of hind limb ischemia a phosphomimetic form of eNOS DNA 
was injected intramuscularly with electroporation to efficiently deliver the transgene. 
The transgene-treated (eNOS KO) animals had improved blood flow compared with 
untreated animals and also avoided limb loss and had healthier muscle fibers59. Earlier, 
the use of a phosphomimetic eNOS suggested an improvement over wild-type eNOS 
with increased NO generation and a lower tendency to uncouple60. Therefore, the use 
of this form of eNOS in cardiovascular disease models should be further evaluated.
Furthermore, adenoviruses as vectors are on the one hand efficient as a method of 
gene delivery but elicit an immune response. This alone can abolish any positive effect 
achieved by gene therapy. New vectors, both viral and non-viral, need to be developed 
and tested to overcome this obstacle. One strong candidate is the third-generation or 
helper-dependent adenoviral vector. This vector has had the coding sequence for the 
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viral genome deleted. Viral proteins that initiate an immune response can therefore not 
be synthesized61. This has the added effect of prolonging transgene expression, which 
could be advantageous in the cardiovascular setting62.
Stem cell therapy
Stem cell-based (gene) therapy may appear as the current most promising for the stim-
ulation of vascular remodeling in cardiovascular disease. The multifactorial mechanism 
of action of adult stem cells leads to positive effects on all types of vascular remodeling, 
including positive side effects on for example myogenesis and scar remodeling, and 
may therefore be the most comprehensive therapeutic option (Figure 4).
Mechanisms of action of adult stem/progenitor cells in vascular remodeling 
Cell homing and tissue incoporation 
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Paracrine 
effects 
Vasculogenesis 
Angiogenesis 
Arteriogenesis 
Functional improvement 
Attraction/activation of 
resident stem cells 
Myocyte 
apoptosis 
Modulation of 
inflammation 
Scar 
Remodeling 
Host tissue effect 
myocyte 
proliferation 
Myogenesis Modulation of 
vascular tone 
Intrinsic 
mechanisms 
GF, Chemokines 
BM-derived cells 
recuitment 
Figure 4. Multifactorial mechanisms of action of stem cells in vascular remodeling suggest stem cell-
based therapy as the most promising and comprehensive for the stimulation of vascular remodeling.
However, optimizing a (stem) cell-based therapy is a long and multifactorial procedure, 
in which several steps need to be taken to go from the bench to bedside. Initial clinical 
experience may reveal new riddles that lead us back to the bench for further scrutiny 
before going to another clinical phase. Thus, rather than being a linear ‘one-way street’, 
therapy design can be more adequately represented as a cyclic track (Figure 5).
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Figure 5. New hurdles in stem cell therapy for vascular remodeling. Optimizing a (stem) cell-based 
therapy is a long and multifactorial procedure, in which several steps (‘hurdles’ 1–5) need to be taken to 
go from the bench to the bedside. (Modified from Aranguren et al63 with permission)
While questions about safety, dose, and administration route/timing/frequency were 
the hurdles to be taken in the first round, other issues may prevail in the next. The 
choice of the better cell source/subset is a first hurdle to be taken, which requires com-
parative studies between different cell types from the stem cell ‘hierarchy’ or between 
several subfractions of a certain source (hurdle 1). In our studies, we used autologous 
bone marrow-derived mononuclear cells, overcoming the problem of host immune 
response and exerting a strategy of multifactioral mechanisms of action on vascular 
remodeling, both direct and indirect, and on additional types of remodeling, both 
described in following hurdles. Secondly, the local environment should be optimized 
for stem cell-based neovascularization (hurdle 2). Locally elevated eNOS expression 
in the endothelium was shown to attract an increased amount of stem cells towards 
ischemic tissue. Thirdly, determining the mechanism of action is not merely an aca-
demic question but is of significant clinical relevance. Cells can directly contribute by 
being incorporated into nascent vessels. Alternatively, cells can deliver growth factors 
that instruct endogenous vascular cells (hurdle 3). We have demonstrated that eNOS-
(over)expressing bone marrow cells also increase vasodilation and vasopermeability in 
ischemic vessels as a first step in the neovascularization response. A new mechanism 
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is that transplanted cells instruct host cells to secrete angiogenic growth factors. Com-
bining revascularization with muscular regeneration (‘angiomyogenesis’) could be an 
important added value for long-term therapeutic benefit (hurdle 4). Finally, exploiting 
the full potential of (stem) cell therapy in ischemic cardiovascular disease may require 
decisions about the appropriate differentiation state, the need for arterial prespecifica-
tion and other forms of genetic, chemical, or physical preconditioning (hurdle 5). In the 
context of this hurdle, our research on eNOS overexpression shows eNOS modification 
as a promising preconditioning tool for optimizing (stem) cell-based therapy. Therefore, 
we believe that in the near future the combination of stem cell therapy and eNOS gene 
targeting can lead towards a successful therapy for vascular remodeling in patients 
with cardiovascular disease.
And thus the final conclusion is: “Vascular Remodeling: Just say NO!”
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“Een mens is net zo oud als zijn endotheel…”
Hart- en vaatziekten en kanker zijn verantwoordelijk voor het grootste gedeelte van 
ziekte en sterfte in de Westerse wereld in een vergelijkbare verhouding. In patiënten 
met hart- en vaatziekte functioneert de binnenbekleding van de bloedvaten, het endo-
theel, minder goed. Endotheel is de initiator en modulator van de continue aanpassing 
van bloedvaten tijdens vele gezonde of ziekteprocessen in ons hart- en vaatstelsel, zo-
als embryonale ontwikkeling, wondgenezing, hoge bloeddruk, tumorgroei en aderver-
kalking (atherosclerose). Wanneer bloedvaten vernauwd of afgesloten geraken, passen 
zij zich aan door middel van vaatverwijding of verschillende vormen van vaatgroei. Dit 
proces wordt vaatremodellering genoemd. Een normale vaatremodellering is essenti-
eel voor een gezond hart- en vaatstelsel. Omgekeerd is bij hart- en vaatpatiënten dit 
aanpassingsvermogen gestoord als gevolg van een verminderde endotheelfunctie. Zo 
ontstaat atherosclerose met als gevolg vaatvernauwingen en -afsluitingen en tenslotte 
complicaties door zuurstoftekort, zoals een hartinfarct of weefselversterf van het been.
Zeg YES tegen vaatremodellering…
Een adequate vaatremodellering behoedt het lichaam voor complicaties van een 
bloedvatvernauwing. Vaatremodellering wordt gekenmerkt door een acute vaatver-
wijding gevolgd door vaatgroei. Er wordt onderscheid gemaakt tussen verschillende 
vormen van vaatgroei. Collateraalvorming beschrijft de expansieve groei van reeds 
aanwezige bloedvaten tot nieuwe netwerken die de bloedstroom om de afsluiting 
leiden. Neovascularizatie bestaat uit drie mechanismen van vaatgroei: vasculogenese 
beschrijft de vorming van bloedvaten door endotheliale voorloper-stamcellen, angio-
genese is het ontstaan van nieuwe haarvaten en arteriogenese refereert aan de stabili-
satie van deze nieuwe vasculaire structuren. De initiële trigger voor collateraalvorming 
is de verandering van bloedstroom door collaterale bloedvaten, terwijl de stimulans 
voor neovascularisatie het zuurstoftekort in het weefsel stroomafwaarts van de vaat-
afsluiting is. In het verdere proces hierna reguleren echter dezelfde groeifactoren en 
ontstekingscellen de verschillende vormen van vaatremodellering. Hierdoor worden, 
in het geval van vernauwend vaatlijden, de verschillende vormen van vaatremodel-
lering beschouwd als complementaire onderdelen van het proces van bloedstroom- en 
weefselperfusie herstel.
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Zeg NO in het hart- en vaatstelsel…
Er zijn maar weinig ontdekkingen van het kaliber van de impact die NO (stikstofmo-
noxide) heeft gehad op de biologie sinds 25 jaar geleden ontdekt werd dat het gas NO 
een belangrijk molecuul bleek in het hart- en vaatstelsel. In 1992 werd NO door het 
blad Science uitgeroepen tot molecuul van het jaar en in 1998 kregen de ontdekkers 
van de rol van NO in het cardiovasculaire systeem hiervoor de Nobelprijs. In het hart- en 
vaatstelsel speelt de productie van NO een essentiële rol door regulering van vaatver-
wijding, vaatgroei, vaatverkalking en vaatontsteking. NO wordt in vrijwel het gehele 
lichaam geproduceerd door het enzym NOS (Nitric Oxide Synthase). Voor het hart- en 
vaatstelsel is de productie van NO door het endotheel via eNOS (endotheliaal NOS) 
het belangrijkst. In patiënten met hart- en vaatziekte is als gevolg van verminderde 
endotheelfunctie de activiteit van eNOS gestoord en daardoor de productie van NO 
verminderd. Deze verminderde beschikbaarheid van NO bij alle hart- en vaatpatiënten 
wordt grotendeels verantwoordelijk gehouden voor het ontstaan van ziektes als athe-
rosclerose, suikerziekte en hoge bloeddruk.
Doel van het proefschrift
Het doel van dit proefschrift was ten eerste het verder ophelderen van de precieze 
rol die NO speelt in vaatremodellering. Vervolgens werden de effecten van “therapeu-
tische” verhoging van eNOS op vaatremodellering onderzocht, zowel in gezonde als 
zieke hart- en vaatstelsels bij muizen.
De eNOS transgene muizen
In hoofdstuk 2 en 3 worden het genereren en de karakterisering van twee verschillende 
genetisch gemodificeerde muizen besproken. De eNOS transgene (TG) muis heeft in zijn 
eigen DNA het menselijk eNOS gen (DNA fragment) ingebouwd gekregen. De eNOS-
GFP TG muis heeft eveneens een menselijk eNOS gen ingebouwd gekregen, waarbij 
tevoren dit gen gekoppeld is aan een gen voor een fluorescerend eiwit (GFP; Green 
Fluorescent Protein) , waardoor het eNOS eiwit door het gehele lichaam gevisualiseerd 
kan worden door de fluorescentie van het GFP. Lokalisatiestudies laten in beide muizen 
zien dat het humane eNOS in alle endotheelcellen aanwezig is. In beide typen eNOS TG 
muizen is zowel de eNOS activiteit als de NO productie tien keer verhoogd vergeleken 
met niet genetisch gemodificeerde controle muizen. Hierdoor hebben de eNOS TG 
muizen een duidelijk lagere bloeddruk, een lager cholesterolniveau in het bloed en 
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significant minder atherosclerose. Concluderend, zijn deze eNOS TG muizen de enige 
muizen in de wereld met een verhoogd humaan eNOS, leidend tot een karakteristiek 
gunstig hart- en vaatrisicoprofiel en daardoor zeer bruikbaar om de rol van NO in het 
gezonde en zieke cardiovasculaire systeem verder te onderzoeken.
Zonder eNOS wel, maar zonder NO geen collateralen…
In hoofdstuk 4 wordt de rol van eNOS in collateraalvorming onderzocht met behulp 
van drie muismodellen met een verschillende hoeveelheid eNOS. In de hierboven be-
schreven eNOS TG muizen is de eNOS activiteit vele malen verhoogd vergeleken met 
een normale gezonde muis. In eNOS-deficiënte (“knockout”; eNOS KO) muizen staat het 
eNOS gen uitgeschakeld en is eNOS activiteit dus geheel afwezig. Dit diermodel is jaren 
geleden in een ander laboratorium ontwikkeld en inmiddels commercieel verkrijgbaar 
via gespecialiseerde proefdierbedrijven. Als controle muizen worden normale gezonde 
muizen gebruikt. Door de liesslagader af te binden halverwege het bovenbeen ontstaat 
een situatie specifiek voor collateraalvorming waarbij zuurstoftekort geen prominente 
rol speelt, maar juist de verandering van bloedstroom. Verhoging van eNOS activiteit 
bleek in dit model alleen een positief effect op het herstel van de bloedstroom te hebben 
direct na de operatie, maar uiteindelijk geen verschil te maken in collateraalvorming. 
Dit effect wordt veroorzaakt door een krachtige acute vaatverwijding. In eNOS KO mui-
zen daarentegen veroorzaakte het afbinden van de liesslagader een sterk vertraagd 
herstel van bloedstroom en aanzienlijk weefselversterf als gevolg van de afwezigheid 
van eNOS. Microscopisch onderzoek liet echter evenveel en even grote collateralen 
zien in eNOS KO muizen als in gezonde muizen. De veroorzaakte weefselschade in de 
eNOS KO muizen blijkt veroorzaakt te worden door het feit dat de collateralen in de 
eNOS KO muizen niet kunnen vaatverwijden. De conclusie van dit hoofdstuk luidt dan 
ook dat bij het herstel van de bloedstroom in geval van een vaatafsluiting eNOS geen 
onmisbare rol speelt bij het vormen van collateralen, maar wel bij het (acute) proces van 
vaatverwijding. In een latere vervolgstudie is door onze onderzoeksgroep aangetoond 
dat NO zelf wel een onmisbare rol speelt in collateraalvorming omdat in afwezigheid 
van eNOS een andere vorm van NOS (inducible NOS) de noodzakelijke productie van 
NO overneemt. Dit gebeurt via een complex nog niet volledig ontrafeld mechanisme 
van balans en compensatie tussen de verschillende NOS isoformen.
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eNOS beschermt tegen atherosclerose in vaten met hoge bloeddruk…
Bij het ontstaan van atherosclerotische laesies (kalkafzettingen in de vaatwand, ook 
wel plaques genoemd) is de belangrijke eerste stap de hechting aan het endotheel 
en vervolgens binnendringen in de vaatwand van ontstekingscellen uit de bloedbaan. 
In gedeelten van bloedvaten waar hoge bloeddruk of hoge oscillerende druk door 
turbulentie heerst, is het endotheel gevoeliger voor het aanhechten en binnendringen 
in de vaatwand van deze cellen en daarom ontstaan op deze plekken vaker plaques. 
In hoofdstuk 5 wordt de rol van eNOS en NO beschreven in dit mechanisme. Door een 
geïsoleerde muizen halsslagader, opgehangen in een proefopstelling met variabel 
bloeddruksysteem, werden ontstekingscellen geperfundeerd. Aan het endotheel van 
bloedvaten onder hoge bloeddruk hechtten drie keer zo veel ontstekingscellen als aan 
endotheel van bloedvaten onder normale bloeddruk. In muizen zonder eNOS (eNOS 
KO) was dit verschijnsel identiek. In de eNOS TG muizen daarentegen was de celaan-
hechting onder normale bloeddruk gelijk aan die bij gezonde muizen, maar steeg deze 
niet in condities van hoge bloeddruk. Concluderend, beschermt een verhoogde eNOS 
activiteit en dus een verhoogde NO beschikbaarheid tegen hechting van ontstekings-
cellen aan de vaatwand van bloedvaten onder hoge bloeddruk. Hiermee kan één van 
de mechanismen waardoor NO beschermt tegen het ontwikkelen van atherosclerose 
verklaard worden.
eNOS voor meer nieuwe vaten…
In eerdere studies is de cruciale rol van eNOS in neovascularizatie al aangetoond. In 
eNOS muizen blijkt de neovascularizatierespons op een doorbloedingsstoornis sterk 
verminderd te zijn, wat resulteert in ernstig weefselversterf. Daarentegen wordt de neo-
vascularizatierespons juist versterkt bij proefdieren waarbij de eNOS activiteit verhoogd 
is, bijvoorbeeld door middel van gentherapie. In hoofdstuk 6 wordt het bovenstaande 
bevestigd in een gezonde situatie en vervolgens onderzocht in een hart- en vaatziekte 
achtergrond. Het model, dat hiervoor gebruikt wordt, is vergelijkbaar met het model 
uit hoofdstuk 4, omdat eveneens de liesslagader van een muis wordt afgebonden. Het 
gebruikte model in hoofdstuk 6 is echter een model waarbij de slagader hoger (dich-
ter bij de buik) in de lies wordt afgebonden om niet alleen collateraalvorming door 
verandering van bloedstroom, maar voornamelijk neovascularizatie door het ontstane 
zuurstoftekort te stimuleren. In dit model hadden onze eNOS TG muizen een versterkte 
neovascularizatierespons na het afbinden van de liesslagader vergeleken met normale 
muizen, met als gevolg betere doorbloeding en meer nieuwe bloedvaatjes in het on-
derbeen. Muizen met een hart- en vaatziekte, zoals atherosclerose of diabetes, hadden 
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in hetzelfde afbindmodel echter een sterk verminderde neovascularizatierespons. Als 
deze muizen gekruist werden met een eNOS TG muis bleken daarentegen de eNOS 
TG atherosclerotische of eNOS TG diabetische muizen net zo’n adequate neovascula-
rizatierespons te hebben als gezonde normale muizen. Verhoging van eNOS activiteit 
in het lokale weefsel herstelt dus de gestoorde neovascularizatierespons van muizen 
met een hart- en vaatziekte. Het mechanisme hierachter bestaat uit een krachtigere 
vaatverwijding en een toename van vaatgroei, zowel de uitgroei van bestaande als het 
ontstaan van nieuwe bloedvaatjes, door verhoogde NO productie door eNOS.
eNOS voor betere stamcellen en (dus) nog meer nieuwe vaten…
In het tweede deel van hoofdstuk 6 wordt de rol van stamcellen om neovascularizatie 
te stimuleren onderzocht. Vanuit eerdere wetenschappelijke literatuur is bekend dat 
stamcellen van gezonde muizen de neovascularizatierespons na afbinden van een 
liesslagader krachtig kunnen stimuleren en dat stamcellen van diabetische of atheros-
clerotische muizen dit niet of minder goed kunnen. In onze studie werden een dag na 
het afbinden van de liesslagader bij dezelfde muizen 1 miljoen vers geoogste stamcel-
len in de bloedbaan geïnjecteerd. Stamcellen van normale muizen bleken net zo goed 
neovascularizatie te stimuleren als stamcellen van de eNOS TG muizen. Stamcellen 
van atherosclerotische en diabetische muizen bleken een vergelijkbaar (namelijk geen 
positief ) effect op de neovascularisatierespons te hebben als een injectie met placebo. 
Echter, stamcellen van eNOS TG atherosclerotische en eNOS TG diabetische muizen 
hadden hetzelfde stimulerende effect op neovascularizatie als de stamcellen van de 
gezonde muizen. Het verhogen van de eNOS activiteit in de stamcellen van muizen 
met hart- en vaatziekte is dus een manier om de verminderde neovascularizatie-stimu-
lerende functie van deze stamcellen op te heffen. Dit gunstige effect wordt verklaard 
door een toegenomen NO productie van deze cellen, een toegenomen differentiatie 
van deze stamcellen in de richting van vaatcellen en een toename in de productie van 
vaat-groeifactoren door deze stamcellen.
Is NO een oplossing voor het “Janus fenomeen”…?
Janus was een mythologische Romeinse god met één hoofd en twee gezichten kijkend 
in tegenovergestelde richtingen. De term het “Janus fenomeen” is gebruikt voor het 
duale effect van therapeutische neovascularizatie op de groei van atherosclerotische 
plaques. In eerdere studies is aangetoond dat zowel eiwit- als stamceltherapie in 
een atherosclerotische muis met een afgebonden liesslagader niet alleen vaatgroei 
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stimuleert, maar ook een significante groei van de atherosclerotische laesies. Dit kan 
verklaard worden doordat de aangrijpingsmechanismen voor het stimuleren van 
verschillende vormen van vaatgroei, zoals arteriogenese en collateraalvorming, vaak 
dezelfde cellulaire mechanismen volgen als de groei van atherosclerose. NO lijkt 
hierop één mogelijke uitzondering, omdat van NO zowel pro-neovascularizatie als 
anti-atherogene effecten zijn aangetoond, hoewel altijd los van elkaar. Als gunstig 
neveneffect in onze studie uit hoofdstuk 6 bleek echter dat de injectie van eNOS TG 
atherosclerotische stamcellen in atherosclerotische muizen zelfs een remmend effect 
had op de groei van de atherosclerotische laesies. Dit effect zou verklaard kunnen 
worden door een anti-ontstekingseffect van verhoogde eNOS activiteit. Dit is de eerste 
keer dat in eenzelfde studie zowel pro-neovascularizatie als anti-atherogene effecten 
van NO zijn gevonden.
Vasculaire remodellering: Zeg maar NO!
De combinatie van inzichten in de recente literatuur en bovenstaande studies maken 
aannemelijk dat NO één van de belangrijkste schakels is in vasculaire remodellering. Dit 
maakt de stimulering van vasculaire remodellering door het verhogen van de beschik-
baarheid van NO een veelbelovende kandidaat voor de ontwikkeling van een nieuwe 
therapie voor hart- en vaatziekten. Stimuleren van NO of NO-gemedieerde effecten 
kan plaatsvinden via multipele mechanismen, zoals het genetisch opreguleren van 
eNOS, het verhogen van substraten voor de productie van NO en het bevorderen van 
eiwit-eiwit interacties met eNOS. Hiervoor worden momenteel verschillende farmaco-
logische, gen- en stamceltherapieën in preklinische of klinische situaties onderzocht. 
Ons inziens vormt de combinatie van stamceltherapie en eNOS gen-modulatie één van 
de meest kansrijke strategieën voor een succesvolle therapie voor vasculaire remodel-
lering in patiënten met hart- en vaatziekte.
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Stellingen
behorende bij het proefschrift
Vascular Remodeling: Just say NO!
Barend Mees, Juni 2011
1. Vasodilatatie via een NO-werkingsmechanisme speelt een fundamentele rol bij het 
herstel van de bloedstroom na een arteriele occlusie (dit proefschrift).
2. Zonder NO geen collateralen, maar zonder eNOS wel (dit proefschrift).
3. Het feit dat eNOS overexpressie zowel in diabetische muizen als in atheroscleroti-
sche muizen de gestoorde neovascularizatie-respons herstelt is een nieuwe aanwij-
zing dat NO fungeert als een “hoofdschakelaar” op het moederbord van vasculaire 
remodellering (dit proefschrift).
4. Het verhogen van eNOS activiteit is anno 2011 de meest veelbelovende strategie 
voor een effectieve therapeutische vasculaire remodellering zonder nadelige 
neveneffecten op de progressie van atherosclerose (“Janus Fenomeen”; dit proef-
schrift).
5. Het phenotype van de eNOS transgene muis is de droom voor iedere vaatpatiënt 
(dit proefschrift).
6. Therapeutische vasculaire remodellering is net als wijn maken: het geheim ligt vaak 
in de “terroir”.
7. Ook al is de ontwikkeling van het elektronisch patiënten dossier door de politiek 
tot stilstand gebracht, dit proefschrift demonstreert dat de digitale revolutie in de 
geneeskunde niet te stoppen is.
8. Een amputatie bij een vaatpatiënt is geen operatie voor een (ongesuperviseerde) 
assistent.
9. Het ultieme wetenschappelijke onderzoek van de chirurg dient erop gericht te zijn 
om het vak van chirurg overbodig te maken.
10 Het leren zien van schoonheid is even belangrijk in de wetenschap als in het leven. 
(geïnspireerd door Schoonheid in de Wetenschap van Hans Galjaard)
11. “The way you cut your meat reflects the way you live” (Confucius).
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Book chapters
“Endothelial nitric oxide synthase in cardiovascular homeostasis and disease”.
Observations in endothelial NO synthase transgenic mice.
Duncker D, van Haperen R, van Deel E, de Waard M, Mees B, de Crom.
In: Ince C. (Ed): “The Physiological Genomics of the Critically Ill Mouse”. Kluwer Academic 
Publishers, Amsterdam 2004.
Hoofdstuk vaatchirurgie
Barend Mees & Hero van Urk.
In: Leidraad Chirurgie, Bohn Stafleu van Loghum, Houten 2005.
Peer-reviewed articles
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PhD Portfolio Summary
Summary of PhD training and teaching activities
Name PhD student: Barend Mees
Erasmus MC Department: Cell Biology & Vascular Surgery
Research School: MGC & COEUR
PhD period: 2003 – 2011
Promotors: Prof. H. van Urk & Prof. J. Hamming
Supervisor: Dr. M. de Crom
1. PhD training
Year Workload (ECTS)
General academic skills 
- Experimental animal course (art. 9)
- How to write an article (NTtvG)
- Advanced radiation course (Boerhaave)
2003
2007
2010
3
0.5
1
Research skills
- Basics of epidemiology (Boerhaave) 2009 1
In-depth courses (e.g. Research school, Medical Training)
- Master in Cardiovascular Research (COEUR) 
- Master of Molecular Medicine (MGC)
2003 – 2006
2003 – 2006
7.5
7.5
Presentations
- National conferences 
 (o.a. Chirurgendagen, Endotheeldag, SEOHS)
- International conferences 
 (o.a. AHA, ACC, ESVS, ESSR, IVBM, EVGN)
2003 – 2011
2004 – 2011
5
5
Seminars and workshops
- Journal club
- MGC symposia & workshops
- EVGN seminar (Paris)
2003 – 2006
2003 – 2005
2006
0.5
1
0.5
2. Teaching activities
Year Workload (ECTS)
Lecturing
- Teaching OR nurses in training
- Teaching Medical students during internship
2003 – 2004
2006 – 2011
0.5
5
Supervising practicals and excursions
- Supervising first aid examinations (Medical students) 2003 – 2004 0.5
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Personal details
Name  Mees, Barend Mathijs Eduard
Date of birth October 10, 1975 
E-mail  bmemees@hotmail.com
Profile
An ambitious team player, taking the lead towards improving performance with positive 
and creative energy. Always eager to innovate. Humor is an important asset. Responsible 
and reliable. Caring for patients, with honest interest and respect. Family man.
For more
 Barend Mees
 http://nl.linkedin.com/in/barendmees
Follow me 
 @barendmees
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